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Exclusive enteral nutrition (EEN) is a first line treatment for active paediatric Crohn’s disease 
(CD) but is used less frequently in adult patients.  A meta-analysis of six controlled trials in 
adults found EEN to be less efficacious than corticosteroids at inducing CD remission. In 
contrast, paediatric studies have found EEN to be an effective treatment.  Paediatric EEN 
regimens often use a polymeric nutrition formula provided orally; this regimen has not been 
studied in a cohort of adults with active CD.  
 
This research aimed to investigate patient acceptability of EEN, the efficacy of EEN and a 
sequential EEN and partial enteral nutrition (PEN) regimen in young adults, and the impact 
of these treatments on disease activity, inflammatory and nutrition markers, quality of life 
and the gut microbiota.  This research also aimed to investigate health professional 
awareness and perception of EEN in the treatment of CD. 
 
Thirty five patients with CD attending hospital outpatient appointments were surveyed.  
Patients blind tasted an elemental and a polymeric formula then ranked them on measures of 
palatability. Patients were also asked whether they would consider using EEN, if it could 
induce disease remission, to treat active CD.  Patients rated polymeric formula more 
palatable and the majority of patients would consider using EEN to treat moderate to severe 
CD symptoms. 
 
Two prospective non-randomised clinical trials of eight weeks of EEN or a sequential EEN 
and PEN regimen were undertaken.  Thirty-eight patients aged 16 to 40 years old with active 
CD were recruited. Twenty-five patients started EEN of which 17 (68 %) responded or 
achieved disease remission. Thirteen patients started PEN and eight (62 %) responded or 
achieved disease remission.  There were significant improvements in serum CRP and insulin 
 iv 
like growth factor-1.  EEN or PEN treatment was completed by 23/38 (61 %) and resulted in 
significant reductions in anxiety and depression and improvements in quality of life. 
 
Faecal samples were collected prior, during and after EEN or PEN treatment.  The faecal 
microbiota of six patients who used EEN was characterised.  EEN treatment shifted the 
phylogenetic structure of the faecal microbiota and changes in the abundance of specific 
species were observed.  
 
An electronic survey was completed by 58 dietitians and 42 gastroenterologists working in 
New Zealand.  Most dietitians and gastroenterologists had limited experience using EEN but 
believe EEN is an appropriate treatment option for some adult CD patients.  Health 
professionals would like more guidance on how to use EEN and more evidence to supports its 
use with adults. 
 
Based on the findings in this thesis, EEN effectively induces disease remission in young 
adults with active CD and its use should be considered within the profession and presented as 
an option to patients.  There is also a need for further research investigating therapies, such 
as PEN, which may be more appealing and efficacious for a greater number of adult patients.  
Patients who are interested in an alternative to corticosteroids should be offered nutrition 
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     Chapter 1 
Introduction 
1.1 Crohn’s disease 
Crohn’s disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD) 
characterised by recurring and remitting inflammation, which leads to chronic symptoms 
such as diarrhoea, abdominal pain and rectal bleeding.(1)  CD, unlike UC, can affect the lining 
of the gastrointestinal tract anywhere from the mouth to the anus but most commonly 
disease is isolated to the terminal ileum, the colon, or both the ileum and the colon.  CD 
presents as transmural inflammation, which means that it may affect the whole depth of the 
intestinal lining, not just the mucosa, as seen in UC.  In addition, CD may be present in 
multiple locations in the bowel with healthy sections of bowel separating them, which is 
referred to as skip lesions.  There is currently no known cure for CD or UC and therefore 
current treatments are focused on minimising inflammation and extending periods of disease 
remission. 
 
CD can be diagnosed at any age, however the peak age of diagnosis is between 15 and 30 
years of age, leading to many years of disease and associated morbidity.  A decade ago 
Canterbury, New Zealand (NZ) had one of the highest incidence rates of CD in the world at 
16.5/100,000/year.(2)  The incidence and prevalence of IBD is increasing world-wide(3) and 
NZ is not immune from this trend.  In 2014 the annual incidence of CD in Canterbury, NZ 
had increased 1.5 fold in a decade to 26.0 per 100,000.(4)  The drivers of this increasing 
incidence of disease are not yet fully understood but are hypothesised to be a complex 
interaction between genetic factors, the gut microbiome, the western diet and industrialism, 




People with CD commonly also suffer from poor nutritional status during periods of active 
and inactive disease.(6)  Optimal management of CD requires a multidisciplinary approach 
involving a gastroenterologist and/or surgeon, specialist gastroenterology nurses, dietitians, 
psychologists and other specialties.(7)  In NZ, patients are often diagnosed and managed by a 
specialist gastroenterologist in a tertiary centre.  However, dietary outpatient care may be 
provided by dietitians in tertiary centres or those working in provincial centres.  The role of 
UK paediatric and adult dietitians in the management of IBD patients has been well 
documented,(8, 9) but the role(s) of NZ dietitians in the management of CD patients is not 
defined in the literature. 
 
1.2 Treatment of Crohn’s disease 
The treatment of CD often involves a multi-pronged approach including therapies to treat 
active disease and therapies to maintain disease remission.  The most common therapies are 
described in the following paragraphs.   
 
1.2.1 Immunomodulatory Medications 
1.2.1.1 Corticosteroids 
The standard first line treatment in adults with active CD is corticosteroid (CS) therapy, 
which is effective at inducing remission in approximately 60 – 68 % of patients.(10)  CS 
suppress the immune response in the intestines thereby reducing acute inflammation.  
However, CS therapy has many well-documented acute side-effects and numerous long term 
adverse effects due to repeated or continual use.(11)  Also, CS resistance can occur in 8-22% of 
patients and CS dependency occurs in 15-36% of patients.(12)  Alternative therapies that can 
effectively induce disease remission whilst avoiding the short and long term side effects of CS 





Maintenance of disease remission is often managed with immunosuppressant thiopurine 
medications (Azathioprine, 6-Mercaptopurine).  These medications are prescribed in varying 
doses depending on the individual’s thiopurine S-methyltransferase (TPMT) enzyme activity 
and serum thioguanine nucleotide (TGN) metabolites.  Side effects mostly occur soon after 
initiating the treatment and may include nausea, vomiting and anaemia.  As with all 
immunosuppressant medications, patients are more susceptible to infections.   
 
1.2.1.3 Biologics 
Biologic therapy can be used to induce and maintain disease remission.  In NZ, subcutaneous 
adalimumab (trade name Humira) and intravenous infliximab (trade name Remicade) are 
Pharmaceutical Management Agency (PHARMAC) funded for patients who have refractory 
disease despite trying standard therapies.  These medications inhibit the action of a key 
cytokine in the inflammatory process: tumour necrosis factor (TNF)-α.  Their use is 
associated with improved quality of life(13) and greater rates of mucosal healing, which is 
considered the optimal outcome for CD therapy and thought to improve the disease 
course.(14)  However, the patient needs to take the medication regularly and 23-46 % of 
patients will lose response to the medication after one year.(15)  Research into new biological 
treatments and combination therapy with immunosuppressant medications is on-going.  
 
1.2.2 Nutrition Therapy 
The most common nutritional therapy used to treat active CD is exclusive enteral nutrition 
(EEN).  EEN is the ingestion of an elemental or polymeric nutritional formula for a period of 
four to eight weeks along with the exclusion of solid and liquid foods and drinks apart from 
water.  EEN treatment protocols may also allow ice blocks, boiled sweets and black tea and 




The replacement of usual foods and fluids with an liquid formula was initially used to rest the 
gut and thought to improve inflammatory markers and clinical symptoms by reducing the 
exposure of the intestines to foreign proteins.(17)  This may in part be the case but it is now 
also known that there is/are active ingredients in enteral formula which exert their effect via 
a number of mechanisms.  In-vitro studies show the elemental and polymeric formula have 
positive effects on intestinal tissue cytokine response(18, 19) and reduce the permeability of the 
gut lining.(20)  In vivo studies of EEN in paediatric(21) and adult(22) cohorts have confirmed in-
vitro findings.  Patients treated with EEN achieve reductions of pro-inflammatory cytokines 
which were associated with histologic and endoscopic healing of the gut.(21, 22)  Mucosal 
healing consequent to EEN have been confirmed in a subsequent study where EEN was 
found to result in higher rates of mucosal healing than corticosteroid treatment.(23)  EEN 
treatment also results in significant changes to the intestinal microbiome,(24, 25) although the 
impact of these changes on intestinal inflammation is not yet fully understood.  
 
In children, EEN has been shown to be an effective and feasible alternative to CS(26).  In 
addition to avoiding the adverse effects of CS exposure, EEN provides additional benefits 
over and above those provided by CS.  Consequently, EEN is now recommended as a first line 
therapy for children newly diagnosed with CD and is often used to treat a disease flare in 
children with existing disease.(27)  EEN therapy is associated with higher rates of mucosal 
healing,(28) changes in the intestinal microbiome,(24) greater weight gain,(29) improved vitamin 
D status,(30), enhanced bone turnover,(31) an early rise in the nutrition marker IGF-1,(32) and 
better quality of life after treatment.(33)  The administration of supplementary enteral 
nutrition (SEN) once disease remission is achieved has also been shown to be beneficial in 
maintaining remission compared with a free diet in children(34) and Japanese adults.(35)   
 
However, in adult CD populations, EEN is generally not viewed as a first line therapy for 
newly diagnosed CD or those with a flare of pre-existing CD.  Many clinical guidelines(36, 37) 
only recommend EEN if a patient declines drug therapy or as an adjunctive therapy to 
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support nutrition, rather than as a primary therapy.  These guidelines are primarily based on 
the 2007 Cochrane systematic review of six randomised controlled trials,(38) which found a 
pooled OR of 0.33 (95 % CI: 0.21-0.53) in favour of CS and concluded that CS were superior 
to EEN in the induction of remission of disease.  The use of EEN with adult populations will 
be discussed in more detail in section 1.4. 
 
1.2.3 Surgical Treatment 
Medical treatments are the first line approach for CD but when these fail or cannot provide 
adequate resolution of symptoms, surgical intervention is required.  Surgery is a not a 
curative procedure for CD and recurrence of disease post-surgery is common.  Population-
based studies show that 30 – 50 % of patients will require surgery within 10 years of 
diagnosis.(39)  There is some evidence to suggest that since the advent of biological treatments 
rates of surgery have decreased, however the evidence is not yet conclusive.(39)  It is beyond 
the scope of this thesis to provide an in-depth discussion of surgery for CD but in general, 
current surgical practice tends to target the most inflamed part of the bowel rather than 
removing all diseased parts of the bowel.(36)  
 
1.3 Holistic Measures of Treatment Success 
The success of CD treatments can be assessed by objective and subjective means.  The 
following sections introduce some of the measures typically used in practice, and research, to 
measure the extent of disease and the success of CD treatments on, not only objective 





1.3.1 Nutritional Status 
Malnutrition is associated with poorer outcomes and poorer quality of life.(40)  The prevalence 
of malnutrition in patients with CD is high.  In a large American study of 50,000 hospitalised 
patients with IBD the adjusted odds ratio for malnutrition was 5.57 [95 % CI: 5.29 – 5.86] 
compared to non-IBD hospitalised patients.(41) The aetiology of malnutrition in CD is 
multifactorial and summarised in Table 1.1.(42) 
 
The United Kingdom and Australian IBD standards of care both recommend the inclusion of 
a specialist gastroenterology dietitian in the IBD multidisciplinary team.(7, 43)  However, an 
international survey of IBD centres suggests currently that dietitian involvement in the IBD 
team is infrequent.(44)  A 2014 audit of UK IBD centres found that 23 % of centres did not 
have access to a specialist dietitian.(9)  Improving patient access to a specialist dietitian 
provides patients with an opportunity to address dietary and nutrition concerns and utilise 




Table 1.1.  Causes of malnutrition in Inflammatory Bowel Disease.(42) 
Associated with 
malnutrition 
Potential causes of associations 
Decrease in oral intake Restrictive diets, therapeutic fasting 
By the disease itself: diarrhoea, abdominal pain, nausea and 
vomiting, etc. 
Alteration in taste: due to drugs, vitamin and mineral deficiencies, 
pro-inflammatory mediators 
Anorexigenous effect of pro-inflammatory mediators 
Gastrointestinal losses Diarrhoea 
Rectorrhagia/haematochezia 
Loss of mucus and electrolytes 
Protein-losing enteropathy 
Metabolic disorders Increase in resting energy expenditure 
Enhanced fat oxidation 
Increase in nutritional 
requirements 
Inflammatory states 
Increased basal oxidative metabolism 
Infectious complications 
Post-surgery 
Drug interaction Corticoids and calcium reabsorption 
Corticoids and protein catabolism 
Sulfasalazine and folates 
Methotrexate and folates 
Cholestyramine and liposoluble vitamins 
Antimicrobials and vitamin K 
Anti-secretors and iron 
Poor absorption of 
nutrients 
Reduction in absorptive surface: intestinal resection, enteric fistulas, 
hypertrophy of the villi, blind loops, bacterial overgrowth 




1.3.1.1 Serum Albumin 
Serum albumin is commonly used as a marker of nutrition status in clinical practice.  
Albumin is a readily available measure but is not a reliable marker of malnutrition.(45, 46)  
Albumin is an acute phase protein, which decreases in response to inflammation, therefore, 
during active disease albumin may be falsely low.(40)   
 
1.3.1.2 Body Mass Index 
Body mass index (BMI) is also commonly used a marker of nutrition status in clinical 
practice.  BMI is calculated by dividing body weight (kg) by height (m) squared (BMI = 
kg/m2).  BMI measurements are readily available but do not provide a reliable indication of 
malnutrition.(45, 46)  BMI is a ratio of weight to height and does not take into account the ratio 
of lean body mass to fat mass therefore, is not a sensitive marker of malnutrition in 
overweight patients or patients with oedema.(45)  Alternatively, lean body mass measurements 
may provide more accurate and functional information on nutritional status but lean body 
mass measurement methods are either very expensive, in the case of whole-body magnetic 
resonance imaging (MRI), or have their own methodological limitations in the case of 
bioelectrical impedance analysis (BIA).(40, 45)  
 
1.3.1.3 Serum Insulin-like Growth Factor -1 
Insulin-like growth factor -1 (IGF-1) is a novel serum marker of nutrition status.  It is a 
hormone predominantly produced by the liver.  The production of IGF-1 varies with age and 
sex and may also be affected by nutrition intake, body composition and inflammation.(47)  In 
paediatric cohorts, EEN treatment has been associated with an early rise in IGF-1, which 
could be suggestive of an anti-inflammatory effect as well as improvement in nutritional 




1.3.1.4 Serum Vitamin D (25-OHD) 
Synthesis of Vitamin D in the skin is reliant on exposure to ultraviolet B (UVB) radiation 
from the sun.  Christchurch is located at latitude 43.5321° S and longitude 172.6362° E which 
means that during the winter months the sun is far away and there is limited opportunity for 
the population to synthesise vitamin D.  The 2008/09 NZ National Nutrition Survey found 
that a third of the sample population had insufficient serum vitamin D (25-OHD), less than 
50 nmol/L, and that at the end of Winter the serum vitamin D concentrations of New 
Zealanders in the South Island of NZ were lower than New Zealanders living in the north of 
NZ.(49)  Patients with CD living in Dunedin, a city further south than Christchurch, have a 
high incidence of insufficient serum vitamin D.(50)  The serum vitamin D status of patients 
living in Christchurch has not previously been reported.  It has been suggested that low 
serum vitamin D is associated with disease activity,(51) immune response(52) and that vitamin 
D status may affect response to treatments.(53)  However, further research is needed to 
confirm these initial findings. 
 
1.3.1.5 Serum Iron Status 
Iron deficiency anaemia commonly occurs in patients with CD with negative effects on 
quality of life.(54)  Patients at risk of iron deficiency anaemia are pre-menopausal women with 
poor dietary iron intake,(45) patients with active disease and presence of chronic 
inflammation.(54)  Serum ferritin is usually used as marker of iron stores in healthy 
populations but ferritin is an acute phase protein and therefore can be falsely elevated during 
periods of inflammation.(55)   
 
1.3.2 Disease Activity Indices 
There are three main validated clinical and composite measures of disease activity: Crohn’s 
Disease Activity Index (CDAI), Harvey Bradshaw Index (HBI) and Van Hees Activity index 
(VHAI).  The VHAI is calculated using serum albumin and erythrocyte sedimentation rate, 
body mass index, abdominal mass, gender, fever, loose stools, bowel resection and CD 
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complications. The VHAI correlates moderately (r = 0.67) with the CDAI(56) and disease 
remission is usually defined as a score of less than 120. 
 
The HBI is a simple disease activity measure, which is calculated from a one day history of 
general well-being, abdominal pain, loose stools and presence of abdominal mass and CD 
complications.(57)  Clinical disease remission is usually defined as an HBI of less than five.(57)  
The HBI correlates well with the CDAI (r = 0.8)(57) and, for this reason, is often used as an 
activity index in place of the more burdensome CDAI.   
 
The CDAI score combines a seven day history of patient reported subjective symptoms of 
general well-being, abdominal pain, loose stools with the objective measures of disease 
including the presence of abdominal mass and CD complications, anti-diarrhoeal use, 
haematocrit and weight.(58)  Clinical remission is usually defined as a CDAI of less than or 
equal to 150 points(59) whereas, clinical response, as a secondary endpoint, is defined as a fall 
in CDAI of 70 – 100 points.(59)  The CDAI is the activity index that is recommended for use in 
medical clinical trials by the Clinical Trials Task Force of the International Organization of 
Inflammatory Bowel Disease.(59)   
 
One the limitations of all of these disease activity scores is that they do not correlate well with 
objective measures of disease activity such as endoscopic and histology findings.(60, 61)  The 
development of more accurate surrogate markers of intestinal inflammation is desirable.  
 
1.3.3 Biomarkers of Gut Inflammation 
Ileocolonoscopy with biopsies is the gold standard to assess the degree of disease activity or 
intestinal inflammation but it is an invasive and expensive procedure.  In clinical practice, 
biomarkers are used as a non-invasive and less expensive measure of intestinal inflammation 
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in comparison to invasive procedures.  There are many biomarkers of inflammation (Table 
1.2) but the following sections summarise the literature on the most prevalent existing 
biomarkers and a novel faecal biomarker of CD activity.  
 
Table 1.2.  Biomarkers of gut inflammation. 
Biomarker  Attributes of biomarker 
Serum CRP 
> 5 mg/L 
Sensitive but non-specific acute phase protein(62, 63)   
Serum ESR 
> 10 or 15 mm/hr 
Changes more slowly than CRP, concentration may differ depending on 
location of disease(62) 
Faecal calprotectin 
> 50 µg/g 
Increasingly used in practice. Non-specific protein from many sources 
including neutrophil accumulation at intestinal inflammation(64) 
Faecal S100A12 
> 10 mg/kg(65) 
Used mainly in research setting.  Neutrophil derived protein and sensitive 
measure of disease activity(66) 
Faecal lactoferrin 
> 7 – 10 ug/mL 
Neutrophil derived protein, marker of intestinal inflammation(67) 
Faecal OPG 
> 62.5 pg/mL 
Member of TNF receptor family, associated with moderate to severe 
intestinal inflammation(68) 
Note: CRP, C – reactive protein; ESR, erythrocyte sedimentation rate; OPG, osteoprotegerin; TNF, 




1.3.3.1 Serum C - Reactive Protein 
In clinical practice, serum C – reactive protein (CRP) is the most commonly used biomarker 
of gut inflammation in IBD.  It is readily available and relatively inexpensive.  CRP is an acute 
phase protein, which increases rapidly with inflammation and decreases quickly once 
inflammation has resolved.(62)  CRP is a sensitive marker in the diagnosis of CD and it 
correlates well with active CD.(62, 63)  However, there are individual variations in CRP 
response and some patients with active disease may have a low CRP.(63)  Serum CRP has been 
investigated as a predictor of CD relapse and some studies have shown that it predicts disease 
relapse whereas other studies have not.(62, 63)   
 
One of the main limitations of CRP is that it is not a specific marker of CD inflammation.  As 
an acute phase inflammatory protein, CRP increases in response to inflammation outside, as 
well as inside, the gastrointestinal tract.  The desire for more specific markers of CD 
inflammation has resulted in the investigation of faecal makers of inflammation.  
 
1.3.3.2 Faecal Calprotectin 
Faecal calprotectin (FC) is commonly used as a biomarker of intestinal inflammation.  
Calprotectin (S100A8/S100A9) is a member of the calcium binding S-100 protein family and 
is found in many cells in the body including epithelial cells.  It was coined ‘calprotectin’ due 
to its ability to bind calcium and its antimicrobial protective characteristics.(69)  Calprotectin 
is involved in many biological processes, but in CD, it is important in the regulation of the 
inflammatory process.(70)   
 
Calprotectin is a constituent of neutrophil cytoplasm and is present on the membranes of 
monocytes and acute phase macrophages.(64)  During inflammation, neutrophils accumulate 
at the site of intestinal inflammation, at which point calprotectin is released into the gut 




In clinical practice, FC may be used as a diagnostic tool to differentiate between IBD and 
non-inflammatory conditions such as irritable bowel syndrome (IBS).  A systematic review of 
the utility of FC to distinguish between IBS and IBD found that a cut-off of 50 µg/g had a 
sensitivity of 93 % and specificity of 94 % in adult populations.(71)  FC is also used as a non-
invasive biomarker of intestinal inflammation in patients with IBD.(72)    FC has been shown 
to be positively correlated with endoscopic disease activity.(73-76)  However, a FC of less than 
50 µg/g of stool does not exclude the presence of intestinal inflammation.(67, 76)  
 
1.3.3.3 Faecal Osteoprotegrin 
Osteoprotegerin (OPG) is another potential biomarker of intestinal inflammation.  OPG is a 
member of the TNF receptor family and is expressed in many cells in the body including 
colonic epithelial cells.(77)  OPG can be measured in serum, intestinal cells and faecal samples, 
although faecal OPG is not stable in stool at room temperature and samples need to be frozen 
soon after collection to avoid OPG decay.(78)  
 
OPG has been widely researched in the context of bone health and has been shown to 
promote bone maintenance.  In bone, OPG is a decoy receptor for receptor activator of NF-κB 
(RANK) and binds RANK ligand (RANKL) thus, inhibiting the formation of osteoclasts and 
therefore inhibiting bone breakdown.(79)  However in IBD it appears that OPG has a pro-
inflammatory role in intestinal inflammation.  
 
In vitro research has shown that OPG binds TNF-related apoptosis inducing ligand (TRAIL) 
and thus inhibits dendritic cell and T cell apoptosis.(80)  In inflamed epithelial cell lines OPG 
expression has been shown to be increased(77) and the presence of OPG in cell culture media 




In vivo, OPG has been shown to be associated with moderate to severe CD inflammation.(68)  
In a cohort of 82 children with CD and 45 healthy children, serum OPG was elevated in 
moderate to severe CD but not mild disease however, mucosal OPG was not significantly 
elevated in biopsy samples compared with control biopsies.  Faecal OPG was also elevated in 
moderate to severe CD but also in cases of mild disease compared to controls.  
Notwithstanding this no significant correlation was found between faecal, serum and 
mucosal OPG nor with paediatric CD disease activity index scores.(68) 
 
The study by Nahidi et al(68) also assessed change in faecal OPG in ten children subsequent to 
treatment with EEN.  Faecal OPG fell significantly with EEN treatment but levels were still 
significantly elevated compared with healthy children at treatment completion. 
 
OPG is not currently used in clinical practice as a marker of intestinal inflammation and 
there is no data available concerning OPG concentrations in adults with IBD.   
 
1.3.4 Health Related Quality of Life Measures 
CD is a chronic disease in which the disease symptoms and treatments can have significant 
impacts on many facets of life.  Health related quality of life (HRQOL) measures have been 
developed to evaluate the impact of diseases and their treatments on physical, emotional and 
psychosocial functioning.(82)  HRQOL has been shown to be lower in patients with CD 
compared to the general population,(83, 84) and the impact of CD on patient quality of life may 
be underestimated by physicians.(83)   
 
Multiple clinical and treatment related determinants of HRQOL scores have been identified. 
A systematic review and meta-analysis by van der Have et al(85) concluded that HRQOL is 
multifactorial and that poor HRQOL is associated with active disease, hospitalisations, 
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corticosteroid treatment and work disability.(85)  Whereas, better HRQOL scores were 
associated with biological treatments.(85)   Since this review, further studies have shown 
improved HRQOL subsequent to biological treatments(13) and also subsequent to nutritional 
therapy with EEN.(33, 86)     
 
A recent review of HRQOL assessment tools identified ten different questionnaires that have 
been validated for use with IBD patients.(87)  It is beyond the scope of this thesis to discuss all 
of these measures, however two of the most commonly used measures in IBD research, the 
Hospital Anxiety and Depression Scale (HADS) and the Inflammatory Bowel Disease 
Questionnaire (IBDQ), have been reviewed. 
 
1.3.4.1 Hospital Anxiety and Depression Scale 
In 1982 a patient self-assessment tool (HADS) was proposed to estimate the presence of 
depression and anxiety in patients attending non-psychiatric hospital clinic appointments.(88)  
Since then the HADS has been administered in many languages,(84, 89-91) with patients of 
varying age,(90, 92) medical conditions,(90, 91) and with healthy populations.(89, 90, 92)   
 
The HADS is composed of 14 questions that screen for emotional stress, depression and 
anxiety.  The presence of anxiety and depression are scored separately: possible scores range 
from 0 to 21.  A score of eight to ten suggests borderline anxiety or depression and a score of 
11 or more suggests the presence of moderate to severe anxiety or depression.(88)  The 
sensitivity and specificity of the HADS to identify cases of anxiety and depression is 
approximately 0.80.(93)   
 
Previous research has shown that patients with IBD have higher rates of anxiety and 
depression than the general population.(94, 95)  Table 1.3  summarises the recent literature that 
has assessed anxiety and depression using the HADS in IBD cohorts.  These studies report no 
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difference in the presence of anxiety and depression between patients with CD and UC;(84, 94, 
96) anxiety is suffered in at least 30 % of patients and depression is present in 10 – 20 % of 
patients.  In patients with CD, anxiety has been significantly correlated or associated with 
greater disease knowledge,(97, 98) greater disability,(99) greater levels of perceived stress,(94) 
active disease(100-102) and functional defecation disorders.(103)  Depression, however, has been 
correlated with perceived stress and increasing age(94), active disease(101), disease severity(101) 
and functional defecation disorders.(103)   
 
Active CD is associated with greater anxiety and depression symptoms(100-102) and a few 
studies have suggested that medications used to treat active disease also impact on anxiety 
and depression symptoms, although the results are variable.  Corticosteroid use has been 
associated with depression in one study(104) but not in another.(101)  In contrast, anti-TNF and 
thiopurine medications have not been associated with increased anxiety or depression.(101)  A 
literature search found no studies that have used HADS to document changes in anxiety and 
depression subsequent to EEN treatment in children or adults.  
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Table 1.3.  Prevalence of anxiety and depression in IBD cohorts using the Hospital Anxiety and Depression Score (HADS). 
Study location and 
year published 
Number of patients (CD, 
UC, mean age, % with 
active CD) 
Criteria applied Anxiety 




(% of cohort) 
HADS-D 
Mean (SD) 
Rome, Italy 2011(105) 
(abstract) 
27 IBD (46 years) > 10 
8 - 10 
55 % 
30 % 
N/A N/A N/A 
Edinburgh, UK 
2011(104) (abstract) 
582 IBD (326 CD, 256 
UC) 
> 11 43 % N/A N/A N/A 
Sweden 2003(98) 489 IBD  >10 
8 - 10 
16 % 
14 % 
N/A N/A N/A 
Sydney, Australia 
2012(97) 
258 IBD (47 years) > 10 
8 - 10 
19 % 
22 % 
N/A N/A N/A 
Singapore 2015(99) 
(abstract) 
164 IBD (77 CD, 87 UC, 
N/A) 
N/A 24 % 
 
N/A 13 % N/A 
France 2012(101) 1663 IBD (1062 CD, 600 
UC, 20) 






Study location and 
year published 
Number of patients (CD, 
UC, mean age, % with 
active CD) 
Criteria applied Anxiety 




(% of cohort) 
HADS-D 
Mean (SD) 
East London, UK 
2012(94) 
204 IBD (101 CD, 103 UC, 
42 years) 
> 10 33 % 
 
8.60 (3.90) 4 % 4.70 (3.30) 
Spain 2013(84) 793 IBD (323 CD, 470 UC, 
45 years, 39) 
>11 11 % 
 
4.93 20 % 7.40 
Canterbury, New 
Zealand 2015(96) 
54 IBD (29 CD, 22 UC, 34 
years, 59 % 
> 7 23 % 5.19 (3.36) 9 % 3.15 (2.71) 
Adelaide, Australia 
2008(103) 
61 IBD (31 CD, 30 UC, 51 
years) 
8 or more 39 % 
 
6.57 (3.52) 11 % 4.18 (2.89) 
Melbourne, Australia 
2015(100) 
81 IBD (56 CD, 25 UC, 35 
years) 
> 10 
8 - 10 
23 % 
20 % 
7.21 (4.75) 13 % 
9 % 
5.35 (4.90) 




1.3.4.2 Inflammatory Bowel Disease Questionnaire 
The IBDQ is a commonly used IBD-specific HRQOL assessment tool.  It is a 32-item 
questionnaire developed in 1989 for use in clinical trials to describe how IBD affects the 
quality of patients’ lives.(106)  It includes four sections (bowel symptoms, systemic symptoms 
and emotional and social function) and each question is answered on a seven-point scale.(106)  
The IBDQ score is the sum of the 32 answers in which 32 represents the worst and 224 is the 
best HRQOL function.  Each of the four dimensions can also be summated individually for 
further analysis.  A score of ≥ 170 corresponds to clinical remission and an increase of ≥ 16 is 
considered a meaningful response to intervention.(107) 
 
Active CD symptoms, including diarrhoea, abdominal pain and fatigue, are likely to impair 
normal activities.  Objective measures of disease activity, including endoscopic disease 
activity, CRP and FC, are not significantly associated with IBDQ scores whereas, many 
studies have shown that CDAI correlates well with IBDQ scores.(108-110)  Also, females often 
have lower mean IBDQ scores compared to males with similar disease activity.(111, 112)  The 
CDAI contains objective measures of disease activity (haematocrit, weight loss, anti-diarrheal 
use, extra-intestinal manifestations) but also, subjective measures (general well-being, 
intensity of abdominal pain) which probably, in part, explains the strong correlation between 
CDAI and IBDQ.  Mean IBDQ scores of patients with a CDAI of less than 150 (defined as in 
remission) are greater than those of patients with active disease, however, even when the 
disease is in remission IBDQ scores are still less than optimal.(110)   
 
There are numerous medication options available to manage active CD and the aim of all 
treatments is to reduce inflammation and disease symptoms and achieve disease remission.  
However, some treatments are associated with better HRQOL than others.  For example, 
some studies show that despite symptom improvements on corticosteroids, IBDQ scores do 
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not reflect those improvements.(111, 112)  In contrast, other studies have found disease severity, 
rather than corticosteroid use, had a greater impact of IBDQ scores.(113)  On the other hand, 
biological treatments used to induce disease remission and as a maintenance treatment are 
associated with sustained improvement in IBDQ scores.(109, 114) 
 
Few studies have assessed HRQOL in adults with CD using EEN.  Research with paediatric 
populations has shown that the use of EEN is associated with improved HRQOL,(33) even for 
children who require nasogastric tubes to administer the feed.  Similarly, Japanese adults 
with CD in remission who were using a half elemental nutritional formula diet to maintain 
disease remission had similar IBDQ scores to those on a free diet.(35)  The impact of EEN 
treatment on HRQOL has not been assessed in western adults.  
 
1.3.4.3 Short Inflammatory Bowel Disease Questionnaire 
The IBDQ requires 15 – 20 minutes to complete making it an inappropriate tool to use in 
outpatient clinical practice setting.  Subsequently, a short IBDQ (SIDBQ) version, with only 
10 questions, was developed in 1996 for use in clinical practice.(115)  The short version 
includes questions from each of the four domains of IBDQ and each question is answered on 
a seven-point scale.  The responses to the 10 questions are summed and divided by ten; the 
final SIBDQ score can range from one (poorest HRQOL) to seven (optimum HRQOL).  
Occasionally, the sum of the SIBDQ is reported in a fashion similar to that of the IBDQ.  In 
the initial validation study involving 150 patients with CD, the SIBDQ explained 92 % of the 
variance in the full IBDQ and clinical changes in disease activity were reflected in SIBDQ 
score variations.(115)  The SIBDQ correlates well with CDAI (Pearson correlation r = -0.54; p < 
0.001) and a significant change in the SIBDQ is observed between patients with active and 




The SIBDQ has not been used in clinical trials as often as the IBDQ.  A recent study combined 
SIBDQ score with FC as a non-invasive predictor of mucosal healing.(116)  The study showed 
that a combined FC of greater than 30 µg/g and a SIBDQ of less than 6 were good predictors 
of active endoscopic disease with a sensitivity of 81 % and a specificity of 75 %.(116)  The 
SIBDQ has also been used in combination with the HBI to predict severe illness requiring 
hospitalisation or surgery.(117)  There has been no published studies that have investigated 
HRQOL using the SIBDQ in adult patients using EN to treat active CD. 
 
1.3.5 Dysbiosis of the Gut Microbiota 
The gut microbiota is defined as all the microorganisms present in the digestive tract, of 
which the greatest number reside in the colon.  It is estimated that the gut microbiota 
contains up to ten times more cells than the human body(118)  including bacteria, archaea 
(single-celled microorganisms) and eukaryote (protozoa, yeast and fungi).   The gut 
microbiota is defined as the community of microorganisms residing in the gastrointestinal 
tract.  Whereas, the gut microbiome is the genes encoded by all of the microbial genomes.  
The gut microbiome is much larger than the human genome and encodes 100 times more 
genes than the human genome.(119) 
 
The microorganisms present in the human colon usually live in symbiosis with the host and 
improve the health of the host through the production of vitamins, fermentation of 
undigested carbohydrates and subsequent production of short-chain fatty acids, and the 
metabolism of bile acids, sterols and xenobiotics.  However, pathogenic microorganisms may 
also coexist in the gut and may result in changes in the microbiota and disruptions to the gut 
environment, for example, after infectious gastroenteritis.(120, 121)  In the case of CD, changes 
to the gut microbiota, coined dysbiosis, are apparent.(121, 122)  Microbiota dysbiosis is also 
observed in other chronic diseases including obesity,(123) type II diabetes(124) and IBS.(122, 125)  
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The exact cause of dysbiosis in CD is not fully understood and it is not yet clear if this is a 
result of the disease or precedes the development of disease.  
  
It is currently thought that CD is the result of an abnormal immune response to a 
gastrointestinal stimulus in a genetically susceptible person.(126)  One of the theories is that 
dysbiosis is associated with impaired immunity and inflammation of the gut mucosa.(127) For 
example, dysbiosis may occur for example,  as a result of antibiotic exposure or an 
opportunistic infection in a person with a genetic mutation on the NOD2 gene.(127)  The 
change in the balance of the gut microbiota results in decreased mucin production (the 
protective layer between the gut lumen and epithelial cell) and decreased antimicrobial 
peptide production.  These impaired defence mechanisms allow microorganisms or other 
luminal contents to cross the epithelium stimulating an immune response.  In depth analysis 
of the gut microbiota and microbiome is required to allow further investigation of its role in 
the development and treatment of CD.  
 
1.3.5.1 Tools Used To Characterise the Intestinal Microbiome 
The composition of the gut microbiota varies along the gastrointestinal tract.  The stomach 
and duodenum are usually more sparsely colonised compared with the colon(128) and the 
microorganisms present within the small and large intestine vary as well.(129-132)  Further to 
this, the tools used to collect the microorganisms alters the microbiota’s composition; for 
example faecal samples contain different species of bacteria compared with mucosal 
samples.(133)   
 
Gut bacteria are classified into phyla, class, order, family, genus and species based on their 
genetic and functional similarities.   
Table 1.4 provides three examples of the scientific classification of bacteria from the most 
prevalent phyla, Bacteroidetes (gram negative) and Firmicutes (gram positive), and one of 
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the less abundant phyla Proteobacteria.  Bacteroidetes and Firmicutes constitute 
approximately 90 % of the bacteria in the gut followed by Actinobacteria and 
Proteobacteria.(133)   
 
Table 1.4.  Scientific classification of microorganisms. 
Scientific 
classification 
E. coli F. prausnitzii B. fragilis 
Characteristics Gram negative, 
anaerobic, produce 
vitamin K, some species 
are pathogenic(134) 
Gram-positive, 
abundant in healthy 








Phylum Proteobacteria Firmicutes Bacteroidetes 
Class Gammaproteobacteria Clostridia Bacteroidetes 
Order Enterobacteriales Clostridiales Bacteroidales 
Family Enterobacteriaceae Fuminococcacaea Bacteroidaceae 
Genus Escherichia Faecalibacterium Bacteroides 





Extensive microbiota data has become available with the advent of genetic sequencing 
techniques.  The early literature investigating the gut microbiota used bacterial culture 
methods which only identified a limited number of culturable species.  Older molecular 
techniques such as polymerase chain reaction (PCR), terminal restriction fragment length 
polymorphism (T-RLFP) and denaturating and temperature gradient gel electrophoresis 
(DGGE and TGGE) allowed profiling of communities, quantification of specific species and 
estimation of genetic diversity and abundance.  Newer genetic sequencing technologies have 
broadened our depth of knowledge of gut microorganisms, bacterial communities and their 
functions in the gut.   
 
Initially, sequencing technology focused on the 16S ribosomal RNA, which is a section of 
relatively stable section ribosomal RNA.  Data obtained using 16S rRNA sequencing resulted 
in the development of specific sequencing probes and has allowed more in depth research 
into the specific bacterial species.  The most recent advance has been next generation 
sequencing (pyrosequencing or metagenomics), which sequences all of the bacterial genes 
present in a sample.  Such genetic technology is rapidly improving and becoming faster and 
cheaper.  Pyrosequencing can provide data on both the type and the quantity of 
microorganisms present in a sample.  The sequencing data produced by both of these 
techniques are compared with genetic libraries in order to ascertain which bacteria are 
present in the sample.  DNA sequencing techniques produce a huge amount of data which 
require specialist bioinformatics skills to interpret and analyse.  
 
1.3.5.2 Dysbiosis in Crohn’s disease 
It is beyond the scope of this thesis to include a full literature review of dysbiosis in CD but 
this section summarises the main themes in the literature.  There is no one ‘normal’ CD 
microbiome profile.  Each person has their own unique microbiome,(132, 133, 137, 138) which is 
influenced by environmental and genetic factors, antibiotic use and diet.  Dietary substrates 
such as fibre have a significant impact on the composition of the microbiome.  A diet very 
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high in fibre and low in fat and animal protein, such as that consumed by rural African 
children, is associated with a faecal microbiota rich in Bacteroidetes with a lower relative 
abundance of Firmicutes.(139)  On the other hand, a typical Western diet high in animal 
protein, refined carbohydrates and fat and low in dietary fibre is associated with the presence 
of more Proteobacteria and a greater abundance of Firmicutes than Bacteroidetes.(139)  
 
CD is associated with significant dysbiosis, which likely has a key role in the development and 
resolution of inflammation.  As our functional understanding of the microbiome increases it 
has become apparent that gut microorganisms can stimulate the immune system and 
mitigate inflammatory processes.(140)  CD dysbiosis is characterised by reduced microbial 
diversity and reduced abundance of commensal bacteria.(118, 141, 142)  Additionally, recent 
research has shown that CD is not only associated with bacterial dysbiosis but fungal 
dysbiosis as well.(142)  
 
More recent literature has used 16S rRNA or metagenomic sequencing techniques to study 
dysbiosis in children and adults with CD and have found that active CD is often characterised 
by alterations in abundance of particular groups of bacteria and specific bacterial species.  





Table 1.5.  Characteristics of bacterial dysbiosis in children and adults with active CD. 









Genera Escherichia(121, 142, 143) 
Fusobacterium(143, 145) 




At a species level, F. prausnitzii is probably the most widely researched bacterial species in 
CD patients.  F. prausnitzii is a member of the Clostridia class of Firmicutes and in healthy 
populations is one the most abundant species of the Firmicutes phylum.(147)  One of the 
functions of F. prausnitzii is fermentation of dietary fibre and the production of butyrate, a 
short chain fatty acid (SCFA).  SCFAs are a source of fuel for colonocytes and are thought to 
prevent cell death and maintain the integrity of the intestinal cell lining.(148)  Another major 
producer of butyrate in the gut are the Roseburia species (spp).(149)  The abundance of F. 
prausnitzii has consistently been found to be reduced in the faecal samples of patients with 
active CD.(143, 146)  F. prausnitzii, and other fibre fermenting and SCFA producing bacteria, are 
also thought to maintain the health of the intestinal mucus layer and inhibit inflammation via 
the protective effect of SCFAs.(150)   
 
Dietary fibre intake has a significant impact on the abundance of F. prausnitzii in faecal 
samples.  In both healthy volunteers and people with active CD the consumption of a fibre 
deficient liquid diet results in a significant reduction in the abundance of F. prausnitzii,(151, 152) 
despite reduced gut inflammation in the patients with active CD.(152)  Previous studies have 
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not yet confirmed whether reduced abundance of F. prausnitzii during active colitis is a 
result of consuming a lower fibre diet during periods of active disease or a function of active 
disease.  
 
1.3.5.3 Impact of Nutritional Therapy on the Microbiome 
Considering that microbiome dysbiosis is prevalent in CD and that gut bacteria appear to 
have an active role in intestinal inflammation, it would be useful to have a greater 
understanding of the impact on the microbiome of nutritional therapies, such as EEN, used 
to manage CD.   
 
The effect of EEN on microbial diversity in children has been studied by various groups and 
was recently reviewed.(153)  Essentially, treatment with EEN has been shown to further reduce 
the diversity of the faecal microbiota, along with further reductions in the abundance of fibre 
fermenting species including F. prausnitzii despite children achieving disease remission on 
the treatment.(152, 153)  After treatment with EEN concluded, and children were re-established 
on their usual diet, microbiota diversity increased.(152) 
 
As our knowledge of the microbiome and the function of specific bacterial species grows 
there may come a time when gut bacteria, or microbial metabolites, become therapeutic 
targets of the clinical management of IBD.  Given that a reduction in abundance of SCFA 
producing bacterial genera are associated with IBD dysbiosis(143) the use of fibre containing 
diets as an IBD maintenance treatment has recently been studied.  A USA study of 1130 
patients with CD and 489 with UC found that a lower dietary fibre intake was associated with 
a past history of surgery and hospitalisations, being female and having CD.(154)  The study also 
found that in patients with CD (but not UC), those with the highest fibre intake (median 
intake 23.7 g/day) had an adjusted OR of 0.57 (95 %CI (0.37 - 0.87)) of having a flare within 
six months compared with those in the lowest quartile of fibre intake (median intake 10.4 
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g/day).  In the study by Brotherton et al.(154), researchers did not explore the reasons for fibre 
restriction in the study participants but suggest that further studies investigate this practice.  
They also did not have accurate information on patient disease phenotypes but suggest that 
prospective studies are needed to further explore the use of dietary fibre in certain disease 
phenotypes (for example, non-stricturing disease).(154)  Furthermore, investigation of the 
association between dietary fibre intake, abundance of SCFA producing bacteria and CD 
flares would be helpful to further our understanding of the role nutrition may, or may not, 
play in gut inflammation. 
 
At present it is not fully understood how dysbiosis contributes in IBD outcomes, however 
there is much research being conducted investigating the role of the intestinal microbiome in 
IBD and how manipulating it may alter outcomes.  Such research may allow for more 
targeted and individualised dietary and nutritional interventions. 
 
1.4 Nutrition Therapy in the Treatment of Crohn’s Disease 
For most adult populations, EEN is not recognised as a first line therapy for newly diagnosed, 
or pre-existing, CD.  European(36) and North American(37) clinical guidelines recommend EEN 
if a patient declines drug therapy or as an adjunctive therapy to support nutrition status, 
rather than as a primary therapy.  These recommendations are primarily based on the results 
of a 2006 Cochrane systematic review of six randomised controlled trials including 192 
patients treated with EEN and 160 patients treated with CS.(38)  The review found a pooled 
OR of 0.33 (95 % CI: 0.21-0.53) in favour of CS and concluded that CS were superior to EEN 
in the induction of remission of CD.  In contrast to these guidelines, published Japanese 
experience demonstrates the efficacy of EEN to treat active CD in adult populations.(35)  It is 
not clear why the benefits of EEN therapy observed in paediatric populations have not to date 
been achieved in Western adult populations but, given the potential benefits of the nutrition 
treatment (as discussed in section 1.2.2) and the limited side effects compared with CS 
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treatment, it is worthwhile exploring whether EEN could be a useful first line treatment for 
Western adults. 
 
1.4.1 Exclusive Enteral Nutrition for Adults with active Crohn’s Disease 
The following sections will outline the current evidence for and against the use of EEN in the 
treatment of adults with active CD.  Also, some of the potential reasons for the discrepancy of 
results between the adult and paediatric EEN studies are explored. 
   
1.4.1.1 Exclusive Enteral Nutrition Compared to Corticosteroids to 
Induce Remission 
Eleven studies, published between 1984 and 2002, have compared EEN with CS treatment in 
adults (Table 1.6).  Two of these were abstracts(155, 156) and the rest were full articles.  The 
studies were conducted in Europe, North America and Asia: three in England,(17, 129, 155) one in 
Spain,(157) one in Greece,(156) one in Italy,(158) one in the United States of American,(159) one in 
Japan(160) and three(161-163) were multi-centre European trials.  All but two studies enrolled a 
mix of patients with newly diagnosed CD (naïve to prior treatment) and existing CD.  All but 




Table 1.6.  Studies of adults that compared EEN with corticosteroid therapy. 
   Participants 
(n) 
Disease remission 
(%) (intention to 
treat) 
 EEN intervention 








(% of EEN 
group) 
EEN CS EEN CS Significant 
difference 
(p value) 








1993 England 23-54 Not stated 7 4 100% 100% P= NS HBI < 6.0 0 0 100% 100% 
Gassull et al 
a (161) 
2002 Europe  31.3 (3.3) 50% 20 19 20% 79% P = 
0.0005 
VHAI < 120 5 (25%) 0 27% 79% 
Gassull et al 
b (161) 
2002 Europe  30.8 (4.1) 43.5% 23 19 52% 79% P = NS VHAI < 120 4 (17%) 0 63% 79% 
Gonzalez-
Huix et al(157) 





31.6 (3.0) 50% 22 20 45% 85% P < 0.05 HBI – mean < 2 9 (41%) 2 91% 89% 
Lindor et 
al(159) 
1992 USA 34.7 (26–
64) 
33% 9 10 50% 33% P = NS CDAI decrease > 
100 points 
3 (33%) 1 60% 63% 
Lochs et 
al(162) 
1991 Europe  27.5 (1.5) Not stated 55 52 53% 79% P < 0.01 CDAI decrease > 
100 points or 40% 
7 (13%) 0 60% 85% 
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  Participants 
(n) 
Disease remission 
(%) (intention to 
treat) 
 EEN intervention 











(% of EEN 
group) 
EEN CS EEN CS Significant 
difference 
(p value) 








1990 Europe  30.1 
(11.5) 
20% 51 44 41% 71% P < 0.05 CDAI decrease > 
100 points 40 %  
20 (39%) 0 71% 91% 
Mantzaris et 
al(156) 
1996 Greece Not 
stated 
20% 10 10 40% 70% P = NS CDAI < 150 or 
decrease > 100  
0 0 40% 70% 
Okada et 
al(160) 
1990 Japan 21.0 
(3.3) 
100% 10 10 80% 30% P < 0.01 HBI < 1 0 0 80% 30% 
O’Morain et 
al (17) 
1984 England 31.9  
(15–60) 
100% 11 10 82% 80% P = NS HBI – mean < 3 2 (18%) 0 100% 100% 
Zoli et al(158) 1997 Italy 33.5 
(15.9) 
Not stated 12 10 67% 50% P = NS HBI < 3 1 (8%) 1 80% 50% 
Notes: a, b = Gassull et al had two EEN arms: a – high oleic fatty acid formula, b – high linoleic fatty acid formula  
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EEN        CS 
Engelman et al(155) Peptamen Semi-EF 2 1.0  Pro 16, CHO 51, 
Fat 33 
Orally 30 – 35  100% 100% 
Gassull et al(161) High oleic acid  PF 
(powder) 




Not stated 27% 79% 
Gassull et al(161) High linoleic acid  PF 
(powder) 




Not stated 63% 79% 
Gonzalez-Huix et al(157) Edanec HN PF 4 1.0  Pro 22, CHO 46, 
Fat 32 
NGT Not stated 80% 88% 
Gorard et al(129) Vivonex TEN EF 4 1.0  Pro 15, CHO 82, 
Fat 3 
Orally, or NGT 2100 kcal/day 91% 89% 
Lindor et al(159) Vital HN Semi-EF 4 1.0  Pro 17, CHO 74, 
Fat 9 
Orally 40  60% 63% 
Lochs et al(162) Peptisorb Semi-EF  4-6 1.0  Pro 16, CHO 69, 
Fat 15 
NGT or NDT 35  60% 85% 
Malchow et al(163) Survimed Semi-EF   3–6 1.0  Pro 14, CHO 76, 
Fat 10 
























EEN        CS 
Mantzaris et al(156) Nutrison HE PF 4 1.5  Pro 16, CHO 49, 
Fat 35 
NDT 2250 kcal/day 40% 70% 
Okada et al(160) Elental  EF  6 1.0  Pro 19, CHO 81, 
Fat 1 
NDT 40 – 60  80% 30% 
O’Morain et al(17) Vivonex EF 4 1.0  Pro 15, CHO 82, 
Fat 3 
Orally, or NGT 40 – 60  100% 100% 
Zoli et al(158) Peptamen Semi-EF   2 1.0  Pro 16, CHO 51, 
Fat 33 
Orally Not stated 80% 50% 
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These studies utilised a range of nutritional products, in varying regimens, as summarised in 
Table 1.7.  Eight of the studies used elemental formula (EF) and three studies used polymeric 
formula (PF).  Most formulae were 1 kcal/ml concentration apart from one which used a 1.5 
kcal/ml formula.  Duration of EEN treatment ranged from 2–6 weeks but most studies used 
EEN therapy for four weeks.  Mode of delivery of the EN formula was either oral, via a 
nasogastric tube (NGT) if not tolerated orally, continuous feeding via a NGT or nasoduodenal 
tube (NDT).  Nutrition composition of the formulae varied depending on the type and brand 
of formula used.  All formulae had relatively similar amounts of protein (14–22 % of total 
energy), whereas fat content varied considerably (1–35 % of total energy).  Carbohydrate 
content varied relative to fat content (49–82 % of total energy).   
 
The only study that compared two different enteral formulae and CS was published by 
Gassull et al.(161) They compared two formulae that were the same except for the predominant 
type of fat: one was high in oleic acid and the other was high in linoleic acid.  Study 
recruitment was ended prematurely because less than 33 % of the high oleic acid formula 
group had achieved disease remission and the remission rate was significantly different from 
that of the other treatments.  
 
Corticosteroid protocols also ranged between the evaluated studies.  Usual initial CS dosage 
was between 0.5 mg/kg/day and 1.0 mg/kg/day, with subsequent weaning courses.  CS were 
given orally in two studies(157, 161) but the route of administration was not specified in the 
majority of studies.  Two studies administered CS and sulfasalazine (anti-inflammatory) 
concurrently.(162, 163) 
 
Withdrawals from treatment varied between studies.  EEN study group withdrawals were 
mostly due to unpalatable EN formula (Table 1.6).  The number of withdrawals for this 
reason was as high as 41 % of the EEN group in one study but 0 % in other EEN study groups.  
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Occasionally patients had to withdraw in situations where urgent surgery was required.  
Withdrawals from CS groups were much lower.  Common reasons cited for withdrawing were 
side effects, non-compliance with treatment or urgent surgery was required. 
 
All 11 of the studies recorded the disease location of patients.  The majority of patients had 
ileocolonic disease and smaller numbers had ileal or isolated colonic disease.  No studies 
found disease location to be associated with the likelihood of achieving disease remission 
using EEN or CS therapy.  
 
The age of the participants was recorded differently across the 11 studies.  The mean age of 
patients enrolled in the studies was 27.5–34.7 years old.  Inclusion of older adults aged 50 - 
70 was not uncommon.  Only one study included mostly younger adults (mean 21.0 ± 3.3 
years).(160)   
 
Disease remission was achieved with EEN therapy on an intention to treat basis in 20–100 % 
of patients and 30–100 % of patients on CS therapy (Table 1.6).  Seven of the 11 studies found 
no significant difference between EEN and CS treatments to induce disease remission.(17, 155-
159, 161)  Of those patients who completed the course of EEN therapy disease remission was 
achieved in 23 – 100 % of patients and in 30 – 100 % of patients that completed CS 
treatment.(17, 129, 155-163)  Patients who did not complete the course of EEN therapy were usually 
withdrawn from the study and started on CS therapy. 
 
1.4.1.2 Factors That May Influence Exclusive Enteral Nutrition Outcomes 
There are multiple factors which may influence treatment outcomes in adults treated with 




The disease remission criteria used by researchers can have a profound impact on the study 
results.  Comparison of disease remission rates between studies is challenging when disease 
remission is not universally defined.  Five of the 11 studies that compared EEN with CS used 
the HBI to measure disease remission.(17, 129, 155, 158, 160)  Two of the studies that used the HBI 
did not describe their remission criteria;(17, 129) however, the mean HBI of participants after 
the EEN intervention was less than 4, which corresponds with standard interpretations of 
clinical remission.  Another study used a HBI cut off of less than six points with 100 % of 
participants in both the EEN and CS therapy groups achieving remission in this study.(155)  
The fourth study to use the HBI used a cut-off of 0–1 points to define disease remission.(160)  
Of the CS group only 30 % of patients achieved remission using this criterion compared with 
80 % of the EEN group.  It is unknown if a more liberal cut-off would have increased the 
number of patients achieving disease remission in the CS group.  In all of these five studies at 
least 80 % of the EEN group participants that completed the course of EEN achieved disease 
remission using the HBI.  
 
Four of the 11 studies used the CDAI to measure disease remission.(156, 159, 162, 163)  The 
remission rates of the EEN therapy group in all four studies were low (40 – 53 %), with the 
two larger studies  concluding that, on an intention to treat basis, CS therapy induces disease 
remission in significantly more patients that EEN therapy.(162, 163)  In two of the studies at 
least one third of the patients withdrew from the EEN group due to unpalatable formula.(159, 
163)  Withdrawals from the CS groups were much lower (20 % or less).  Of those that did 
complete the course of EEN therapy only 40 – 71 % of patients achieved disease remission, 
whereas remission was achieved in 62 – 98 % of those that completed the course of CS 
therapy.  The disease remission rates of the two studies that used the VHAI to define disease 
remission were quite different.  Gassull et al(161) hypothesised that the formula high in linoleic 
acid, an n-6 polyunsaturated fat, would be less effective than a high monounsaturated fatty 
acid formula because n-6 fatty acids are pro-inflammatory precursors.  Of the 20 patients 
enrolled in the high oleic acid EEN group only 20 % achieved disease remission after 4 weeks 
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of therapy, compared with 52 % of the high linoleic acid group and 79 % of those using CS 
therapy.  This research suggests that the type of fat in EEN formulae may affect the efficacy of 
EEN therapy however, another study that compared similar formulae found no difference 
between high and low long chain triglyceride formulae.(164)  The other study that used the 
VHAI to define disease remission found that EEN therapy was as effective as CS therapy: 80 
% of those on EEN therapy achieved disease remission compared with 88 % of those using CS 
therapy.(157) 
 
The criteria used to define disease remission should not impact greatly on the results of the 
study; however, in this case, the studies can be grouped into categories based on the 
remission criteria applied;   
 studies that used the HBI found that EEN therapy was at least as effective as CS 
therapy in inducing disease remission 
 larger studies that used the CDAI found that CS therapy was superior to EEN therapy  
 studies with small participant numbers found no significant difference 
 studies that used the VHAI found that there was no significant difference between 
polyunsaturated PF and CS therapy, apart from the high monounsaturated fat 
formula study 
 
Based on the observation that only studies using the CDAI found that CS was superior to 
EEN, future research into the use of EEN with adults should consider using the CDAI to 
define the effectiveness of EEN to induce disease remission.  It should also be noted that 
there may be differences in study protocols between studies with higher and lower patient 
numbers that could influence patient outcomes, such as patient support to initiate and 




There is some evidence to suggest that EEN therapy is more effective in newly diagnosed CD 
patients compared with patients who have existing CD.(29)  Day et al(29) showed that, of 15 
newly diagnosed CD patients, 12 (80 %) entered remission after eight weeks of EEN, whereas 
only seven of the 12 (58 %) children with long-standing disease entered remission (p > 0.05).  
In other paediatric studies with newly diagnosed CD patients disease remission was achieved 
in 79 – 93 % of those that completed EEN treatment and 70 – 79 % on an intention-to-treat 
basis.(28, 165) 
 
Differences in treatment response rates according to time since diagnosis are not limited to 
EEN therapy.  Response and remission rates achieved with biologic therapy are better in 
children than adults(166) which may, in part, be due to the duration of disease prior to 
initiation of the treatment.  Similarly, adults with a shorter duration of CD are more likely to 
respond and achieve remission with biologic therapy.(166)  The use of immune-modulators 
early in the disease course in adults and children has also been shown to reduce the 
probability of long term CS and need for intestinal surgeries.(167) 
 
Two studies of adult patients have compared EEN with CS therapy in treatment-naïve 
patients.(17, 160)  In both studies, 80 % of those treated with EEN achieved disease remission 
after 4 – 6 weeks of an elemental diet (comparable to remission rates in those treated with 
CS).  Other studies of adult patients comparing EEN with CS have not differentiated between 
patients with newly diagnosed CD and existing CD in their analyses.  One study, with only 
two newly diagnosed patients, mentioned that both patients responded to EEN treatment(156) 
but the numbers enrolled in the study were too small to show if there was a statistically 
significant difference in response to treatment between the two groups.  A study of 22 
patients treated with EEN found that EEN therapy was as effective in newly diagnosed 
patients as those with existing disease,(129) although 40 % of patients did not complete the 
course of EEN.  The authors do not indicate how many of those that completed EEN 
treatment had existing or newly diagnosed disease.  The two larger multi-centre European 
62 
 
trials did not differentiate between those that had and had not received previous CD 
treatment.(162, 163)  
 
Longer duration of CD is associated with more complications including tissue scaring, 
fistulae, abscess formation, strictures, perianal disease and bowel resections.(168)  EEN 
therapy has been shown to induce disease remission by reducing mucosal inflammation.(23, 
169, 170)  Complications of CD are often non-inflammatory in nature; therefore, EEN may be 
less effective in treating these patients.  Interestingly, a case series of three children with 
perianal disease at diagnosis found that EEN (used in combination with surgery and 
antibiotics) was effective at inducing disease remission and assisted in the healing of perianal 
disease.(171)  EEN was used as a maintenance therapy in all three children without the return 
of perianal disease.  A clinical trial has not been conducted to further investigate the potential 
role of EEN in the management of perianal CD.   
 
Overall, studies in adult patients of EEN compared with CS therapy have not excluded 
patients with complicated disease.  Usual exclusions included imminent surgery, intestinal 
perforation, ileus, abscesses, massive bleeding, short bowel syndrome with ileostomy and, in 
some cases, previous surgery.  The presence of other complications of existing CD such as 
scaring, perianal disease or previous bowel surgery is not detailed in the adult literature.  It is 
impossible to ascertain whether those who did not respond to EEN therapy had more or less 
complications than those who did respond.  Furthermore, the studies had only small 
numbers of patients within each disease sub-group and were unable to conduct in-depth 
statistical analysis of these sub-groups.  
 
Non-adherence with EEN treatment was a limiting factor in the success of EEN therapy in 
many studies.  A number of reasons for non-adherence of adult CD patients with EEN 
therapy have been postulated including poor taste of the formula, lack of support and poor 
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motivation to complete the treatment.  The characteristics of the EEN regimens that were 
used in the studies comparing EEN with CS treatment in adults are summarised in Table 1.7. 
 
Unpalatable EN formula was the most common reason for non-adherence in the studies 
performed to date.  Many early studies that compared EEN with CS treatment used elemental 
formulas.  Although, it is now known that EF and PF are equally effective at inducing 
remission of disease in children(172) and adults.(38)  The difference between PF and EF is that 
the protein fraction in PF is in its whole form rather than as individual amino acids or 
peptides in semi-elemental formulae. In addition, EF tend to have a lower total fat 
content.(172, 173)  EF have a distinctive smell and flavour mostly due to the presence of amino 
acids, which have a bitter flavour.  Bitterness is negatively correlated with palatability, 
whereas sweetness and sourness are positively correlated with palatability.(174)  Fat content 
may also affect the palatability of the formula.(175)  The EF used in the studies were low fat (1 - 
3 % of total energy) compared with semi-elemental (9 - 33 % of total energy) and PF (32 - 35 
% of total energy).  PF are therefore thought to be more palatable.  However, there is limited 
research comparing the palatability of the two formula types.  A retrospective study of 
children who received EF from 1992 – 2001 and children who received PF from 2000 – 2004 
found that adherence to treatment did not differ between the two groups but that those 
receiving PF were less likely to need a NGT inserted to deliver the feed.(176)   
 
The mode of delivery of the formula may also play a role in patient compliance.  Many studies 
with high adherence rates administered EF via NG or NDT rather than orally.  More recent 
paediatric studies have encouraged oral intake of PF and use of NG tubes only if needed.(28, 29, 
165)  For free living (non-hospitalised) patients, taking the formula orally may be more socially 




Studies that used EF given exclusively via NG or NDT had low rates of non-adherence (0 – 13 
%).(160, 162)  Whereas studies that reported high rates of non-adherence (33 – 41 %) used EF or 
semi-EF given orally and if a patient did not tolerate EEN orally a NGT was placed.(129, 159, 163)  
However, three of the six studies using EF or semi-EF orally reported higher adherence 
rates.(17, 155, 158)  Two of these studies(155, 158) only used EEN for 2 weeks and patients were given 
a peptide based semi-EF (Peptamen) orally rather than an amino acid-based EF.  Of the 19 
patients using EEN in these two trials, only 1 patient was non-adherent with the treatment.  
The third study, by O’Morain et al,(17) was one of the first to compare EEN to CS treatment.  
Patients were asked to take the EF orally for four weeks and if they could not tolerate it a 
NGT was placed.  Of the 11 patients in the EEN group, two (18 %) could not tolerate the 
formula orally or via a NGT.   
 
Of the three adult studies that used PF, two administered it via NG or NDT with 100 % 
adherence.(156, 157)  The third study used a PF powder (a high oleic and high linoleic acid 
formulation) given orally or via NGT if not tolerated orally.(161)  Non-adherence with the 
treatment was 17 -25 %.  No published adult studies have used a ready-to-drink PF given 
orally.  There are, however, various studies with children that have shown that PF are 
palatable orally.  Borrelli et al(28) studied 19 children with CD who drank an isocaloric PF 
(Modulen) as their sole source of nutrition for 10 weeks.  Thirteen children took the formula 
orally; four required overnight feeding via a NGT, in addition to taking it orally during the 
day, to meet their nutritional requirements and two children could not manage to take the 
required volume of formula orally or via a NGT.  Of the 17 children that successfully 
completed the 10 week intervention 15 (88 %) achieved disease remission.  Day et al(29) 
studied 27 children with CD who were prescribed EEN with isocaloric PF (Modulen or 
Osmolite) for up to 8 weeks.  Nineteen children managed the required volume of formula 
orally, five needed to take some of the formula via a NGT and three could not tolerate the 
required volume orally or via a NGT.  Of the 24 children who completed at least 8 weeks of 




Both of these paediatric studies used an isocaloric PF.  It appears that the major reason for 
non-adherence in these cohorts was difficulty tolerating the volume required for nutritional 
requirements rather than unpalatable formula. It is not clear whether the volume required to 
meet an adult’s nutritional requirements (e.g. 8 - 12 cartons (200 ml) of ready-to-drink 
isocaloric PF per day) may lead to poor adherence.  The use of a concentrated PF, (e.g. 1.5 
kcal/ml formula), may help alleviate this issue. 
 
Disease location is thought to affect the efficacy of EEN therapy.  In particular, colonic 
disease may be more refractory to treatment than disease with ileal involvement.  However, 
due to the small participant numbers in most adult EEN studies there has been insufficient 
statistical power for subgroup analyses.  A pooled meta-analysis of mainly adult studies from 
the 1980s and 1990s found that there was insufficient data to perform subgroup analyses by 
disease location.(38)  
 
Some paediatric studies have specifically investigated the impact of disease location on 
response to EEN therapy.  Afzal et al(33) studied 65 children aged 8–17 years old with newly 
diagnosed CD of which 12 had ileal disease, 39 had ileocolonic disease and 14 had isolated 
colonic disease.  This study found that disease remission was harder to induce with EEN 
therapy in patients with colonic disease – remission achieved in 50 % compared with 82 % in 
those with ileocolonic disease and 92 % in those with ileal CD (p = 0.02).  This study also 
used colonoscopy to assess mucosal healing after EEN therapy and found that there was no 
improvement in colonic mucosal inflammation in those with colonic or ileocolonic disease.  
 
Conversely, Buchanan et al(11) investigated the effect of disease location on remission rates 
after EEN therapy and found that colonic CD responded just as well as ileocolonic disease.  
This study included 114 children (median age 11.6 years), all with recently diagnosed CD.  
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Nineteen patients had colonic disease, four had ileal disease, 29 had ileocolonic disease, 49 
had upper gastrointestinal tract disease and 9 had disease that could be not be classified 
using the Vienna classification. Of those with colonic disease 79 % went into remission after 
eight weeks of EEN therapy compared with 86 % with ileocolonic disease, 88 % with upper 
gastrointestinal disease and only 25 % with ileal disease.  It should be noted that there were 
only 4 patients with ileal disease compared with at least 20 in the other three groups.  
Further evidence is needed to confirm whether CD location affects the efficacy of EEN.   
 
Current guidelines suggest that EEN therapy is more appropriate treatment in paediatric 
rather than adult patients.(26, 38)  There are no studies with adults that have assessed whether 
age affects response to EEN therapy.  Although, the mean age of adults included in the 11 
EEN compared with CS studies was approximately 30 years, the age range varied 
substantially and was not always published.  Of those studies that did publish the age range 
of patients it was common to include patients aged 20 up to 50 or 60.(17, 155, 159) It is unknown 
if age affects response to EEN therapy, or if duration of disease, rather than age, may have a 
great impact on outcomes.  Age may well influence compliance with treatment and further 
research is required to investigate whether EEN compliance is influenced by factors 
associated with age, for example social impacts of excluding usual foods and fluids. 
 
1.4.2 Partial Enteral Nutrition for the Treatment of Active Crohn’s 
Disease 
There is much evidence to support the use of EEN in the treatment of CD and also positive 
Japanese data to support the use of supplementary EN, after disease remission is achieved 
with EEN, to assist in the maintenance of disease remission.(35, 177)  In  Japan, CD treatment 
guidelines recommend patients consume 900-1200 kcal/day from an elemental enteral 
nutrition formula(178) as a maintenance therapy.  This volume corresponds to 50 % of total 
energy from enteral formula.  Two Japanese studies have shown that supplementary EN 
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reduces disease relapse compared with consuming a free diet or a free diet plus less than 900 
kcal/day of EN.(35, 177)   
 
The use of EN in combination with a solid food diet (partial EN) has been scarcely 
investigated as a means to induce CD remission.  To date, partial EN (PEN) as a treatment to 
induce disease remission has been investigated in only three prospective studies (Table 1.8).  
Two of these studies(179, 180) included children and adolescents and allowed the consumption 
of unrestricted normal foods in addition to an EF.  The third study(181) included children and 
young adults and used PF with a specific exclusion diet which included 18 – 20 g of fibre per 
day and was gluten, dairy, animal fat, emulsifier and preservative free.  The median energy 
intake from enteral formula was approximately 50 % of total energy in all three studies, 
although in the Lee et al(179) study there was a large range of 25 – 90% of total energy.     
 
In these three studies,(179-181) intention-to-treat disease remission subsequent to PEN varied 
from 15 – 70 % of patients and, EEN was found to be more effective at inducing disease 
remission in both of the studies that compared the two treatments.(179, 180)  In the 2006 study 
by Johnson et al(180) only 15% of patients achieved disease remission, additionally disease 
remission was only achieved by 42 % of patients on EEN and one third of the patients in this 
group withdrew from the study early.  Given that the remission rates on EEN observed in this 
study are much lower than the greater than 75 % of paediatric patients quoted in most of the 
paediatric EEN literature(27) it may be expected that treatment success with PEN was poor.  
 
The use of a specific exclusion diet in conjunction with a polymeric formula produced the 
most positive PEN results and used the most stringent disease remission criteria (Paediatric 
Crohn’s disease activity index (PCDAI) < 7.5 or HBI <4).  Disease remission was achieved in 
27 of the 40 patients (67 %) that used PEN and 10 patients (25 %) failed to complete the 
treatment.(181)  Authors attributed the higher response rate, compared to the previous PEN 
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study by Johnson et al, to the dietary exclusions.  Their justification for this was that seven of 
the enrolled patients who did not tolerate the polymeric formula followed exclusively the 
dietary regimen and six of these patients achieved disease remission.  Also, another seven 
patients had previously been using PEN with a free diet but when they changed to using the 
exclusion diet with PEN their disease responded to the treatment and went into clinical 
remission.(181)   
 
The most recent PEN study by Lee et al(179) further supports Signall-Boneh et al’s hypothesis.  
In this study patients were prescribed 80 % of their estimated energy requirements (EER) 
from EN but were allowed to consume an unrestricted free diet as well.  Patients on average 
consumed 78 % of their EER from formula but then consumed another 73 % of their EER 
from regular food and drinks.  Overall, regular food contributed 50 % TE intake, similar to 
the other two studies.  The authors concluded that EEN is more effective than PEN because 
EEN primarily excludes aggravating dietary factors rather than just providing adequate 
amounts of nutrients. 
   
This research provides some evidence that it may be possible for children and young adults to 
include some food in an EN treatment regimen.  The optimal ratio of food to EN is not yet 
known and more evidence is required to be able to recommend a specific exclusion diet.  It is 
not yet known whether a PEN regimen is applicable to a wider portion of the adult CD 
population.  The EEN research suggests that adherence to EEN is poor with adult 
populations therefore maybe a more liberal regimen such as PEN would be more appealing to 




Table 1.8.  Treatment of active Crohn's disease with partial enteral nutriton. 
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n (%) (PP)* 
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Johnson et 
al(180) 
2006 UK 12  
(3.8-16.0) 
24 26 Elemental 028 
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2015 USA 12  
(7.2-17.8) 
22 16 PEN: Peptamen 















2014 Israel 16  
(9-31) 






for 50 % 
- 70 - - 27/40  
(68) 




Initial reports(17, 182) demonstrated that EEN was effective in inducing remission in adults with 
active CD and proposed this intervention as an alternative to CS therapy.  However, subsequent 
larger studies failed to reproduce these results.(162, 163)  Since then many studies have been 
conducted in paediatric populations and numerous benefits over and above achieving disease 
remission have become apparent.  It therefore seems timely to readdress the disparity between 
the results achieved in paediatric EEN studies compared to the adult EEN studies.  One of the 
main limiting factors in the success of EEN in the adult literature is the high treatment 
withdrawal rate.  To overcome this the use of polymeric formula provided orally, which has not 
previously been studied in adult patients, may improve treatment compliance and allow adult 
patients to reap the many other benefits of EEN that have been shown in children over and 
above achieving disease remission and improving nutritional status.  Additionally, investigating 
patient interest in such EN treatment is fundamental, as is understanding the experience and 
knowledge of gastroenterologists and dietitians that would be involved in recommending and 





The specific hypotheses generated for this thesis all stem from the overarching hypothesis that 
nutritional therapy modulates gut inflammation in young adults with CD leading to clinical and 
biochemical remission.  The hypotheses that are explored in this research thesis are: 
 That polymeric nutritional formula is more palatable than elemental nutritional formula. 
 That adults with CD are interested in using nutritional therapies in place of corticosteroid 
treatments. 
 That enteral nutrition therapy induces clinical and biochemical (faecal and serum 
markers of inflammation) disease remission in adults with active CD. 
 That enteral nutrition therapy improves markers of nutritional status in adults with 
active CD.  
 That enteral nutrition therapy is associated with improved HRQOL scores in adults with 
active CD. 
 That enteral nutrition therapy alters faecal microbiota structure in adults with active CD 
and healthy adults. 
 That treatment with a PEN regimen induces disease remission as effectively as EEN in 
adults with active CD. 
 That gastroenterology health professionals have limited experience with, and awareness 
of, EEN in adult patients with active CD. 
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     Chapter 2 
Methods 
2.1 Clinical Trial  
2.1.1 Recruitment of Patients 
A non-randomised pilot intervention clinical trial of patients aged 16 to 40 years old with active 
CD involving the ileum was undertaken over a 48 month (4 year) period.  Patients were eligible 
for the study if they had active Crohn’s disease and were willing to either consume EN (exclusive 
or partial) for eight weeks or undertake corticosteroid treatment.  However, patients were 
excluded if they had isolated colonic disease, active psychological illness or had taken 
corticosteroids in the last fortnight.  Concomitant use of other CD medications did not limit 
eligibility.  The patient inclusion and exclusion criteria were designed based on literature 
presented in Chapter 1, section 1.4.1.2.  An upper age limit of 40 years old was chosen for two 
reasons; firstly the Montreal classification (Table 2.1) divides adult patients into two age 
categories, 16 to 40 years and greater than 40 years therefore by following this construct this 
research may more easily be compared with similar studies.  Secondly, older patients may have 
had CD for a longer period of time and as discussed in Chapter 1, section 1.4.1.2 patients with 
long standing disease may respond differently compared with patients with more recent disease 
onset.  Local gastroenterologists referred eligible patients, following patient agreement, to the 
candidate who was a registered NZ dietitian.  Upon receiving the referral the candidate contacted 
the patient, explained the study, sent written information to the patient as required and 
arranged an initial appointment if the patient consented to take part.  The target for recruitment 





Initially only patients with newly diagnosed CD were eligible for the study.  A diagnosis of CD 
was confirmed by endoscopy and/or histology reports and the location and behaviour of disease 
was classified according to the Montreal classification (Table 2.1).(183)  However, study 
recruitment was slower than expected therefore the inclusion criteria were revised to include 
patients with existing CD having a flare.  A patient was defined as having a flare if they had an 
elevated faecal calprotectin or elevated inflammatory markers (C-reactive protein, erythrocyte 
sedimentation rate) or a CDAI of greater than 150.  This change in protocol required an 
amendment to the initial ethical approval application (section 2.1.2).  
 
 
Table 2.1.  Montreal classification of Crohn's disease.(183) 
Age at diagnosis A1 – below 16 years 
A2 – between 17 and 40 years 
A3 – above 40 years 
Location L1 – ileal 
 L2 – colon 
 L3 - ileocolonic 
 L4 – isolated upper disease* 
Behaviour B1 – non-stricturing, non-penetrating 
 B2 – stricturing 
 B3 – penetrating 
p   – perianal disease modifier# 
* L4 can be added to L1-l3 when concomitant upper gastrointestinal disease is present.  




2.1.2 Ethical Approval 
Ethical approval to conduct this clinical trial was given by the Northern B Health and Disability 
Ethics Committee on 2 April 2013 (ethics reference 13/NTB/11).  The initial application was to 
study patients with newly diagnosed CD.  An amendment, which allowed patients with existing 
disease having a flare as well as those with newly diagnosed disease to be recruited, to the study 
was approved on 20 March 2014 (ethics reference 13/NTB/11/AM01). 
 
In August 2014 a further amendment to the study protocol was submitted for ethical approval to 
the Health and Disability Ethics Committee.  This amendment was to recruit healthy volunteers 
with no history of gastrointestinal issues to use EEN for two weeks.  This amendment received 
ethical approval on 23 September 2014 (ethics reference 13/NTB/11/AM03). 
 
A final amendment to the original application was submitted for ethical approval in February 
2015.  Once at least 20 patients had been recruited to the EEN treatment an amendment to the 
study protocol was submitted to the Health and Disability Ethics Committee.  The original 
application included two interventions – standard treatment with corticosteroids or treatment 
with EEN.  This subsequent change to the study protocol was to replace the EEN treatment 
option with PEN treatment.  This amendment was approved on 26 February 2015 (ethics 
reference 13/NTB/11/AM04). 
 
2.1.3 Corticosteroid Treatment 
The standard first line treatment for adults with active Crohn’s disease is corticosteroids.  
Patients who chose to use corticosteroids, rather than nutrition therapy, started on a standard 
reducing dose, as per their gastroenterologist, of 40 mg orally for seven days and then 5 mg less 
every seven days until the dose had finished.  This medication course took eight weeks to 
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complete.  This treatment group had the same assessments as the EN treatment groups and are 
described in the subsequent sections. 
 
2.1.4 Intervention Treatment: Exclusive Enteral Nutrition  
In parallel to corticosteroid treatment, the research targeted the recruitment of 20 patients to the 
EEN intervention group.  Treatment with EEN required the patient to go without usual foods 
and fluids for eight weeks and drink a commercial polymeric 1.5 kcal/ml oral nutritional formula 
(Ensure Plus).  Ensure Plus is a ready-to-drink formula available in four flavours: chocolate, 
vanilla, fruits of the forest and banana.  The EEN nutritional formula provided patients with all 
of their calculated nutritional needs.  The macronutrient composition of each flavour was the 
same with the exception of saturated fat which varied from 0.44 to 0.48 g/100 mL.  Table 2.2 
describes the average nutrition composition of the formula.   
 
Each patient’s nutritional requirement was calculated based on their basal metabolic rate (see 
section 2.1.7.1 for further details) multiplied by a physical activity factor (Table 2.3).(184).  Based 
on this calculation a daily calorie target was set, for example seven x 200 ml tetrapaks (2100 
kcal/day).  In additional to the prescribed EEN, patients were also encouraged to drink at least 
1500 ml per day of additional fluids either as water and/or black unsweetened tea, coffee or 
herbal tea.  Caffeinated tea and coffee were allowed to reduce the potential impact of caffeine 
withdrawal on initial tolerance of the EEN regimen.  Patients were not encouraged to start 
drinking caffeinated beverages but rather to maintain their usual intake.  
 
The nutritional formula was provided on prescription with a special authority number and was 
delivered to the patient’s home or a specified delivery address.  The candidate applied for a 
special authority number for each patient and wrote the prescription.  This particular product is 
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only partially funded by PHARMAC therefore it has a surcharge.  This surcharge was paid by the 
research study, therefore each patient received the nutritional formula free of charge during the 
eight week intervention period.    
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Table 2.2.  Average nutrient composition of Ensure Plus (Abbott Nutrition) per 100 ml. 
Nutrient Unit Quantity Nutrient Unit Quantity 
Energy kJ (kcal) 632 (150) Carbohydrate,  
     Total 
g 20.20 
Protein g 6.25      Sugars g 6.80 
Fat, total g 4.92 Dietary Fibre, 
total 
g 0 
     Saturated g 0.44 Water g 77.43 
Vitamins   Minerals   
Vitamin A 
(palmitate) 
µg RE 88 Sodium mg 92 
Vitamin A (β-
carotene) 
µg RE 29 Potassium mg 160 
Vitamin D3 µg 2.0 Chloride mg 110 
Vitamin E mg α TE 2.1 Calcium mg 120 
Vitamin K1 µg 12 Phosphorus mg 100 
Vitamin C mg 12 Magnesium mg 30 
Folic acid mcg 40 Iron mg 2.1 
Vitamin B1 mg 0.20 Zinc mg 1.6 
Vitamin B2 mg 0.27 Manganese mg 0.50 
Vitamin B6 mg 0.27 Copper µg 220 
Vitamin B12 µg 0.55 Iodine µg 22 
Niacin mg NE 2.6 Selenium µg 8.3 
Pantothenic Acid mg 1.1 Chromium µg 13.5 
Biotin µg 6.0 Molybdenum µg 16 






Table 2.3.  Activity factors used to estimate daily calorie requirements.(184) 
Activity level Males Females 
Sedentary – very physically inactive in work and 
leisure 
1.3 1.3 
Lightly active  – some walking or intense activity 
1-2 x/week e.g. students 
1.6 1.5 
Moderately active – intense exercise 20-45 mins 
3x/week or active job 
1.7 1.6 
Very active – intense exercise > 60 mins daily or 






The EEN treatment was initiated over a three day period whereby each day one meal was 
replaced by one to two tetrapaks of nutritional formula.  By day four patients were expected to 
have only the nutritional formula and no other foods except specified liquids.  Tolerance of the 
treatment was assessed by telephone on day five and then again on day seven to ten depending 
on how well the patient tolerated the treatment on day five.  Tolerance of the treatment was 
assessed based on the patient’s ability to drink an adequate number of nutritional formula 
tetrapaks without worsening nausea, diarrhoea and/or abdominal pain compared with baseline. 
 
Anecdotally, an experienced paediatric dietitian and paediatric gastroenterologist at 
Christchurch Hospital had found that EEN can exacerbate existing reflux and nausea symptoms 
therefore, patients with known upper gastrointestinal CD or with a history of reflux were started 
on a proton pump inhibitor at baseline to help minimise intolerance of the EEN.  Patients with 
nausea at baseline were started on anti-nausea medication as per their gastroenterologist’s 
direction.  If a patient developed constipation, because of the fibre deficient EEN regimen, a 
stool softener called lactulose was initiated.  Patients typically took 20-30 ml of lactulose once 
daily or as required. 
 
Once established on the treatment, patients were assessed fortnightly at a formal study follow up 
appointment.  Patients were able to contact the candidate by text message or phone call between 
appointments as necessary.  Patients who did not tolerate EEN or did not respond to the 
treatment within the first four weeks were restarted on their usual diet and referred back to their 







Figure 2-1.  Clinical trial data collection time-points. 
 
Patients attended seven study assessment appointments; fortnightly during the eight week 
intervention phase and at four weeks and four months after completion of EN (Figure 2-1).  At 
each appointment the following were completed: body composition measures, blood and faecal 
inflammatory markers, blood nutrition markers, symptom questionnaires, quality of life 
questionnaires.  Patients also provided urine and stool samples for subsequent measurement of 
urinary metabolomics (results not presented in this thesis) and faecal microbiome analysis 
undertaken in collaboration with the Department of Microbiology and Immunology.   
 
At the end of the eight-week treatment patients reduced their consumption of the nutritional 
formula and increased their consumption of solid foods and usual fluids.  This was usually 
completed over a three day period.  Patients were given the option of continuing to use 200-400 
ml per day of nutritional formula as well as their usual diet to assist in maintaining disease 
remission and to maintain the nutritional quality of their diet.  The research study did not fund 




2.1.5 Intervention Treatment: Partial Enteral Nutrition 
The target was to recruit 20 patients to the PEN intervention group.  Treatment with PEN was 
also an eight week intervention consisting of two weeks of EEN followed by six weeks of PEN 
with one small meal per day.  Patients underwent the same assessments as detailed in the EEN 
section 2.1.4.  The use of EEN for two weeks was chosen based on a combination of observations.  
Firstly, the pilot faecal microbiota analysis of six patients who had used EEN (presented in 
Chapter 7).  This analysis showed that there was a change in the faecal microbiota within two 
weeks of using EEN (Figure 7-1 and Figure 7-2).  Secondly, clinical preliminary data from the EEN 
cohort of the study showed that serum inflammatory markers and symptoms of active disease 
started to improve with two weeks of EEN treatment.  Lastly, the PEN regimen was designed to 
be a more attractive treatment option then EEN whilst still optimising treatment outcomes.  It 
was felt that two weeks of EEN would be achievable for most patients and just long enough to see 
improvements in markers of inflammation before regular food was re-introduced. 
 
 
After two weeks of EEN patients were provided guidelines on how to introduce one small meal 
per day of solid food in conjunction with EN.  The one small meal per day was to provide no 
more than 33 % of total daily calories with the remaining calories and nutrients provided by the 
nutritional formula.  The ratio of nutritional formula to solid food was calculated based on each 
patient’s intake of nutritional formula during the first two weeks and any change in weight.  Each 
patient chose whether they ate the meal at lunch or dinner and they could alternate the timing of 
the solid food meal depending on social engagements.  Lunch and dinner were chosen over 
breakfast because these meals are more likely to contain larger amounts of protein and vegetable 
fibre than breakfast which can help reduce reliance on lactulose as a result of following the fibre 
deficient EEN diet.  Patients were encouraged to eat a balanced meal including foods that 
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contributed protein (meat, fish, chicken, eggs, and legumes), carbohydrate (rice, bread, pasta, 
starchy vegetables) and fibre (vegetables).   
 
A list of foods was provided to assist with the transition from EEN to EN plus one meal of solid 
food.  This food list broke foods into three categories based on their fat and fibre content 
(Appendix A).  Patients started at phase 1, which included low fibre bland foods with no pips, 
seeds and skins.  Patients were encouraged to move from phase 1 to 2 and then onto phase 3 
based on their own tolerance of the foods.  At the end of the eight-week treatment, it was 
expected that patients would be able to eat a greater range of foods including foods from all three 
of the food phases.  Nutrient intake during the six weeks of PEN was assessed using an electronic 
food diary.  Details of the food diary and nutrient analysis are described in section 2.1.12 of the 
methods section.  
 
At the end of the eight week treatment patients reduced their consumption of the nutritional 
formula and increased their consumption of solid foods and usual fluids.  Patients were given the 
option of continuing to use 200-400 ml per day of nutritional formula as well as their usual diet 
to assist in maintaining disease remission and to maintain the nutritional quality of their diet.   
 
2.1.6 Intervention in Healthy Controls: Exclusive Enteral Nutrition 
Healthy individuals who were willing to consume a nutritional formula (Abbott Nutrition, 
Ensure Plus) as their sole source of nutrition for two weeks were recruited as control subjects 
primarily for faecal microbiome analysis and secondly to compare changes in body composition 
subsequent to the intervention and tolerance of the intervention.  Subjects had no history of 
gastrointestinal problems and did not have first degree relatives with CD.  The healthy controls 
(HC) were initially recruited through current and previous EEN study patients (e.g. partners, 
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flatmates, friends) and then via advertisements at the university.  The HC completed two weeks 
of EEN in the same fashion as patients with CD: three days of phasing in EN and phasing out 
solid food and then 10 days of EEN.  Their nutritional requirements were calculated based on 
basal metabolite rate data from bioimpedance analysis (details in section 2.1.7.1) and usual 
physical activity levels (Table 2.3).  Tolerance of the EEN was monitored by text message and 
phone calls at day four or five and then day seven or eight.  The HC provided stool samples at 
baseline, week 2 and week 6 (four weeks after completing EEN).  At these time points they also 
had weight and bioimpedance measurements (detailed in section 2.1.7.1).  They did not provide 
blood samples or answer any quality of life questionnaires. 
 
2.1.7 Body Composition Analysis 
At the initial appointment, height was measured using a static tape measure attached to a wall.  
Participants stood without shoes with their heels against the wall and looked straight ahead.  The 
tape measure was lowered to touch the crown of the head and a height reading was taken.  At 
each appointment, participants had their body weight recorded using electronic scales (Tanita 
SC-330, Tania Corporation, Japan) without shoes and in light clothing.  Participants with CD 
had a waist and hip circumference taken at baseline and week 8.  Waist circumference was 
measured at the midpoint between the bottom rib and the iliac crest.  Hip circumference was 
taken at the widest part around the middle of the buttocks.  A hip to waist ratio was then 
calculated. 
 
Body composition was measured using bioimpedance analysis (BIA) at each study appointment 
and skinfold thickness measurements at baseline and week 8 at the end of the treatment.  Study 
appointments were made for a similar time of day each time to minimise the effect of time of day 
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or hydration on body weight and body water.  The methods used for the BIA and skin fold 
measurements are detailed below. 
 
2.1.7.1 Bioimpedance Analysis 
The Biodynamics BIA 450 (Biodynamics Corporation Seattle, Washington, USA) machine used a 
50-kilohertz electrical current to measure resistance and reactance in the body and calculates an 
impedance phase angle.  Based on these measurements the machine estimates body composition 
from established equations.   
 
The BIA 450 machine had a physical activity option but hours of activity were not entered for 
study patients with the exception of one participant who had a very physical job (builder - 
entered as 25 hours per week of exercise).  The basal metabolic rate was multiplied by an activity 
factor as described in section 2.1.4 to calculate each person’s estimated energy expenditure and 
thus daily estimated nutrition requirements. 
 
The BIA data were used to compare body composition within and between patients over time.  
Lean body mass (kg) and fat mass (kg) were expressed as fat-free mass index and fat mass index 
(mass (kg)/(height)2) to allow for comparisons between participants and HC of different heights.   
 
2.1.8 Clinical Outcomes – Blood Markers 
2.1.8.1 Albumin 
Albumin is a marker of nutrition and an acute phase protein, which means that the 
concentration of plasma albumin falls in response to inflammation.  Albumin was monitored at 
all seven time points during the study and measured by Canterbury Health Laboratories (CHL) 
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using a bromocresol purple albumin assay kit read of an Abbott C series analyser.  The CHL 
normal range for serum albumin was 32 -48 g/L. 
  
2.1.8.2 Insulin-like growth factor-1 
Insulin-like growth factor -1 (IGF-1) is a hormone predominantly produced by the liver.  The 
production of IGF-1 varies with age and sex and affected by nutrition intake, body composition 
and disease state.  IGF-1 was monitored at all seven time points during the study and measured 
by CHL endocrine laboratory.  Initially the laboratory measured IGF-1 using a manual 
radioimmunoassay method (Endolab RIA).  Part way through data collection for the EEN study 
the laboratory changed the method by which they measured IGF-1 to a commercial kit (iSYS 
assay by manufacturer Immune Diagnostic Systems (IDS)).  The laboratory conducted their own 
analysis of the two methods (n = 129 samples) and found that the new method correlated well (r 
= 0.987) with the previous manual method however statistical analyses produced a significantly 
different Deming regression slope (0.949 (0.922 to 0.976) with an intercept of 20.74 (17.75 to 
23.72).  Consequently, the new method produces slightly higher values (5 % higher) at lower 
levels of IGF-1.  In addition to these differences the standard deviation scores are not 
comparable because the two test methods have different non-normally distributed age and sex-
related reference intervals. 
 
In order to standardise the test results the results from the manual method (Endolab RIA) were 
transformed to be comparable with the new iSys method results using the following formula: y = 
mx +c.  ‘Y’ being the new result, ‘m’ the Deming regression slope (0.949), ‘x’ the manual method 
result and ‘c’ the Deming regression intercept (20.74).  Calculation of a new standard deviation 
score for all results allowed comparison of the iSys and transformed manual results.  The scores 




2.1.8.3 Vitamin D 
Baseline Vitamin D concentration were assessed by blood 25-hydroxy vitamin D.  CHL measured 
25-hydroxy vitamin D using high performance liquid chromatography tandem mass 
spectrometry.  In accordance with the NZ Ministry of Health and Cancer Society of NZ 
consensus statement(185) a level of less than 50 nmol/L was defined as suboptimal 25-hydroxy 
vitamin D and less than 25 nmol/L as deficient.  If a patient had a suboptimal Vitamin D level 
they were provided with a prescription for cholecalciferol as per their gastroenterologist.  
 
2.1.8.4 C-Reactive Protein 
CRP is an acute-phase protein present in serum, which is usually elevated in response to 
inflammation.  CRP was measured at all seven time points during the study by CHL using 
immunoturbidimetry analysed on the Abbott C series analyser.  CHL reported a normal CPR was 
a value less than 5 mg/L. 
 
2.1.8.5 Erythrocyte Sedimentation Rate 
ESR measures the rate at which red blood cells settle in one hour (mm/hr).  ESR is a non-
specific measure of inflammation.  During periods of inflammation there is more fibrinogen 
present in the blood, which results in red blood cells sticking together and settling faster.  ESR 
was measured at all seven time points in the study by CHL on an automated analyser.  CHL 
reported normal ESR was less than 10 mm/hr in adults aged 30 years and younger and less than 





Haematocrit is the percentage volume of red blood cells in the blood.  It is a marker of anaemia 
and is included in the CDAI calculation.  Haematocrit was measured at baseline, week 4 and 
week 8 of the study by CHL using an automated analyser.  CHL reported a normal haematocrit 
for females was 0.35 – 0.46 and males was 0.40 – 0.52. 
 
2.1.8.7 Ferritin 
Ferritin is a marker of anaemia but in the presence of inflammation ferritin levels are increased. 
Ferritin was measured at baseline by CHL using chemiluminescent microparticle immunoassay.  
CHL reported a normal ferritin in the absence of inflammation was greater than 20 µg/L. 
 
2.1.9 Clinical Outcomes – Faecal Markers 
Faecal samples were collected to enable analysis of faecal inflammatory markers and changes in 
the faecal microbiome consequent to EN treatment.  Patients provided a stool sample at each 
study appointment, which they collected at home in a sterile collection pottle no more than 24 
hours prior to each appointment and stored in a home refrigerator until their appointment.  If 
patients did not bring a sample to the appointment, they dropped it off, as soon as practical, at 
the CHL reception.  The laboratory stored all samples in a refrigerator until collected for 
processing.  All samples were processed within 24 hours of the patient collecting their sample 
and processed in a microbiological sterile hood into six aliquots of 0.5 – 1.0 ml of faeces and 
stored in 2ml Eppendorf tubes at -80°C. 
 
Occasionally a patient could not attend a follow up appointment, usually for geographical 
reasons. In this situation the patient collected a faecal sample as usual and stored it immediately 
in the home freezer (-12 to -18°C) in a sterile collection pottle.  The patient then brought the 
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sample, still frozen, to their next appointment.  The sample was aliquoted while still frozen to 
minimize any effects of thawing and then refreezing the sample.  
 
2.1.9.1 Faecal Calprotectin 
Faecal calprotectin is a marker of intestinal inflammation. Faecal calprotectin (S100A8/S100A9) 
of stored stool was measured using a sandwich ELISA technique.  A BÜHLMANN fCAL ELISA 
(BÜHLMANN Laboratories AG, Switzerland) commercial kit was used as per the manufacturer’s 
instructions.   
 
Stool stored at -80°C was thawed and aliquots of 50-100 mg were mixed with an extraction 
buffer according to the following formula: mg of stool multiplied by 49 = y µL of extraction 
buffer.  The sample was homogenised for 30 minutes on a shaker at the maximum speed.  The 
homogenate was transferred to an Eppendorf tube and placed in a centrifuge for five minutes at 
3,000 g.  The resultant supernatant was removed and stored at -20°C until further analysis. 
 
The BÜHLMANN fCAL ELISA kit has two working ranges – 10 - 600 µg/g or 30 – 1800 µg/g of 
calprotectin.  Further dilution of samples extended the range to 60 – 3600 µg/g.  It was expected 
that most patients would have elevated calprotectin therefore the extended range of 60 – 3600 
µg/g was used.  Especially as the normal range for a healthy person without intestinal 
inflammation is < 50 µg/g.  Stool extracts stored at -20°C were defrosted and diluted to 1:7500 
with incubation buffer, vortexed and left to equilibrate for at least five minutes.  The microtiter 
plate provided was pre-coated with anti-Calprotectin monoclonal capture antibody.  The plate 
wells were washed twice with 300 µL of wash buffer (100ml of wash buffer concentrate was 
diluted with 900 mL of deionized water) before 100 µL of blank (incubation buffer), calibrators 
(standards containing 4, 12, 40, 120, 240 ng/mL of calprotectin), low and high controls (lot 
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specific native human calprotectin) and diluted sample were added to the plate wells.  The plate 
was covered and incubated at room temperature on a plate rotator set to 450 revolutions per 
minute (rpm) for 30 minutes.  The plate wells were then washed three times with 300 µL of wash 
buffer before 100 µL of enzyme label (anti-calprotectin antibody conjugated to horseradish 
peroxidase) was added.  The plate was covered and incubated at room temperature for 30 
minutes on a plate rotator set to 450 rpm.  The plate was washed five times with 300 µL of wash 
buffer.  Next 100 µL substrate solution (tetramethylbenzidine and hydrogen peroxide) was 
added to each well and the plate was covered and incubated at room temperature, out of direct 
sunlight, on a plate rotator set to 450 rpm for 15 minutes after which time 100 µL of stop 
solution (0.25 M sulfuric acid) was added.  The optical density of each well was determined using 
a microplate reader (SpectraMAX 190, Molecular Devices, US) set to 450 nm.  The lower range 
of assay was 30 µg/g calprotectin and the upper range was 1800 µg/g calprotectin.  If samples 
contained greater than 1800 µg/g calprotectin the stool extract was further diluted (1 in 450, 
rather than 1 in 150) with incubation buffer prior to repeating the assay.  Further dilution of the 
faecal extract extended the range of the assay up to 5,400 µg/g. 
 
2.1.9.2 Faecal Osteoprotegrin 
Faecal OPG is also a marker of intestinal inflammation.  Stool stored at -80°C was thawed and 
aliquots of approximately 250 mg were mixed with an extraction buffer in equal parts.  The 
extraction buffer contained phosphate buffered saline (PBS) with 0.5 mM 4-(2-aminoethyl) 
benzenesulfonyl fluoride, 2.5 µg/ml leupeptin hemisulfate and 11 µg/ml aprotinin.  Samples were 
vortexed until stool was well suspended in buffer then homogenised for 30 minutes on a 
suspension mixer and centrifuged for 10 minutes at 13,500 g.  The resultant supernatant was 




Natural and recombinant OPG was measured using a sandwich ELISA technique (DuoSet 
ELISA, R&D Systems, Minneapolis).   The ELISA was run according to the manufacturers’ 
protocol, which is summarized in the following paragraph.   
 
The ELISA was performed at room temperature using a 96-well microplate.  After each step the 
plate was aspirated and washed three times using a wash solution.   Initially the plate was coated 
with a capture antibody (360 µg/mL mouse anti-human OPG per 1.0 mL of PBS) and incubated 
overnight.  Next, a reagent diluent (1 % bovine serum albumin in PBS) was added which was 
incubated for one hour.  The sample supernatant or standard (recombinant human OPG) were 
then added in duplicate and incubated for two hours.  A detection antibody (36 µg/mL 
biotinylated goat anti-human OPG in 1.0mL of reagent diluent) was added and the plate was 
incubated for two hours before streptavidin horseradish-peroxidase (1.0 ml Step per 11.9ml of 
reagent diluent) was added to each well.  The plate was incubated for 20 minutes after which a 
substrate solution (equal parts hydrogen peroxide and tetramethylbenzidine) was added.  The 
plate was then incubated for a further 20 minutes and then a reaction stop solution (2.5M 
H2SO4) was added.  The optical density of each well was determined using a microplate reader 
(SpectraMAX 190, Molecular Devices, US) set to 450 nm.  The lower detection limit of the assay 
was 62.5 pg/mL.  Results lower than this detection limit are presented as 62.5 pg/mL. 
 
2.1.9.3 Faecal Microbiota 
Faecal microbiota analysis of stored faecal samples required additional funding and specialist 
expertise.  A Laurenson Trust Award funded a pilot study to characterise the faecal microbiota of 
serial faecal samples.  Professor Gerald Tannock and his team at the Department of Microbiology 
and Immunology, University of Otago, Dunedin completed the microbiota analysis, including the 
DNA extraction and bioinformatics.  The methods used to extract the bacterial DNA and 
characterise the microbiome were the same as the Dunedin team used in a study characterising 
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the microbiome of human infants fed goats, cow or human milk.  Due to the exact nature of the 
extraction and characterisation process the following sections are quoted from a publication 
prepared by the Dunedin team.(186)  
 
Faecal samples stored at -80°C were sent on dry ice to Dunedin by overnight courier.  Upon 
receipt of the stool samples microbial DNA was extracted using the following method.  “A one-
tenth (weight/volume) faecal homogenate was prepared in sterile phosphate-buffered saline (pH 
7.0).  A 500 µl aliquot of homogenate was made up to 1.0 ml with sterile phosphate-buffered 
saline and centrifuged at 150 g for 5 min at 5°C.  The supernatant was transferred to a 
microcentrifuge tube and centrifuged at 5,000 g for 5 min at 5°C.  The pellet was suspended in 
200 µl of lysis buffer (20 mg lysozyme, 80 µl 10 mM Tris-HCl-10 mM EDTA) and incubated at 
room temperature for 30 min.  Fifty microliters of 20 % (weight/volume) sodium dodecyl 
sulphate (SDS) solution was added together with 300 µl of 50 mM sodium acetate-10 mM EDTA 
(pH 5.1) solution.  The preparation was transferred to a beadbeater tube, and 300 µl of phenol 
saturated with 50 mM sodium acetate-10 mM EDTA buffer (pH 5.1) was added to the tubes. The 
sample was shaken at 5,000 rpm for 2 min in a beadbeater. After centrifugation at 14,000 g for 
10 min at 4°C, the supernatant was transferred to a microcentrifuge tube, and 600 µl of phenol 
saturated with sodium acetate- EDTA buffer (pH 5.1) was added. Samples were mixed by 
vortexing for 1 min and centrifuged under the conditions described above. Then, 600 µl of 
phenol-chloroform-isoamyl alcohol (25:24:1) was added to the supernatant, and the mixture was 
vortexed for 1 min and centrifuged. This step was repeated once. Then, 600 µl of chloroform-
isoamyl alcohol (24:1) was added to the supernatants, which were vortexed for 1 min and 
centrifuged for 5 min at 14,000 g. This step was repeated once. Nucleic acids were precipitated 
in 1 ml of isopropanol overnight at 20°C. The precipitated nucleic acids were obtained by 
centrifugation at 14,000 g for 20 min at 4°C. They were washed with 1 ml of 80 % ethanol and 
centrifuged at 14,000 g for 10 min, the supernatant was discarded, and the pellet was dried in air 
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at 37°C. Further purification of DNA was achieved using the Qiagen-AllPrep DNA/RNA 
minikit.”(186) 
 
Purified DNA was “sent to Macrogen (Korea) for unidirectional sequencing from the reverse 
primer using the Roche-454 genome sequencer with titanium chemistry. Sequences were 
processed using a combination of methods from both the QIIME version 1.2.1 and RDP 
pyrosequencing pipeline packages. Sequences were excluded from analysis if they were 250 or 
550 bases in length, had an average quality score of 25, contained one or more ambiguous bases, 
had one mismatch with the sequencing primer, or had a homopolymer run of > 6. Following 
splitting into barcoded samples and initial quality filtering, the sequences were passed through 
the QIIME pipeline using default parameters, including chimera checking.”(186)  
  
“Species-level taxonomy was obtained by filtering operational taxonomic unit (OTU) tables, 
containing taxonomic data generated using the RDP classifier, at a genus level; extracting 
representative sequences; and using BLAST to identify species-level matches within the NCBI 
database. Biplots, showing principle coordinate clustering of samples alongside weighted 
taxonomic group data, were generated as part of the beta-diversity analysis in QIIME using 
family-level summarized OTU tables.”(186)  
 
Based on the results of the faecal microbiota pilot study, and due poor recruitment to the 
corticosteroid group, the candidate designed and executed a study with health volunteers as 
detailed in section 2.1.6.  The primary aim of this study was compare changes in the faecal 
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microbiota of adults with and without CD consequent to two weeks of EEN.  A collaborative 
funding grant has been submitted to enable the sequencing and analysis of the remaining faecal 
samples. 
 
2.1.10 Clinical Outcomes: Disease Activity Indices 
2.1.10.1 Crohn’s Disease Activity Index 
CDAI is a validated tool to assess disease activity.(58)  It was calculated at baseline, week 4 and 
week 8.  It was not calculated at every follow up appointment because it requires the patient to 
record their symptoms for the previous seven days.  How the CDAI is calculated and what is 
included in the calculation are detailed in Table 2.4. 
 
2.1.10.2 Harvey Bradshaw Index 
The HBI is a validated simple index to described CD activity(187) and correlates well with the 
more detailed CDAI.(57)  It was calculated at all seven study appointments.  The HBI is a one day 
history of symptoms and extra-intestinal manifestations.  The items included in the index and 





Table 2.4.  Calculation of the Crohn's disease activity index.(58) 
Assessment Formula 
How many liquid stools have you had on each of the last 7 days? Sum x 2 
Rate your abdominal pain over the last 7 days: None = 0, Mild = 1, 
Moderate = 2, Severe = 3 
Sum x 5 
Rate your general well-being over the last 7 days: Well = 0, Slightly 
below par = 1, Poor = 2, Very poor = 3, Terrible = 4 
Sum x 7 
Extra-intestinal manifestations: Yes = 1, No = 0. Arthritis/arthralgia, 
iritis/uveitis, skin/mouth ulcers, perianal disease, other fistula, fever 
Sum x 20 
Use of anti-diarrhoeal drugs: Yes = 1, No =0 Value x 30 
Abdominal mass: None = 0, Maybe = 2, Definitely = 5 Value x 10 
Haematocrit: difference between current value and reference value 
(Males 46, females 42) 
Difference x 6 
Weight: current weight and usual weight 100 x (1- current 
weight/usual weight) 







Table 2.5.  Calculation of the Harvey Bradshaw Index.(187) 
Assessment Formula 
General well-being (yesterday): very well = 0, slightly below average = 1, 
poor = 2, very poor = 3, terrible = 4 
0 - 4 
Abdominal pain (yesterday): none = 0, mild = 1, moderate = 2,  
severe = 3 
0 - 3 
Number of liquid stools (yesterday) As reported by patient 
Do you have any lumps in your abdomen? None = 0, maybe = 1, yes = 2, 
yes, and tender = 3 
0 - 3 
Do you have any of these other symptoms? Arthralgia, uveitis, erythema 
nodosum, aphthous ulcers, pyoderma gangrenosum anal fissure, new 
fistula, abscess 
1 point for each extra-
intestinal manifestation 





2.1.11 Clinical Outcomes: Health Related Quality of Life 
Patients with CD have lower HRQOL than the general population.  The determinants of HRQOL 
are varied but include disease activity, hospitalisations and medications.(85)  In this study quality 
of life was assessed before, during and after treatment using two validated self-assessment QOL 
tools: HADS(88) and SIBDQ.(115) 
 
2.1.11.1 Hospital Anxiety and Depression Score  
The HADS questionnaire contains 14 questions: seven questions relate to anxiety and seven 
questions relate to depression (Appendix B).(88)    The questionnaire was administered at all 
seven appointments.  Each question was scored from 0 to 3 and the sum for depression 
questions and anxiety questions calculated.  A normal score for depression and anxiety was less 
than seven; borderline abnormal was eight to ten and greater than 11 abnormal.  Intra and 
interpatient HADS scores were compared over time. 
 
2.1.11.2 Short Inflammatory Bowel Disease Questionnaire 
The SIBDQ is a ten question questionnaire (Appendix C) which is a shortened version of the 36 
question IBDQ.  The short questionnaire correlates well with the long version(115) and was chosen 
to reduce patient burden.  Patients were asked to complete the SIBDQ at all seven study 
appointments.  Patients’ responses were scored from one to seven and then the mean response of 
all ten questions was calculated.  Intra and interpatient SIDBQ scores were compared over time.  
A clinically significant HRQOL response is a SIBDQ of more than 4.7 points.(115) 
 
2.1.12 Clinical Outcomes: Nutrient Intake  
Patients recruited to use PEN were encouraged to obtain one third of their nutrition from solid 
foods and two thirds from the nutritional formula during the last six weeks of the intervention 
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phase.  At each fortnightly appointment patients were asked to give written examples of the 
meals that they had eaten during the previous fortnight.  Patients completed an electronic food 
diary for at least 4 days during the six weeks of PEN.  Patients recorded a minimum of two non-
consecutive days, including one week day and one weekend day, during the first fortnight and 
two non-consecutive days during final fortnight of the treatment.  An electronic food diary was 
chosen over a traditional paper based food diary as the patient group was relatively young (16 – 
40 years old) and likely to be technology competent.    
 
2.1.12.1 Electronic Food Diary 
Dietary intake during PEN was recorded using a free smart phone/tablet application (App) 
“Evernote”.  If patients did not have their own device Apple iPods were available on loan.  The 
“Evernote” App has been used as an electronic food diary in paediatric research studies with 
children aged 16-19 years and 8 to 10 year olds  and has been validated with these populations 
against a traditional paper based food diary (unpublished data), however it has not yet been 
validated for use with adult patients.  “Evernote” allowed the researcher to set up an electronic 
food diary template that was shared with each study participant.  Once the study participant had 
installed the App on their device the patient opened the App and took a photograph of their 
meal, and another photograph of any leftovers, and entered details of the meal into the App.  
These details included how the food was prepared, cooked, brand names or photographs of meal 
ingredients and also the volume of nutritional formula and other fluids consumed that day.  The 
electronic food diaries were reviewed by the candidate and if further information was required to 
more accurately calculate nutrient intake patients were questioned at their next study 
appointment.  The data recorded in the App was used to calculate average estimated nutrient 




2.1.12.2 Nutrient Analysis 
Nutrient analysis during EEN treatment was calculated by multiplying the average number of 
cartons of nutritional formula consumed each day by the nutrient composition of each carton 
(Table 2.2) plus any additional fluids drunk (water, black tea or coffee).  Nutrient intake during 
PEN treatment was estimated from electronic food diary data plus nutritional formula 
consumption. 
 
The electronic food diary data were entered into dietary analysis programme Kai-culator.  This 
programme is a University of Otago, Department of Human Nutrition (Dunedin), in-house 
nutrient analysis programme.  The food diary data was entered as individual foods/fluids or as 
meal ingredients.  The candidate and another NZ dietitian, who has extensive experience with 
this particular nutrient analysis programme, entered the four-day food diaries of two patients in 
duplicate.  Duplicate entry allowed for comparison of portion size estimates between both 
research dietitians and comparison of food item selection from the nutrient analysis programme.  
There were small disparities between the entries which were mostly related to the choice of food 
items from the nutrient analysis programme, for example lettuce inner leaves rather than lettuce 
mixed leaves or choosing an existing programme recipe rather than entering a new recipe.  These 
differences were discussed and decision was made on how best to interpret food diary data and 
chose the most appropriate nutrient analysis programme items.  These decisions were then 




2.2 Stakeholders in Enteral Nutrition Treatment for Active 
Crohn’s Disease 
Stakeholders in the delivery of enteral nutrition include, but are not limited to, the patient who is 
using the treatment, the dietitian who manages the EN treatment and the gastroenterologist who 
recommends EN treatment and manages the overall treatment plan for the patient.  The 
following sections online the methods used to survey these three stakeholders.  
 
2.2.1 Survey of Patients with Crohn’s Disease 
A common assumption is that PF is more palatable than EF however there is limited research to 
support this assumption.  This study aimed firstly to compare the palatability of polymeric and 
elemental nutrition formulae and secondly to gauge the acceptability of these formulae as a 
treatment option for active CD.  
 
2.2.1.1 Study Outline 
Patients diagnosed with CD attending gastroenterology outpatient clinics at Christchurch 
Hospital, Christchurch, NZ were invited to take part in the study.  They were an unselected 
group of patients.  Patients consented to take part in a taste test to compare the palatability of 
two different nutritional formulae. Patients that consented to take part in the study were asked 
to taste 10ml of an EF (Alitraq, Abbott Nutrition, NZ) and 10ml of a PF (Ensure Plus, Abbott 
Nutrition, NZ).  Alitraq is a powdered nutritional formula specifically designed for acute 
gastrointestinal dysfunction/malabsorption.  The protein source is a combination of peptides 
and free amino acids.  It was prepared according to the manufacturer’s instructions to a 
concentration of 1.0 kcal/ml.  Ensure Plus (1.5 kcal/ml) was provided in a ready-to-drink form.  
Both formulae were vanilla flavoured and were served chilled. Participants were blind to the 
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names and characteristics of the formulae.  Participants tasted each formula in alternating order 
and given 10ml of water to rinse their mouth between samples.  These products were chosen 
because they are both vanilla flavoured milk based formulae, whereas other EFs available in NZ 
are fruit flavoured or unflavoured.  The University of Otago Ethics Committee approved the 
study. 
 
2.2.1.2 Questionnaire Design 
The questions (Appendix D) used in this study were based on those used by Makai et al. (174)  This 
report used a 15 item scale to assess palatability.  The current study used a selection of five of 
these items.  Participants were asked to rate each drink on a 5 point Likert scale as follows: (1) 
difficult to drink/easy to drink, (2) unpleasant flavour/pleasant flavour, (3) poor mouth 
feel/good mouth feel, (4) weak aftertaste/strong aftertaste, and (5) not acrid/acrid.  We also 
asked two additional questions in a slightly different format.  Participants were asked to indicate 
whether they preferred one drink over the other and asked to indicate how likely it is that they 
could drink 200ml of each drink 6 – 8 times per day on a scale of 0-10.  These seven questions 
were selected as they appeared to be most relevant to palatability. 
 
Participants answered a series of questions based on the assumption that using either of the 
drinks for EEN may put their disease into remission.  These questions included whether they 
would rather use EEN for eight weeks or take a course of corticosteroids for eight weeks. They 
also indicated if they would consider using EEN for eight weeks if it could put their disease into 




2.2.2 Survey of Dietitians 
Dietitians are an integral part of the multidisciplinary care of patients with CD.  Dietitians are 
the health professional most likely to manage patients whilst using EEN and therefore New 
Zealand dietitians were surveyed to understand to their use and perception of EEN as a 
treatment for active CD.  
 
2.2.2.1 Survey Design 
The survey questions (Appendix E) were adapted from a survey used with North American 
physicians to understand their attitudes and use of enteral nutrition to treat paediatric CD.(188)  
The survey platform was QuestionPro Online Survey Software Application 
(www.questionpro.com).  It contained single choice, multiple choice and open-ended questions.  
Question branching was included so that dietitians only answered questions relevant to their 
experience with CD patients and enteral nutrition.  An Australian dietitian who frequently uses 
EEN and a colleague who has experience with online survey design pretested the survey.  The 
final version of the survey incorporated their feedback.  A limitation of the survey design is that 
pre-testing was not completed with clinical dietitians with a small CD patient load or limited 
experience using EEN. 
    
The focus of this survey was to understand the current practice of NZ clinical dietitians 
compared to clinical dietitians internationally and current IBD standards of care.  Therefore, the 
survey did not require ethical approval but the data collected from survey respondents were 





NZ dietitians that were members of the national professional association, Dietitians NZ, were 
invited to complete the survey anonymously.  This member group is composed of dietitians 
working in clinical, public health, research, food service and pharmaceutical industry settings.  
The web-based survey link was disseminated via Dietitians NZ’s weekly electronic newsletter to 
488 active members.  An electronic link took dietitians to the online survey.  Three weeks after 
the initial newsletter advertisement dietitians were reminded to complete the survey.   
 
2.2.3 Survey of Gastroenterologists 
Gastroenterologists are specialists in the management of gastrointestinal disorders including 
Crohn’s disease.  The gastroenterologist, in conjunction with the patient, develops a treatment 
plan for the long term and acute management of CD and may refer their patients onto other 
health professionals, including dietitians and IBD nurse specialists to implement and oversee 
treatment plans.  Therefore, understanding gastroenterologists’ perception of EN and its role, if 
any, in the treatment of their patients with active CD is important. 
 
2.2.3.1 Survey Design 
The survey questions (Appendix F) were adapted from a survey of North American physicians to 
understand their attitudes and use of enteral nutrition to treat paediatric CD.(188)  The survey 
platform used was QuestionPro Online Survey Software Application (www.questionpro.com).  
The survey contained single choice, multiple choice and open-ended questions.  Question 
branching was included so that gastroenterologists only answered questions relevant to their 
experience with CD patients and enteral nutrition.  Two gastroenterologists (one adult and one 
paediatric specialist) pretested the survey and committee members of the NZ Society of 




The focus of this survey was to understand the current practice of NZ adult compared with 
paediatric gastroenterologists and compared to gastroenterologists and IBD standards of care 
internationally.  Therefore, the survey did not require ethical approval. However, the data 
collected from survey respondents was managed ethically and anonymity of survey respondents 
was maintained.  
 
2.2.3.2 Participants 
The survey was distributed through the NZ Society of Gastroenterology as most NZ 
gastroenterologists are members of the society.  Society members include consultant 
gastroenterologists and surgeons, gastroenterology registrars as well as scientists and other 
health professionals.  The NZ Society of Gastroenterology disseminated the web-based survey 
link via email list to 130 full members (consultants and trainees) in July 2015.  An electronic link 
took members to the online survey and they received a reminded to complete the survey three 




2.3 Statistical Analysis 
The results from clinical trials and questionnaires are presented as percentage of responses, 
medians and ranges.  Means and standard deviations have not been used because many of the 
variables were not normally distributed and therefore non-parametric statistical analysis based 
on medians and range have been used.  The clinical trial was designed as a pilot study, the results 
of which could be used to inform a randomised controlled trial, therefore a power calculation 
was not required.  Last observation carried forward (LOCF) intention to treat and per protocol 
analysis were conducted with the EEN and PEN study results.  Statistical analyses were 
conducted using Mann-Whitney U test (test statistic U), Wilcoxon paired signed rank test (test 
statistic W), Fisher’s exact test, Chi-squared test and Spearman correlation.  Statistical 
significance was present with p < 0.05.  Open-ended questions were summarised using thematic 






     Chapter 3  
Patient Perspective of Nutritional Therapy 
3.1 Introduction 
EEN is not widely recommended for adults with active CD,(37) mostly as a result of a Cochrane 
meta-analysis(38) of seven studies that found CS to be superior to EEN for the induction of 
disease remission.  Six of the seven studies in the meta-analysis included adult patients and half 
of these studies had 25 to 39 % of patients withdraw due to unpalatable EN formula.(159, 161, 163)  
One reason for this may have been that these studies used an EF provided orally whereas recent 
research in children has mainly used PF administered orally with few withdrawals due to poor 
palatability.(28, 29)  Also, changes in EF and PF formulations in recent years may have led to 
enhanced taste characteristics and increased palatability.(189)     
 
Elemental formula (comprising amino acids and/or peptides) is often assumed to be less 
palatable than PF primarily based on its distinct smell and flavour.  PF (containing whole 
proteins) may also have a distinct smell and flavour but it is often less marked.  The palatability 
or taste preference of nutritional formulae has been examined(174, 176, 190, 191)  and taste preferences 
between patients and healthy controls are often similar.(192-194)  Milk-based supplements are 
rated more highly than fruit based products in most patient groups and countries.(190, 194, 195)  Few 
studies, however, have compared patient preferences or palatability of EF compared with PF(174, 




3.2 Aims and hypotheses 
The aim of this study was, firstly, to compare the palatability of PF and EF in a sample of NZ 
adults with CD and, secondly, to gauge the acceptability of these formulas as a treatment option 
for active CD instead of corticosteroids.  It was hypothesised that: 
 Polymeric nutritional formula is more palatable than elemental nutritional formula 




A blind taste test of one EF and one PF was conducted with patients with CD attending a 
Christchurch Hospital gastroenterology outpatient clinic.  Patients were asked to score each 
formula on characteristics associated with palatability and asked which they preferred.  In 
addition, patients were asked if they would consider using a nutritional formula to treat active 
CD.  The complete study methods are detailed in Chapter 2 section 2.2.2.  
 
3.4 Results 
3.4.1.1 Participant characteristics 
Thirty-five patients agreed, and no patients declined, to take part in the study.  The median age 
of patients was 39 years old (range 19 - 77 years): 63 % were males and 71 % (n = 25) had 
previously used prednisone.  One patient had previously used EEN under the paediatric 
gastroenterology team to treat CD symptoms.  Several patients had previously used nutritional 




3.4.1.2 Palatability ratings 
PF was rated as being easier to drink, had a more pleasant flavour, good mouth feel and was less 
acrid compared to the EF (Wilcoxon matched pairs signed rank test, p < 0.001 for each variable) 
(Figure 3-1).  However, there was no statistically significant difference in aftertaste between the 
two formulae (W = -146.0, p = 0.09). 
 
Overall, the participants preferred the PF (91 %) to the EF (9 %) (W = 535.0, p < 0.001) and felt 
that they would be more likely to be able to drink 200ml of the PF six to eight times per day 
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Figure 3-1.  Participant ratings of elemental and polymeric formula. 
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Figure 3-2.  Likelihood that patient could drink each formula six to eight times per day. 
Note: (0 = highly unlikely and 10 = very likely)   
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3.4.1.3 Acceptability of enteral nutrition  
Of the 25 patients who had previously used prednisone to treat CD flare ups, 15 (60 %) indicated 
that they would rather use EEN for 8 weeks than take another course of prednisone, eight (32 %) 
indicated that they would rather use prednisone than EEN for 8 weeks and two (8 %) were 
unsure which they would prefer. 
 
All patients were asked if they would consider using EEN, if it could put their disease into 
remission, to treat active CD symptoms.  A greater proportion of patients would consider using 
EEN to treat active disease (Chi-square 29.95, p < 0.0001), especially if they had moderate or 












Figure 3-3.  Number of patients that would consider using EEN, if it was efficacious, for 8 weeks to 
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The palatability of enteral formulae has been studied previously(174, 176, 190, 191, 193, 194) but 
comparisons between PF and EF palatability has not been examined widely.(174, 176)  This study 
used a convenience sample of patients who were attending gastroenterology outpatient 
appointments at Christchurch Hospital, NZ.  The study design and questionnaire were both 
based on that of Makai et al.(174) in which they used a selection of 1.0 kcal/ml EF, peptide-based 
formula and PF all of which were unflavoured or coffee and fruit flavoured.  Vanilla flavoured 
milk-based formulae were used in the current study because the non-milk based PF available in 
NZ is not nutritionally complete therefore unsuitable for EEN.  A more calorie dense (1.5 
kcal/ml) formula was chosen as it would be challenging for adult patients with CD using EEN to 
meet their calorie needs orally using only a 1.0 kcal/ml formula. 
   
Makai et al(174) found that some brands of EF were more palatable than others, that peptide-
based formulae scored highly for after-taste and acridity and that overall flavoured formulae 
were more palatable than unflavoured formulae.  Only one of the three EF brands scored 
similarly for palatability compared with the PF.  In the current study participants also found the 
EF less palatable than the PF and rated it more acrid, difficult to drink, disliked the flavour and 
considered it highly unlikely that they could drink enough of it to meet their nutritional 
requirements.  Most participants scored the vanilla flavoured PF highly for drinkability and 
flavour.  Makai et al(174) proposed that the poor palatability of EF is related to the bitterness and 
saltiness of the formula.  They found that fruit flavoured EF was more acceptable and proposed 
that it was probably due to organic acids in the fruit flavourings suppressing the bitterness of the 
free amino acids.(174)  The EF used in this study was a mixture of peptides and free amino acids.  
Peptide-based formulae have been rated poorly for palatability compared with free amino acid 
formulae.(174, 193) In this study if there was a milk-based free amino acid flavoured EF available it 




One of the aims of this study was to assess patient interest in EEN as a potential CD treatment.  
Patients whom had previously used CS were asked if they would rather use EEN for eight weeks 
or take another course of CS.  Of the 25 patients who had previously used steroids, 60 % 
indicated that they would consider using EEN.  CS are just one medication that may be used to 
treat active CD and, like most CD medications, have many side effects including mood changes, 
glucose intolerance, puffy face, acne, reduced linear growth and steroid dependence.(11)  Although 
EEN is burdensome on patients one of its many advantages is the relative lack of side effects and 
avoidance of drugs with many side effects.  High treatment side effects scores are associated with 
lower patient quality of life.(196)  This may explain why patient quality of life has been found to 
improve post EEN(31, 33) even in those using nasogastric tube feeding.(33, 86, 196)  This study 
suggests that patients are interested in avoiding the short and/or long term side effects 
associated with CS treatment.  
 
Patients were also asked if they would consider using EEN to treat severe, moderate or mild 
disease.  More than 80 % indicated that they would use EEN to treat moderate and severe 
disease.  This result was not surprising given that post prandial abdominal pain and diarrhoea 
are often common symptoms of active disease.  Interestingly, 43 % of patients indicated that they 
would consider EEN to treat even mild symptoms.  It appears that adults are interested in using 
EEN, whether to avoid side effects of other CD medications or for some other reason. This was 
not able to be explored further in the current study. 
 
This study provides some insight into the impact that CD symptoms and medication side effects 
may have on patient quality of life.  Forfeiting all solid and liquid food and fluids for eight weeks 
and consuming only a liquid nutritional formula and water is relatively burdensome on patients, 
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however the majority of patients in this study would consider following this regimen to treat 
moderate or severe CD symptoms.  Although data on patient disease severity was not collected, 
70 % of these patients had previously used steroids and two-thirds of those appeared to 
appreciate that the potential benefits of EEN outweigh the negatives in order to avoid the side 
effects of steroids they may have previously experienced.  EEN requires commitment from the 
patient: this study suggests that patients who have had negative experiences with other CD 
medications or suffered from moderate to severe symptoms may consider an alternative 
treatment such as EEN. 
 
3.6 Conclusion 
This study supports the hypothesis that PF is more palatable than EF and that adults with CD are 
interested in using nutritional therapy in place of CS treatments.  Further research involving 




     Chapter 4 
Clinical Trial 
4.1 Introduction 
EEN has been recommended as a first line therapy for children with active CD instead of 
corticosteroid therapy for more than 10 years.(197)  However, in adults EEN is currently only 
recommended as an adjuvant therapy in adults who are malnourished or unable to use 
corticosteroids or for those patients for whom corticosteroids are contraindicated.(36, 37)  Previous 
randomised controlled trials of EEN compared with CS treatment in adult populations 
predominantly used elemental and semi-elemental formulae.(17, 129, 155, 158-160, 162, 163) and three of 
the twelve studies had at least a third of the patients withdraw from EEN due to the reported 
unpalatability of the formula.(129, 159, 163)  EEN with PF is well tolerated by children with active CD 
and has been shown to effectively induce disease remission in approximately 70 – 80 % of 
children.(28, 29, 198)  Polymeric ready-to-drink formula was used with adults for four weeks in two 
randomised controlled trials comparing corticosteroids and EEN.(156, 157)  Both studies delivered 
the formula via a tube and reported 100 % compliance with the EEN regimen and disease 
remission was achieved in 12 of the 15 (80 %) patients in the Spanish study(157) but only 4 out of 
10 (40 %) patients in the Greek study.(156)  PF has also been used with adults in randomised 
controlled trials comparing the efficacy of EF with PF.  These studies found that EEN with PF 
induced disease remission in approximately 60 – 70 % of patients.(172, 173, 199) 
 
Some paediatric EEN protocols allow small amounts of nutrient deficient foods and fluids, 
including small amounts of clear fluids, boiled sweets and formula flavourings.(16)  These 
additions to the regimen do not appear to limit the effectiveness of EEN to induce disease 
remission in the paediatric population.  Whereas, the addition of larger amounts of solid food, in 
addition to the EN formula, does appear to be a less effective means of inducing disease 
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remission compared with EEN.(179, 180)  A regimen which sequentially combines EEN and PEN 
and limits the amount of additional food may be more efficacious than a prescribed volume of 
EN plus unlimited normal diet.  Such a regimen has not previously been studied with paediatric 
or adult patients with active CD. 
 
4.2 Aims and Hypotheses 
The aim of this research was to investigate the feasibility and effectiveness of EEN as a treatment 
for young adults with active CD.  The aim of conducting the PEN trial was to investigate if a 
sequential EEN and PEN treatment is as effective as EEN at inducing disease remission.  It was 
hypothesised: 
 That in a population of young adults with active CD, EEN therapy induces clinical and 
biochemical disease remission. 
 That treatment with a novel PEN regimen induces disease remission and markers of 
disease activity as effectively as EEN in young adults with active CD. 
 
4.3 Methods 
The complete clinical trial methods are detailed in Chapter 2, Section 2.1 and will only be 
described in brief in the following paragraphs.  The clinical study was composed of two phases.  
The first phase of the clinical trial was to recruit 20 patients with active CD who chose to use 
EEN and an additional 20 patients who used corticosteroid therapy to act as a control group.  
Patients who met the study inclusion criteria and were interested in participating in a research 
study using EEN or corticosteroids to treat active CD were referred into the study by 
Christchurch Hospital gastroenterologists.  The EEN group used EN exclusively for eight weeks 
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with the exclusion of all usual foods and liquids apart from water and black, unsweetened tea 
and coffee.  The patients using CS therapy consumed their usual diet.   
 
The design of the second phase of the clinical trial was based on the outcomes of the first study 
and the protocols used in recent PEN literature.   This phase was the same as the first phase 
except patients used a sequential regimen of EEN followed by PEN to treat active CD rather than 
EEN.  The PEN group used EN exclusively for two weeks and then reintroduced a small lunch or 
evening meal plus EN for the remaining six weeks.  Patients were asked to eat a small meal, 
approximately half of their usual portion size, which would theoretically equate to no more than 
one third of their daily energy intake.  There were no restrictions on foods which could be 
included in the meal although patients were encouraged to eat a balanced meal similar to what 
they would eat prior to starting the treatment.  Patients were asked to continue to only drink 
water and tea or coffee throughout the PEN phase but could add milk to hot drinks if preferred.   
 
4.4 Results 
4.4.1 Patient Recruitment 
4.4.1.1 Exclusive Enteral Nutrition Group 
Patient recruitment into phase one of the clinical trial started in May 2013 and finished 22 
months later in February 2015.  During this period 27 patients were referred by Christchurch 
gastroenterologist’s public and private clinics.  Two patients decided not to initiate EEN 
treatment (both did not think that they would be able adhere to the treatment protocol).  A mean 




4.4.1.2 Partial Enteral Nutrition Group 
Patient recruitment into phase two of the clinical trial started in March 2015 and ended in 
December 2015.  During the ten months of recruitment, 13 patients with active newly diagnosed 
and existing CD were recruited to use PEN (a mean of 1.3 patients per month).  Patient 
recruitment was stopped prior to recruiting 20 patients to allow adequate time for the six month 
study follow up to be completed prior to this thesis submission.  All patients referred by their 
gastroenterologists for PEN consented to initiate the treatment.  
 
4.4.1.3 Corticosteroid Group 
Patient recruitment into the CS arm of the study was open for the duration of both the EN 
studies (32 months) and during this time two patients were recruited into the study.  One of 
these patients, female less than 18 years old, initially consented to use EEN but withdrew from 
the study within the first week and then started on CS.  The other patient, a male aged > 35 years 
old, chose to use CS rather than EEN from the start.  Possible reasons for the limited number of 
referrals to the CS study group are discussed in section 4.5 of this chapter. 
 
Both of the patients who used CS had newly diagnosed CD, were on no CD medications, one had 
ileal disease and the other ileocolonic disease.  At baseline they had a CDAI of 150 – 220, a 
normal CRP of 5 mg/L, an ESR < 15 mm/Hr, a normal faecal OPG of 62.5 pg/mL and FC was not 
performed.  Due to the very small numbers in this study group the results of the CS patient group 
have not been compared with the outcomes of patients using enteral nutrition.  In summary, 
after eight weeks of CS treatment both patients had a CDAI < 150, CRP had increased slightly to 
6 and 11 mg/L, ESR was < 15 and 16 mm/Hr and faecal OPG had not changed.  At week 26 both 




4.4.2 Baseline Characteristics 
The two EN intervention groups were similar at baseline and there were no statistically 




Table 4.1.  Baseline characteristics of patients referred for enteral nutrition therapy. 
Baseline characteristics  EEN (n = 25) 
Median (range) or n 
(%) 
PEN (n = 13) 
Median (range) or n 
(%) 
p 
Age 23.3 (15.8, 38.4) 19.2 (16.5, 38.2) 0.443 
Sex - female 18 (72) 12 (92) 0.222 
Ethnicity – NZ European 24 (96) 12 (92) 1.00 
Born in NZ 23 (92) 12 (92) 1.00 
Occupation 
High school student 
























Current smoker 3 (12) 0 (0) 0.538 
Family history of CD 5 (20) 3 (23) 1.00 
Duration of disease, years  
Newly diagnosed 
0.07 (0.0, 14.4) 
21 (84) 




Disease location   
L1  ileal 
L2  colonic 
L3  ileocolonic 















Baseline characteristics  EEN (n = 25) 
Median (range) or n 
(%) 
PEN (n = 13) 




B1  non-stricturing/penetrating 
B2  stricturing 
B3  penetrating 












Disease activity (CDAI) 
< 150 
150 – 220 
> 220  










Disease activity (HBI) 
< 5 
≥ 5 
5.0 (0, 14) 
12 
13 





















< 5 (mg/L) 
9.0 (3, 158) 
8 (32) 
25.0 (3, 71) 
3 (23) 
0.199 
Platelets (x 109/L) 337 (196, 733) 411 (256, 695) 0.181 
ESR (mm/hr) 14 (2, 104) 23.0 (7, 68) 0.152 
Faecal calprotectin (µg/g) 1025 (60, 3600) 1175 (60, 3600) 0.579 




4.4.3 Treatment Withdrawals 
4.4.3.1 Exclusive Enteral Nutrition Group 
Figure 4-1 illustrates the flow of patients through the two EN intervention treatments.  EEN 
treatment was initiated by 25 patients, 11 patients withdrew from EEN treatment with the 
remaining 14 completing the eight-week treatment.  Four patients withdrew from EEN in the 
first two weeks; two young females tried EEN for less than a week and decided that CS would be 
a better treatment option for them and changed to CS treatment, one patient who was pregnant 
had worse nausea on EEN and introduced some food back into her diet, and one patient required 
urgent surgery as a result of a perforated bowel.  A further seven patients withdrew from the 
study between week two and eight of the intervention period for various reasons;  three patients 
did not tolerate the treatment, one patient was drinking soya based Ensure Plus to comply with 
her vegan beliefs and had diarrhoea which resolved when she stopped taking the drinks, one 
patient required a NGT to be placed to help her achieve adequate nutrition intake but the tube 
split and she opted not to have another tube placed and another patient was tolerating EEN well 
but developed nausea after three weeks of treatment which resolved when she stopped taking the 
nutritional formula.  One patient did not manage to do EN exclusively and ate throughout the 
intervention period and one patient used EEN for five weeks but restarted eating usual food in 
response to a stressful situation at work.  The seventh patient was changed to CS treatment at 
week four because there had been no improvements in his clinical or inflammatory markers.  Of 
the 11 patients who withdrew, six were under 18 years old whilst 8 were female and 3 were male. 
 
4.4.3.2 Partial Enteral Nutrition Group 
PEN treatment was initiated by 13 patients; four patients withdrew and 9 patients completed the 
eight-week treatment.  Two of the four patients who withdrew from the study withdrew in the 
first two weeks because they were unable to initiate EEN due to nausea in one case and 
diarrhoea and abdominal pain in the other case.  A further two patients withdrew on PEN, one 
patient had a focal sealed ileal perforation when she was referred for PEN and flared after the 
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two weeks of EEN when food was reintroduced.  She went back onto EEN until she had a bowel 
resection three weeks later.  The second patient had not responded to the treatment at week four 
and was started on CS therapy instead. Of the four patients who withdrew, two were under 18 
years old and three were female. 
 
Total treatment withdrawals due to intolerance of the formula (nausea and/or diarrhoea or 
inability to consume an adequate amount) of EN were 28 % of EEN patients and 15 % of PEN 
patients.  The EEN and PEN treatments were completed by 56 % and 69 % of patients 
respectively.  There was no statistically significant difference in the proportion of patients who 
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of EEN (n = 11) 
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2 weeks (n = 13) 
Withdrew from 
EEN (n = 2) 
Figure 4-1.  Flow diagram of patients recruited to use exclusive or partial enteral nutrition. 
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4.4.3.3 Patients Who Completed EN Treatment Compared With Those Who 
Withdrew From EN Treatment 
The patients who withdrew (n = 15) from the trial were different compared with the patients who 
completed (n = 23) EN treatment.  Patients who withdrew from EN treatment had a higher 
median baseline CDAI compared with those who completed EN treatment (Figure 4-2).  
However, there was no significant difference in the median CRP or FC of the two groups (p > 
0.05).  The median age of patients who withdrew was younger (17.2 years old) than patients who 
completed the treatment (23.1 years old) but the age difference did not reach statistical 
significance (U = 113.5, p = 0.079) (Figure 4-3).  However, the proportion of patients who were of 
secondary school age (< 18 years old), was significantly greater (fisher’s exact test, p = 0.012) in 
the group who withdrew from treatment (Figure 4-3).  There was no difference in the proportion 
of patients who had a CD flare within six months of initiating EN treatment (8/23) compared 
with the patients (7/15 patients) who withdrew from EN treatment and started an alternative 
treatment.  
 
4.4.4 Response to Enteral Nutrition Therapies 
Patients recruited to use EEN and PEN to treat active CD had similar changes in serum and 
faecal markers of inflammation and disease activity scores using LOCF intention to treat and per 
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Table 4.2.  Change in disease activity parameters from baseline to treatment completion of patients using 





Intention to treat 
Median change (range) 
Per protocol 
Median change (range) 
EEN 
(n = 25) 
PEN 
(n = 13) 
p value EEN 
(n = 14) 
PEN 
(n = 9) 
p value 


























































Note:  change in each parameter is calculated by subtracting the value at week 8 from the baseline value.  




4.4.4.1 LOCF Intention-To-Treat Analysis of EN Therapy Outcomes (n = 38) 
LOCF analysis of patients who were recruited to use EEN found that CDAI significantly 
decreased from baseline to week 8 (W = -110.0, p = 0.025) as did CDAI of patients recruited to 
use PEN (W = -59.0, p = 0.006) (Figure 4-4).  At week 8, of the 25 patients referred for EEN, 17 
(68 %) had a CDAI of less than 150 or had a fall in CDAI of more than 70 points.  Treatment with 
PEN resulted in 8 out of 13 (62 %) patients achieving a CDAI of less than 150 or a fall in CDAI of 
more than 70 points.  There was no difference in the response of patients with newly diagnosed 
CD compared with those with existing CD (p >0.05).  Due to the similar response to both EEN 
and PEN treatment (Table 4.2) the two groups have been combined in the following paragraphs 
to analyse the effect of EN therapy on disease activity.   
 
LOCF analysis of all patients referred for EN therapy (n = 38) resulted in a statistically 
significant improvement in CDAI score over the eight week treatment (W = -324.0, p = 0.0005).  
There was also significant improvement in serum CRP within two weeks of EN (W = -189, p = 
0.003) and this change was maintained at week 8 (W = -198, p = 0.010).  There were no 
significant changes in serum ESR, FC or faecal OPG consequent to the EN therapies (p > 0.05 for 
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Figure 4-4.  Change in Crohn's disease activity index of all patients referred for enteral nutrition therapy. 
 
4.4.4.2 Per Protocol Analysis of EN Therapy Outcomes (n = 23) 
Per protocol analysis of the 23 patients who completed either EEN or PEN therapy also resulted 
in statistically significant improvements in disease activity scores and serum CRP but no 
significant changes in the other serum or faecal markers of inflammation.  The CDAI scores of 
patients who used EEN or PEN significantly improved (Figure 4-5) during the eight week 
treatment.  CDAI score had started to improve at week 4 but statistically significant 
improvements were not observed until treatment completion at week 8.  At treatment 
completion 13 of the 14 (93 %) patients using EEN had a CDAI < 150 as did seven of the nine (78 
%) patients who used PEN.  There were no significant differences in the proportion of patients 
who achieved disease remission with EEN compared with PEN or CDAI at week 8 (p > 0.05). 
 
As a result of the comparable improvements in CDAI consequent to EEN and PEN, changes in 
markers of inflammation of the two groups have been combined (n = 23) to improve the 
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statistical power.  Serum CRP at baseline was elevated (CRP ≥ 5 mg/L), or became elevated 
during treatment, in 17 of the 23 (74 %) patients who completed the EN treatment.  The median 
serum CRP at baseline was 9 mg/L (range, 3 – 71) and fell to a median of 5 mg/L (range, 3 – 22) 
after two weeks of EEN and then fell further to a median of 4 mg/L (range, 3 – 61) by week 8 of 
either EEN or PEN treatment (Figure 4-6).   There were no significant changes in serum ESR 
during EN therapy.  
 
FC improved after two weeks of EEN therapy but the initial improvement was not sustained 
throughout EN treatment (Figure 4-7).  The median FC fell from 830 µg/g (range, 60 – 3600 
µg/g) to 570 µg/g (range, 60 – 3564 µg/g) after two weeks of treatment and then increased to 
587 µg/g (range, 60 – 3569 µg/g) at week 8.  FC did not significantly increase in the PEN 
patients (n = 10) in response to introducing a small meal of solid food after week 2.  The change 


































( n  =  1 4 )
P E N
( n  =  9 )
W  =  - 8 5 . 0 ,
p =  0 . 0 0 5
W  =  - 4 5 . 0 ,
p =  0 . 0 0 4
0 4 8 0 4 8W e e k s
C D A I  =  1 5 0
 















W e e k s
W  =  - 9 7 . 0 , p  =  0 . 0 0 4
W  =  - 1 0 0 . 0 , p =  0 . 0 1 6
 





1 0 6 0
2 0 6 0
3 0 6 0























W  =  - 1 4 8 . 0 , p =  0 . 0 2 3
W  =  - 8 1 . 0 , p =  0 . 1 9 8
4 6
 
Figure 4-7.  Change in faecal calprotectin during enteral nutrition therapy (n = 23). 
 
 
4.4.5 Follow Up At Six Months 
Patients were followed up for four months post EEN or PEN.  Four of the 14 patients (30 %) who 
completed EEN, and four of the nine (40 %) patients who completed PEN, treatment had an 
escalation of treatment to treat recurrent active disease within four months of finishing EN.  One 
to two cartons of enteral formula was regularly as a supplement to usual diet by five patients (36 
%) from the EEN group and three patients (33 %) from the PEN group.   
 
4.5 Discussion 
This chapter presents the clinical and inflammatory marker data from the prospective non-
randomised clinical trials of EEN and PEN for the treatment of active CD in young adults with 
ileal or ileocolonic CD.  This patient cohort is different from many of the previous adult studies 
that have trialled EEN for a number of reasons.  Firstly, none of the patients in this study had 
isolated colonic CD.  It has been suggested that children with isolated colonic CD do not respond 
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as well to EEN as patients with any ileal involvement(198, 200) although another paediatric study 
has shown that colonic disease does respond to EEN.(201) A meta-analysis of randomised 
controlled trials of EEN therapy in mostly adult patients with active CD was not sufficient to 
adequately determine if disease location affected EEN treatment outcomes.(38)  The exclusion of 
patients with colonic CD in the current trials may have contributed to the high proportion of 
patients achieving a CDAI of less than 150 and/or a clinical response (fall in CDAI > 70) to EN 
therapy. 
 
The second characteristic which makes this patient cohort unique is that the majority of patients 
(79 %) were female.  Data from Canterbury, New Zealand shows that CD affects slightly more 
females (59 %) than males and that the incidence and prevalence of CD is higher in females than 
males between the current study’s age inclusion range of 16 – 40 years.(202)    Patients were 
referred into the study by their gastroenterologist and they did not provide data on the number 
of patients who were offered EN treatment but chose instead to use corticosteroid treatment.  
These data would have been difficult to accurately collect prospectively, especially as patients 
were referred from public and private clinics.  It is possible that more females chose to try EN 
therapy, although in Chapter 3 the results of an adult patient survey suggested that both males 
and females are interested in using EEN rather than corticosteroids to treat moderate to severe 
CD symptoms.  Referrer bias, offering EN treatment to more females, could also have skewed the 
study sex distribution.  Study recruitment occurred over a three year period therefore, the type of 
patient who was referred may have changed over time as the referring physicians became more 
familiar with the treatment.  A study which focused on adolescents with IBD suggested that EN 
therapy may be more attractive to female patients due to the potential negative impact of CS 
treatment on body image.(203)  But on the other hand, a large (n = 77) paediatric study of EEN 
found that females and older adolescents were more likely to withdraw from treatment due to 
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non-adherence.(198)  The exact reasons for the higher number of female participants in the 
current study are not known but should be explored in subsequent nutrition studies.  
 
This study is also different to previous studies because more patients had newly diagnosed CD 
and the median age of patients was younger than previous large randomised controlled trials 
comparing EEN with CS treatment.(129, 161-163)  EEN has been shown to be an effective treatment 
in children and adults with newly diagnosed disease.(17, 29, 160)  Twenty-nine percent of the study 
participants were less than 18 years old and three quarter of these patients withdrew from EN 
treatment for various reasons.  A Dutch paediatric study found that patients who withdrew from 
treatment were older (15.5 years old compared with 13.4 years old) and that non-adherence was 
more common in females.(198)  Adolescence is a challenging period of life and adolescents with 
IBD face similar social and psychological challenges to adolescents living with other chronic 
diseases(203)  In addition to this, CD diagnosed during childhood is likely to be more extensive 
than CD diagnosed in adulthood.(204)  It is likely that the per protocol outcomes of the present 
study may be better than other adult single centre studies of EN therapy due to the high 
proportion of patients with newly diagnosed disease but that treatment withdrawals may also be 
higher as a result of the proportion of older adolescent patients referred for treatment.  
 
Lastly, the patients who were referred to this prospective nutrition intervention study may not be 
representative of the general population of young adults with CD.  Patients were not randomised 
to the nutrition treatment but opted to use nutritional therapy, in most cases, instead of 
standard CS therapy.  A control group of patients on CS treatment was planned but only two 
patients were referred to the study over the two and half year study period.  The candidate made 
the following efforts to recruit more patients to the control group: attended weekly 
gastroenterology department meetings and periodically remind departmental staff about the 
clinical trial verbally and via email, attended outpatient gastroenterology clinics and reminded 
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gastroenterologists, trainees and the IBD nurse specialist of the study, screened outpatient notes 
for eligible patients.  On questioning, physicians thought that patients were more likely to be 
started on CS treatment in primary care by the family doctor rather than waiting for their next 
outpatient appointment at the tertiary care hospital.  Another possible source of CS referrals was 
patients who were admitted to hospital with a disease flare and required intravenous CS.  This 
group of patients were often started on CS on admission by the house surgeon and were not 
considered as potential study patients because, in most cases, the house surgeon was not aware 
of the study and did not inform the study dietitian and/or the patient was too ill to delay 
treatment until they had been recruited to the research study.  A couple of patients were referred 
for EN therapy from the endoscopy suite but no referrals were received for patients starting on 
CS treatment.  On reflection, recruitment into the control group may have been improved if a 
trainee doctor was involved in the study, because some physicians commented that they tended 
to associate the study dietitian with EN treatment rather than CS treatment and therefore did 
not think of the study when prescribing CS.  
 
The methodology used in this study is unlike most of the other known EN studies with adults.  
The early adult literature compared EEN with CS treatment and these studies tended to use a 
NGT to administer the EN formula(156, 157, 160, 162, 199) or asked patients to drink an EF orally.(17, 129, 
155, 159, 163)  More recent studies with adults have also delivered the formula via a NGT(86, 172, 173) 
rather than rely on patients to drink adequate volumes orally.  Feeding via a NGT allows the 
required volume of formula to be administered to the meet the patients’ needs, whereas asking 
the patient to drink the formula requires patients to adhere to a structured drinking plan.  The 
impact of this method on nutritional markers is discussed in more detail in Chapter 5.  This is 
one of the first studies with young adults that has used a ready to drink 1.5 kcal/mL PF 





The adult EEN literature has been discussed in detail in Chapter 1 section 4: in summary, there 
was a variable response by adults with active CD to EEN treatment.  The two large (51 and 55 
patients each) European multi-centre randomised controlled trials of EEN compared with CS 
found that EEN resulted in a reduction in CDAI of more than 40 % or a decrease in CDAI of 
greater than 100 points in 41 - 53 % of intention to treat patients and 60 – 71 % of per protocol 
patients.(162, 163)  The smaller studies of EEN, which included 10 – 15 patients, also reported a 
variable response to treatment.  Intention to treat disease remission, defined as a CDAI < 150, an 
HBI < 3 or VHAI < 120, was achieved by 40 – 80 % of patients and 40 -100 % of per protocol 
patients.(17, 156-158, 160)  The per protocol remission rate with EEN was the same or better than that 
achieved with CS treatment in four of these five small studies but not in the large multi-centre 
trials.  A Cochrane meta-analysis of randomised controlled trials of EEN compared with CS, 
which included some of the studies already mentioned and one paediatric study, concluded that 
CS were superior to EEN to induce disease remission in patients with active CD.(38)  The present 
study found that EEN therapy induced disease remission (CDAI < 150) in 60 % of patients 
referred for treatment and 93 % of patients who completed the EEN protocol.  The results 
observed in this study are comparable with those observed in earlier single centre studies of EEN 
treatment for active adult CD.   
 
This study used a novel PEN regimen of two weeks of EEN followed by six weeks of PEN plus 
one small meal per day.  Two paediatric studies have compared EEN treatment with a PEN 
regimen.  One of these studies, a multi-centre UK trial of 50 children, found that PEN was 
inferior to EEN as only 15 % of patients who used PEN were in remission (PDCAI < 10) at six 
weeks compared to 42 % of patients using EEN.(180)  This is an unusually low number of children 
achieving disease remission with EEN as other paediatric studies report remission rates of closer 
to 80 % with EEN treatment.(21, 28, 29)  One other paediatric study from North America compared 
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PEN (n = 16), EEN (n = 22) and also anti-TNF α (n = 52) therapy to induce disease remission.(179)  
A clinical response (PDCAI ≤ 10 or fall in PDCAI of ≥ 15) occurred in 64 % of per protocol 
patients using PEN (9/15) compared with 88 % of children using EEN (15/18) and 84 % (41/49) 
of children who used anti-TNF medication.  Both paediatric studies concluded that PEN was 
inferior to EEN to induce disease remission in children with active CD.  The novel PEN regimen 
used in this study with young adults had comparable results to the North American study.  The 
intention to treat response to PEN treatment was 62 % and per protocol response was much 
higher at 88 % of patients.  The possible reasons for this difference in response will be discussed 
in Chapter 5.  The novel PEN regimen used in the current study with 13 adult patients was a 
feasible and acceptable treatment, which was at least as effective as EEN to induce a clinical 
response and induce disease remission. 
 
Mucosal healing, defined as no endoscopic disease activity, is associated with longer periods of 
disease remission.(169)  FC has been suggested as a reliable non-invasive measure of endoscopic 
disease activity(67, 73, 74, 76) and therefore, improvements in FC as a result of treating intestinal 
inflammation are used as a marker of mucosal healing.  Many paediatric studies have shown that 
EEN is associated with complete mucosal healing in 58 – 81 % of children.(23, 28, 170)  Paediatric 
EEN studies have also shown improvements in FC subsequent to EEN, however FC is often still 
elevated post treatment.(165, 205, 206)  The baseline FC of patients in the current study ranged from 
60 – 3600 µg/g and the median was 1104 µg/g (n = 25).  There was a significant decrease in FC 
after two weeks of EEN but this trend did not continue throughout the rest of the treatment and 
at week 8 the median FC was 587 µg/g (n = 23) still ranged from 60 – 3569 µg/g.  Few studies 
have assessed mucosal healing using FC or endoscopy in adults after EEN treatment.  A 
Japanese study used EEN for four weeks in 20 patients and reported endoscopic healing of the 
ileum and the colon in 39 and 44 % of patients respectively and an endoscopic response in the 
ileum and colon in 76 – 78 % of patients respectively.(22)  This Japanese adult EEN study did not 
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achieve the same rates of mucosal healing reported in the paediatric EEN studies.  However, 
larger studies of adults with CD that have assessed endoscopic mucosal healing after anti-TNF 
treatment have reported similar rates of complete mucosal healing as the small Japanese EEN 
study.(207)  Currently there is no one medication or therapy that has achieved high rates of 
mucosal healing in adults with CD.  To achieve this goal, future studies should consider using a 
combination of pharmaceutical and nutritional approaches. 
 
Another potential marker of intestinal inflammation is faecal OPG.  A paediatric study 
investigated changes in serum, mucosal and faecal OPG before and subsequent to a six to eight 
week treatment with EEN in ten children with newly diagnosed CD.(68)  Faecal OPG was elevated 
at baseline and was highest in children with more severe disease.  The mean OPG decreased 
from 1994 ± 2289 pg/mL prior to treatment to a mean of 504 ± 551 pg/mL after treatment (p = 
0.002).  The current study with young adults found that at baseline faecal OPG was elevated in 
16/38 (42 %) of patients whereas in the paediatric study(68) none of the children had normal 
faecal OPG prior to treatment with EEN.  In the current studies, the faecal OPG of all of the 
adults (n = 23) after EEN treatment was normal (62.5 pg/mL).  This concentration of faecal OPG 
at baseline and subsequent to EEN was much lower than that observed in the paediatric 
study.(68)  
 
The difference in the faecal OPG results of the current and the paediatric study(68) may be a result 
of methodological issues.  OPG is present in very small amounts in stool; equivalent to a 
millionth of the concentration of FC.  Both this study and the paediatric study(68) used the same 
stool extraction and ELISA protocol as described in Chapter 2.  Due to the low concentration of 
OPG in the faeces the faecal samples could not be diluted more than two fold during the 
extraction process.  The one to one dilution of faecal sample to extraction buffer meant that more 
solid stool samples did not mix well despite samples being vortexed and homogenised.  If the 
137 
 
extraction buffer does not come in contact with all parts of the stool all of the OPG present may 
not be extracted into the supernatant.  Unfortunately the samples could not be re-tested due to 
the limited number of aliquots of stored stool and the relatively large volume of faecal matter 
required to yield an adequate volume of supernatant to use in the ELISA.  The commercial OPG 
kit is primarily designed to measure serum OPG and based on the above methodological issues 
probably needs to be optimised to ensure that OPG is effectively extracted from stool samples of 
varying consistencies.  
 
4.6 Conclusion 
Nutrition-based therapies are probably not appropriate for all patients but with adequate 
multidisciplinary support, EEN and PEN therapy are feasible and successful treatments for 
selected patients who are interested in using a nutritional approach to treat active CD.  However, 
not all patients will tolerate the treatment and withdrawals should be expected.  The results of 
these two pilot clinical trials support the hypotheses that EEN therapy induces clinical remission 
and partially induces biochemical disease remission and that a PEN regimen is as effective as 
EEN in young adults with active CD.  EN therapies should be considered as a feasible and 
effective option for young adults with active CD.  
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     Chapter 5 
Clinical Trial: Nutrition  
5.1 Introduction 
The treatment of active CD with EEN reduces inflammation and has additional benefits over and 
above inducing disease remission.  In children, these benefits may include improvements in 
nutrition status.(208)  The benefits of EEN on nutrition status are also recognised in malnourished 
adults with CD in whom EEN is considered an appropriate adjuvant treatment option.(36, 37, 209)   
Children with active CD treated with PEN have achieved comparable energy and nutrient intakes 
and had similar improvements in body weight as children using EEN, but PEN did not reduce 
inflammation and induce disease remission as effectively as EEN treatment.(179, 180)  PEN with a 
specific exclusion diet has been used in adults (n = 11) with active disease in one study.(181)  The 
study reported no significant changes in weight or serum albumin.  The literature to date in 
children suggests that PEN has a similar effect as EEN on nutrition status but the impact of the 
two treatments on nutrition status have not been compared in an adult cohort.    
 
Malnutrition is prevalent in patients with active CD and disease in remission.(41, 210, 211)  BMI is a 
simple measure of nutrition status but it does not differentiate between fat mass and functional 
muscle mass.   Adults with CD do have altered body composition compared with a healthy 
population(212) therefore, BMI may not be a good indicator of malnutrition and/or sarcopenia in 
people with CD.  This is especially pertinent as the average BMI of the NZ population 
increases.(213)    
 
Poor nutrition status is reflected not only in altered body composition but also poor 
micronutrient status.  Common micronutrient deficiencies include folic acid, calcium, vitamin D 
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deficiency, iron deficiency anaemia, zinc and, in patients with a previous small bowel resection, 
vitamin B12 deficiency.(45, 209)  Serum albumin may also be low in patients with poor nutrition 
status however, albumin is an acute phase protein which decreases in response to inflammation 
therefore, may not truly reflect nutrition status during active CD.(40)  A less common marker of 
nutrition status is IGF-1.  In older adults IGF-1  is a sensitive predictor of muscle strength(47) and 
in children with CD low IGF-1 is associated with growth retardation.(214)  Adults with CD have 
lower IGF-1 concentrations than age-matched healthy controls.(215)  EEN treatment in children 
with active CD is associated with an early rise in IGF-1, which could be suggestive of an anti-
inflammatory effect as well as improvement in nutritional intake.(48)  Changes in serum IGF-1 
has not been investigated in adults using EEN therapy. 
    
5.2 Aims and Hypotheses 
This chapter presents the nutrition-related results from the three prospective clinical trials of 
EEN and PEN in patients with active CD and EEN in a HC group.  These studies aimed to assess 
various markers of nutrition status and to primarily document the baseline nutrition status of 
young adults with active CD compared with a comparable healthy population.  Secondly, these 
studies aimed to evaluate the impact of EEN and a novel PEN therapy on dietary intake and 
nutrition status in both adults with active CD and healthy adults.  It was hypothesised: 
 That enteral nutrition therapy improves markers of nutritional status. 
 
5.3 Methods 
The clinical trial methods have been described in full in Chapter 2.1 and summarised again in 





All patients and healthy volunteers were prescribed EN based on the BMR calculated as part of 
the BIA assessment multiplied by a physical activity factor.(184)  These calculations provided an 
estimated energy requirement (EER), for example seven cartons (2100 kcal) of nutritional 
formula per day.  If a person’s EER was 7.4 cartons of nutrition formula per day an intake range 
was recommended, for example 7 – 8 cartons (2100 - 2400 kcal/day), and patients were asked to 
drink more cartons on days when they were more active.  For the purposes of calculating EN 
intake as a percentage of EER the mid-point of a cartons/day range was assumed to be the EER, 
for example the EER for a person recommended 7 – 8 cartons/day (2100 - 2400 kcal/day) was 
2250 kcal/day.  
 
The patients who were prescribed PEN completed an electronic food record during the last 
fortnight of the PEN treatment.  The purpose of the food record was to estimate the calorie and 
macronutrient intake from solid foods compared with the EN formula.  The full methods 
describing the electronic food record and the analysis of the food record data are detailed in 
Chapter 2 section 2.1.12.  In brief, oral intake from foods and fluids recorded in the electronic 
food record were entered into the University of Otago, Dunedin, dietary analysis programme 
“Kai-culator” (Department of Human Nutrition, University of Otago, NZ version 1.14f).  The 
average intake from the dietary records was calculated as a percentage of total nutrition intake.  
 
The patients using PEN could introduce a small meal once a day for the last six weeks of the 
treatment.  There were no restrictions on the type of food which patients could consume for this 
meal.  Each patient was provided with some guidelines for reintroducing foods.  The guidelines 
suggested introducing easily digestible foods that are low in fat and fibre and increasing the 




Each patient recorded their average EN intake fortnightly as cartons of formula per day and were 
encouraged to disclose if they had eaten or drunk anything in addition to what was 
recommended.   
 
5.4 Results 
5.4.1 Serum Markers of Nutrition Status at Baseline 
Patients referred for treatment of active CD with EEN or PEN had similar median serum 
haemoglobin, ferritin, vitamin D and IGF-1 concentrations at baseline (Table 5.1) however, the 
median concentration of albumin was lower in the PEN group (Figure 5-2).  All serum markers 
of nutrition, except vitamin D, were correlated with serum CRP (Spearman correlations, p < 
0.01).  Nineteen (50 %) of the patients with CD had lost weight (1.5 to 24 kg) in the three months 
prior to starting EN therapy.  The baseline IGF-1 SDS of this group of patients was significantly 
lower than those who had not lost weight prior to starting treatment (Figure 5-1).  There was no 
significant difference in the baseline BMI of patients who had, or had not, lost weight prior to 
starting EN therapy (Mann Whitney test, p = 0.588).    
 
Serum vitamin D of patients referred for EN therapy varied significantly between the winter 
(May and October) and summer (November to April) months (U = 58.0, p = 0.0007).  The 
median Vitamin D of patients starting EN in the winter months was 43.0 nmol/L (range, 17.0 to 
101 nmol/L) compared with 72.0 nmol/L (range, 42 to 106 nmol/L) for patients starting 
treatment in the summer months.  A serum vitamin D of less than 50 nmol/L (defined as 
insufficient vitamin D(185)) was present in 12 of the 19 patients (63 %) in the winter months 
compared with four of the 17 patients (24 %) in the summer months.  Vitamin D deficiency 
(defined as less than 25 nmol/L(185)) was present in four patients (24 %) starting EN therapy in 
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the winter months and no patients starting EN therapy in the summer months.  Two patients 
were excluded from this analysis; one had recently returned from a two week winter holiday in 
Fiji and another took high dose (50,000 IU/day) vitamin D supplements.  There was no 





Table 5.1.  Baseline serum markers of nutrition status of patients using enteral nutrition therapy. 
Serum markers  EEN (n = 25) 
Median (range)  
or n (%) 
PEN (n = 13) 
Median (range)  
or n (%) 
All patients (n = 
38) Median 
(range)  
or n (%) 
EEN vs PEN 
p  
CRP (mg/L) + 9.0 (3.0, 158.0) 25.0 (3.0, 71.0) 12.0 (3.0, 158.0) 0.199 
Albumin (g/L) 41.0 (34.0, 49.0) 34.0 (26.0, 
45.0)* 
39.0 (26.0, 49.0) 0.022 
IGF-1 (SDS) -0.3 (-2.7, 0.6) 0.0 (-2.9, 0.9) -0.2 (-2.9, 0.9) 0.826 
Haemoglobin (g/L) 
< 115 (g/L) for females 
< 130 (g/L) for males 
130.0 (88.0, 151.0) 
4 (22) 
1 (13) 









< 20 (µg/L) 












< 50 (nmol/L) 













SDS – standard deviation score,  
* Mann-Whitney U test comparing baseline data of EEN group with PEN group, p < 0.05  
+ CRP is included in this table as a marker of inflammation.  The presence of inflammation reduces serum 










Figure 5-2.  Baseline serum albumin concentration in patients referred for enteral nutrition therapy. 
Figure 5-1.  Baseline serum IGF-1 of patients who had, and had not, lost weight  
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145 
 
5.4.2 Baseline Dietary Exclusions 
Patients with active CD referred for EN therapy often excluded foods or drinks from their diets.  
Twenty-two (58 %) patients reported excluding at least one food or drink from their diets and 11 
(29 %) excluded more than one food or drink.  The most common dietary exclusions were dairy 
(9 patients), alcohol (8 patients), wheat/gluten (6 patients), lactose (6 patients), caffeine (5 
patients) and high fat foods (4 patients).  Two patients commented that they excluded foods high 
in fermentable carbohydrates, two were following a low residue diet to manage bowel strictures 
and three patients did not tolerate either apple, citrus or high fructose corn syrup.   
 
5.4.3 Baseline Body Composition 
There were no significant differences in the body composition of patients recruited to use EEN or 
PEN.  Only one male was recruited to the PEN group therefore, the body composition data for 
the EEN and PEN intervention groups have been combined into one CD patient group presented 
in Table 5.2.  The CD patient group had similar body composition parameters compared with the 
HC group (Table 5.2). 
 
The median BMI of patients with active CD and HC was similar and there was no statistically 
significant differences in the distribution of participants across the BMI categories as illustrated 





Table 5.2.  Baseline body composition characteristics of healthy controls and patients with active CD. 
Body composition 
measures 
CD group (n = 38) 
(Male = 8, Female = 30)  
Median (range) 
HC group (n = 21) 
(Male = 7, Female = 14)  
Median (range) 
CD vs HC 
p 
Weight (kg) M: 64.1 (53.8, 110.7) 
F: 63.2 (41.0, 114.6) 
M: 78.2 (71.1, 127.6) 
F: 66.1 (50.8, 97.5) 
0.091 
0.420 
Height (cm) M: 177 (167, 190) 
F: 165.5 (153, 179) 
M: 178.5 (175, 191) 
F: 167.5 (157, 176) 
0.518 
0.398 
BMI (kg/m2) M: 22.8 (16.8, 30.7) 
F: 23.6 (16.5, 37.8) 
M: 25.4 (21.9, 38.0) 
F: 23.7 (18.7, 31.8) 
0.252 
0.795 
Fat mass index 
(kg/m2) 
M: 3.1 (1.9, 9.9) 
F: 6.6 (2.2, 16.3) 
M: 3.8 (2.1, 12.5) 





M: 19.2 (14.7, 22.4) 
F: 16.9 (12.6, 21.5) 
M: 21.2 (19.6, 25.5) 
F: 17.7 (14.7, 20.5) 
0.096 
0.365 








































































C r o h n 's  d i s e a s e  ( n  =  3 8 )
H e a l t h y  c o n t r o l s  ( n  =  2 1 )
147 
 
5.4.4 Adherence to the Enteral Nutrition Protocol  
EEN was used for two weeks by three study groups, two with active CD (n = 32) and a HC group 
(n = 17).  During this time only two of the 49 participants reported eating any food after the 
three-day EN phase-in period.  No one reported drinking fluids other than tap water and black 
unsweetened coffee, tea or herbal tea.  Black tea and/or coffee was drunk by 17 of the 32 (53 %) 
of the patients with CD and 11 of the 17 (65 %) of the HC.  The remainder of the study 
participants drank only tap water.  After two weeks of EEN, the HC participants re-introduced 
usual foods and fluids, whereas the patients with CD either continued with EEN for another six 
weeks or introduced a small meal of usual foods once a day in addition to EN for six weeks (PEN 
group).  
 
Table 5.3 details the additional food and fluids consumed during EEN and PEN interventions.  
Three patients in the EEN intervention group were using EEN on Christmas Day and were 
allowed, by the study coordinator, to have a small meal on this day only.  None of these three 
patients experienced any CD symptoms as a result of eating the Christmas day meal.  The 
additional food that was occasionally consumed was not included as part of the patients’ total 
calorie consumption unless it was habitual, such as the patient in the PEN group who had a row 
of chocolate every evening.  Adherence to the study protocols was greatest during the first two 
weeks of treatment (Table 5.3).  All of the HC group volunteers who used EEN for two weeks 
were 100 % compliant with the liquid diet.  Over the eight EN treatments 3/9 (33 %) of the 
patients who used PEN and 6/14 (43 %) of the patients who used EEN were 100 % adherent with 
the treatment protocols.  There were no significant differences in the baseline characteristics or 
outcomes of patients who adhered to the protocols compared with those who did not.  
 
Two patients in the PEN group decided to continue with EEN for a further two weeks and delay 
reintroducing food.  One of these patients had a known focal sealed small bowel perforation and 
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was awaiting surgery when she started in the study.  Upon reintroduction of food at week two the 
patient flared and it was decided that she would continue on EEN and the date of surgery was 
brought forward.  The patient left the study at week four and had an ileal resection.  The other 




Table 5.3.  Patient reported deviations from the enteral nutrition protocols. 
Intervention 
follow up  
EEN protocol deviations  PEN protocol deviations  Patient adherence to 
study protocol (%) 
Week 2  
EEN (n=21) 
PEN (n=11) 
small snacks throughout the first two weeks (n=1) 
½ a biscuit and couple of potato chips (n=1) 
a flat white coffee (n = 1) 
nil EEN – 86 % 
PEN – 100 % 
HC – 100 % 
Week 4  
EEN (n=18) 
PEN (n=11) 
small meal on Christmas day (n=2) 
black coffee with ½ tsp sugar (n=1) 
1x can lemonade, little shaved ham and ½ 
croissant (n=1), cough lollies (n=1) 
2x energy drink, souvlaki, butter chicken curry, 
‘Subway’ (n=1)  
Fruit drink (n=1), juice (n=1) 
Chocolate nightly (n=1), ½ piece of slice (n=1), handful 
of chips (n=1)) 
1x ½ friand and occasionally some chocolate (n=1) 
 
EEN – 66 % 
PEN – 55 % 
HC – N/A 
Week 6  
EEN (n=14) 
PEN (n=9) 
1x rice and vegetables (n=1), small meal on 
Christmas day (n=1), a flat white coffee (n = 1) 
1x imperial mint, little cupcake batter (n=1) 
1x peanut cookie, moro bar, can lemonade, 
pumpkin/potato mash (n=1) 
Fruit drink (n=1) 
1 square of chocolate (n=1), chocolate nightly (n=1) 
1x ½ friand and orange juice (n=1) 
Non-alcoholic punch with some crackers and chips (n=1) 
 
EEN – 64 % 
PEN – 45 % 
HC – N/A 
Week 8 EEN 
(n=14) 
PEN (n=9) 
1x diet coke and one small meal (n=1) 
1x glass orange juice, 1x chicken and salad 
sandwich (n=1) 1x small cup cake (n=1), cough 
lollies (n=1), potato chips, 1 piece fish, 3x 
chocolate biscuits (n=1) 
Juice (n=2), chocolate once (n=1), 1x biscuit nightly 
(n=1) 
1x mandarin & a row of chocolate (n=1) 
Orange drink and two meals per day (n=1) 
 
EEN – 64 % 
PEN – 33 % 




Most patients using PEN chose to eat dinner as their one meal per day.  This meal was chosen so 
that it could be shared with family members.  Eight of the nine patients completed and uploaded 
an electronic food record for two to four days.  One patient, who lived in a student flat and did 
not share meals or cooking duties with her flatmates, ate smooth peanut butter sandwiches daily 
and occasionally had a smooth yoghurt as well.  The rest of the PEN group patients tended to eat 
meals consisting of chicken, red meat and sometimes fish with a carbohydrate food (potato, rice, 
pasta, bread, pastry) and vegetables either cooked or raw in a lettuce based salad.  There was a 
large range in the calories consumed from the solid food meal of 363 - 1122 kcal which 
contributed 35.5 % (range, 14.7 to 59.9 %) of total energy consumed from both solid food and 
enteral formula.  Patients consumed a median of 1050 kcal/day (range, 750 to 1800 kcal/day) of 
EN formula which equates to a median of 62 % (range, 29 to 103 %) of EER.  Most patients 
consumed less kilocalories than their EER and there were no significant differences in the energy 






Table 5.4.  Average caloric intake as a percentage of estimated energy expenditure during the first and last 







% EER at week 2 93 (64, 117) 
(n = 21) 
90 (69, 129) 
(n = 11) 
88 (75, 105) 
(n = 17) 
% EER at week 8 93 (64, 114) 
(n = 14) 
80 (61, 124) 
(n = 8) + 
n/a 
% kcal from food n/a 35.5 (14.7, 59.9) 
(n = 8)+ 
n/a 
n/a: not applicable.  




5.4.5 Change in Serum Nutrition Markers 
Serum markers of nutrition, albumin and IGF-1, were measured fortnightly during EN therapy 
and at week 12 and 26 after therapy.  These data were analysed using a LOCF and a per protocol 
method.  The LOCF analysis found that patients who used EEN had a statistically significant 
improvement in serum IGF-1 concentration during treatment (W = 125.0, p = 0.01) and serum 
albumin (W = 112.0, p = 0.034).  There was also a non-significant trend towards decreased 
serum CRP (W = -87.0, p = 0.060).  Per protocol analysis with the 14 patients who completed 
the EEN treatment yielded similar results (Table 5.6).  There were no significant changes in 
serum albumin, IGF-1 or CRP in the PEN patient group during treatment using LOCF (n = 13) or 
per protocol analysis (n = 9).  Serum albumin and IGF-1 were no longer correlated with serum 
CRP at week 8 (Spearman correlation, p > 0.05). 
 
There were no statistically significant differences in median serum CRP or IGF-1 between 
patients who used EEN compared with PEN treatment.  Change in albumin was calculated to 
correct for differences in baseline albumin between the treatment groups.   Patients in the EEN 
group trended towards a greater improvement in median serum albumin compared with patients 
in the PEN group (W = 32.0, p = 0.050).  Figure 5-4 shows the individual variation in serum 
albumin in response to the EN treatments.  The change in serum albumin was not correlated 
with change in CRP in the EEN group (p = 0.171) or the PEN group (p = 0.344). 
 
Serum markers of nutrition remained stable after EN therapy once food was reintroduced with 
the exception of serum albumin in the EEN patient group.  Serum albumin significantly 




Table 5.5.  Serum albumin, IGF-1 and CRP of patients during and after enteral nutrition therapy using last observation carried forward analysis. 
 EEN (n = 25) PEN (n = 13) 



















































* Wilcoxon matched-pairs signed rank test of change from baseline to week 8 or week 8 to week 26, p < 0.05  




Table 5.6.  Serum albumin, IGF-1 and CRP of patients during and after enteral nutrition therapy using per protocol analysis. 
 EEN (n = 14) median (range) PEN (n = 9) median (range) 



















































* Wilcoxon matched-pairs signed rank test of change from baseline to week 8, p < 0.05  
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Figure 5-4.  Change in serum albumin during enteral nutrition therapy. 
 
5.4.6 Change in Body Composition 
During the first two weeks of EEN therapy both patients with active CD and HC lost weight 
(Table 5.7).  There was no significant difference in change in BMI observed between the three 
groups.  The EEN intervention resulted in further weight loss over the next six weeks (Figure 5-5) 
but there was no significant difference in the change in BMI between those using EEN compared 
with patients using PEN.   
 
At the completion of the two week intervention in the HC group, and the eight week intervention 
in patients with active CD, each person resumed eating and drinking their usual foods and fluids.  
All study participants (patients with CD and HC) were reviewed after four weeks of consuming a 
usual diet and the median BMI had increased in all groups and was not significantly different 
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Table 5.7.  Change in body mass index from baseline during enteral nutrition therapy and upon 
reintroduction of usual dietary intake. 




HC (n=17)  
Median (range) 
Baseline 23.7 (18.5, 33.8) 25.2 (16.5, 29.5) 23.8 (18.7, 35.0) 
Week 2 -0.20 (-1.1, 0.8) -0.40 (-1.1, 0.7) -0.30 (-1.1, 0.4)** 
Week 8 -0.95 (-2.0, 1.3)* -0.50 (-1.6, 2.0) - 
After 4 weeks of usual 
diet 
-0.35 (-1.9, 1.9) -0.50 (-2.3, 2.2) -0.10 (-2.0, 0.6) 
*p < 0.5, **p < 0.01 BMI at baseline compared with week 2 or week 8 of enteral nutrition intervention   
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5.4.7 Dietary Exclusions after Nutrition Intervention 
As stated in section 5.4.2 many patients referred for EN therapy excluded certain foods at 
baseline.  Six months later, after completion of EN therapy, six patients (26 %) did not exclude 
specific foods and 17 patients (74 %) excluded at least one food from their diet.  Seven of the 17 
who excluded foods at follow up did not exclude foods at baseline.  Another seven patients had 
different food exclusions at baseline compared with follow up at six months.  Common food 
exclusions at follow up were gluten (5 patients), dairy/lactose (4 patients), fatty foods (4 
patients), alcohol (3 patients), spicy foods (3 patients) and foods high in fermentable 
carbohydrates (3 patients). 
 
5.5 Discussion 
This chapter presents the nutrition-related data from the prospective non-randomised clinical 
trial of EEN and PEN for the treatment of active CD in young adults and a trial of EEN in healthy 
young adults.  The baseline and change in nutrition markers consequent to EN therapies will be 
discussed, followed by discussion of the tolerance of EN therapy between patients with CD and 
HC and, finally, adherence to the PEN regimen compared with other PEN studies.  
 
Patients with active CD referred for EN therapy during winter months had a high incidence of 
vitamin D insufficiency.  The general population living in the central and lower South Island of 
NZ also have a high prevalence (18.1 % (95 % CI (12.0 to 26.4))) of vitamin D deficiency (< 25 
nmol/L) in August to October and the prevalence of vitamin D insufficiency (< 50 nmol/L) is 
46.4 % (95 % CI (37.0 to 55.8)).(213)  The prevalence of insufficient vitamin D and vitamin D 
deficiency during the winter months was higher in this study cohort of young adults with active 
CD than in the general central and lower South Island population during a similar time period.  
However, the prevalence of low vitamin D was less extreme than has been observed in a 
comparable population of patients with existing CD from Dunedin,(50) a city further south (45° 
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52’ S, 170° 30’ E) of Christchurch (43° 53’ S, 172° 63’ E).  The Dunedin study measured serum 
25-hydroxy vitamin D in 29 patients in winter (June to September) months and during summer 
(December to March) months and found that 76 % of patients had a vitamin D of less than 50 
nmol/L in the winter compared with only 10 % of patients in summer.(50) The patients included 
in the Dunedin study were not taking vitamin D supplements and the study found no correlation 
between disease activity and seasonal variation in vitamin D concentrations.  This study did not 
aim to specifically assess the impact of vitamin D insufficiency or deficiency and its treatment 
therefore data on sun exposure, sun protective practices, vitamin D status after EN treatment 
and prescription practices were not collected.  Current IBD treatment guidelines recommend 
vitamin D supplementation for people with IBD living in locations with limited UVB sun 
exposure(216), which includes the central and southern South Island of NZ during the winter 
months. 
 
There were no differences in the baseline body composition of patients with active CD and HC.   
Previous research has not conclusively shown that patients with recently diagnosed CD have 
altered body composition.(212)  A limitation of many studies is the lack of a comparable healthy 
population.  One study which assessed body composition using BIA and did have a comparable 
control group found that healthy males had significantly higher fat-free mass compared with 
males with CD, whereas females did not.(46)  There is now research investigating, not only fat-free 
mass, but skeletal muscle mass and the prevalence of sarcopenia in patients with IBD.  
Sarcopenia (defined as appendicular skeletal muscle mass (calculated using dual-energy X-ray 
absorptiometry (DXA)) and hand grip strength of more than one standard deviation below the 
mean) has been observed in free living patients with CD who have a normal BMI.(217)  BIA 
provides basic information on patient body composition but in the absence of normal ranges for 
FMI and FFMI or functional measures of lean body mass BIA may not provide any more insight 




Both the per-protocol EEN and PEN groups had increases in serum IGF-1 and reductions in CRP 
after two weeks of using EEN.  Serum IGF-1 is a marker of nutrition status and has also been 
suggested as a marker of disease activity(48, 218) due to its reduced expression in the presence of 
pro-inflammatory cytokines.(219)  An early rise in IGF-1 has previously been documented in 
paediatric IBD studies subsequent to EEN treatment.(48, 220)  Both paediatric studies concluded 
that early improvements in IGF-1 concentration are due to reduced inflammation and 
improvement in nutrition intake.  There is no research in adults with CD that has assessed 
change in IGF-1 subsequent to EEN therapy.  However, the serum IGF-1 concentration of adults 
with CD and UC has been compared with a HC group in a Greek study.(215)  Greek adults with 
IBD had lower IGF-1 concentrations and higher IL-6 concentration than the HC group.  This 
study did not report the IGF-1 SDS therefore, it is difficult to compare the mean concentration 
with data from the current study because IGF-1 normal ranges vary by age and sex.  Median 
serum IGF-1 concentrations in this study cohort increased during EN therapy, despite 
suboptimal caloric intake of 85 – 91 % of EER and reductions in BMI, and corresponded with a 
reduction in CRP.  These results support the paediatric IBD observations that IGF-1 is more than 
just a marker of nutrition status and that improvements in serum IGF-1 concentration are also 
due to reduced gut inflammation. 
 
During the EN treatments adults with CD, as well as healthy adults, consumed less energy than 
their EER and consequently weight loss was observed.  This trend is the reverse of what is 
usually observed in paediatric studies where weight gain is the goal and many centres use 
nasogastric tubes to meet caloric requirements.(16)  Adults using PEN had a non-significant 
decrease in BMI during the first two weeks of treatment but once some solid food was introduced 
the mean BMI stabilised.  In order for weight to stabilise a natural assumption would be that 
patients were meeting their energy requirements however, analysis of the food records show that 
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mean energy intake was only 85 % of EER compared with 91 % during the EEN phase of the PEN 
regimen.  It is likely that the food records underestimate the average energy intake of patients 
during the six weeks of PEN treatment.  Patients were asked to complete an electronic food diary 
for four days during the six week intervention.  Most patients completed only three days of food 
record therefore, the nutrient intake from solid food is based on a limited number of days for 
eight patients.  In addition a novel food record was used which has not been validated for use 
with young adults.  The electronic app-based food record has been validated (unpublished data) 
for use with NZ children and their parents by the Department of Human Nutrition, University of 
Otago, Dunedin.  It was assumed that it would also be appropriate for young adults given the 
high ‘smartphone’ ownership by young adult New Zealanders.(221)  One patient had trouble with 
the technology and another exceeded their mobile data allowance and used a combination of 
electronic and paper food records.  One of the benefits of the electronic food record is that the 
investigator can gain further information from the photographs of the meals that may not have 
otherwise been included in the description of the food by the participant.  It may also be a more 
accurate method of estimating portion size which may not be captured in a paper record.  One of 
the limitations of the photography method is that the person needs to remember to photograph 
the meal before they start eating, whereas a paper diary could be completed after the meal is 
consumed if required.  There are inherent disadvantages with all methods of food records and 
under-reporting is always an issue.(222)  Overall the use of PEN regimen appears to limit weight 
loss during treatment but despite further weight loss during EEN treatment patients regained 
weight upon reintroduction of food. 
 
The PEN regimen used in this clinical trial is different from those studied previously.(179-181)  This 
PEN regimen combined two weeks of EEN with six weeks of PEN in which patients were 
prescribed a set amount of food to consume in place of a proportion of EN rather than a set 
amount of formula plus unrestricted usual foods.  The mean intake of usual foods during the 
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PEN phase was 33 % (range, 15 – 60 %) of total energy.  There are two paediatric CD PEN 
studies which have allowed the consumption of usual foods and the patients in both studies 
consumed more calories from usual foods than the concurrent PEN regimen.  In the North 
American study(179) children using PEN consumed 47 % (range, 10 - 75 %) of total energy from 
usual foods and the UK study intake of usual foods contributed 53 % (range, 42 – 61 %) of total 
energy in the PEN and 2 % (range, 0 – 11%) of total energy in the EEN group.(180)  The third PEN 
study included 33 children and 14 adults (aged 19 – 32 years old) and prescribed 50 % of energy 
from a 1.0 kcal/ml polymeric EN formula and the other 50 % to come from a specific list of 
foods.(181)  The study did not report the amount of energy patients ultimately consumed from 
food.  The mean energy intake from solid food in the current study was lower than the other 
three PEN studies.  However, even though patients were asked to consume a small meal (half of 
their usual portion size) the evening meal still contributed a large proportion of total calories for 
some patients, particularly those who had a lower total energy intake, such as 600ml of EN 
formula during the day.  In retrospect, patients with lower energy intakes may have benefitted 
from adding a small volume of EN formula to the evening meal to help reduce their total energy 
intake of solid food at that one meal.  Despite the large range in energy intakes from solid food, 
the PEN regimen, as discussed in Chapter 4, was as effective as EEN at reducing symptoms of 
active disease.  
 
The use of exclusion diets, or exclusion of particular foods, in an attempt to manage disease 
flares may be prevalent in patients with CD.(223)  Single and multiple food exclusion were 
common in this NZ cohort of young adults with CD, many of whom were newly diagnosed.  Food 
exclusions appeared to change over time suggesting that patients are experimenting with how 
food may or may not affect their gastrointestinal symptoms or their tolerance of certain foods 
may be affected by disease activity.  This study did not investigate the reasons for excluding 
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foods from the diet but given the high prevalence of malnutrition in patients with CD it would be 
interesting to investigate if long term food exclusion behaviour affects nutrition status. 
 
5.6 Conclusion 
The current study shows that, in a real world setting, as opposed to the hypothetical setting in 
Chapter 3, EEN with an oral polymeric ready-to-drink formula is a palatable and mostly well 
tolerated treatment for adults with active CD.  Intolerance of the formula and regimen should be 
expected and occurs in a proportion of healthy adults and adults with active CD.  The treatment 
of active CD with EEN results in an early and statistically significant continued improvement in 
serum IGF-1 concentrations and a trend towards increased serum albumin, but a statistically 
significant reduction in BMI.  Conversely, treatment of active CD with PEN resulted in less 
weight loss and no statistically significant changes in serum IGF-1 or albumin.  These data 





     Chapter 6 
Clinical Trial: Psychological Outcomes 
6.1 Introduction 
It is well established that many patients with CD have poorer HRQOL(83, 84) and higher rates of 
anxiety and depression(94, 95) than the general population.  Previous literature suggests that 
anxiety is present in up to 40 % of adults with CD(94, 101, 103, 104) and that up to 10 % suffer from 
depression.(99-101, 103)  The determinants of HRQOL are varied and may include disease activity, 
hospitalisations and disease treatments.(85)  The impact of EEN therapy on HRQOL has not been 
investigated in Western adults with CD.  
 
6.2 Aims and hypotheses 
The aim of assessing HRQOL in this study’s patient cohort was to document the baseline 
characteristics of young adults with active CD and to evaluate the impact of EN therapies on 
HRQOL.  It was hypothesised: 




HRQOL was assessed before, during and after EN treatment using two validated self-assessment 
QOL tools: HADS(88) and SIBDQ.(115)  The complete methods are detailed in Chapter 2.1.11.  In 
summary, the HADS tool assesses the presence of symptoms of anxiety and depression.  A HADS 
subscale score of less than eight suggests the absence of depression; a borderline abnormal score 
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is eight to ten and a score greater than 10 is abnormal.  A cut-off of greater than eight is 
recommended to detect the presence of anxiety and/or depression.(93)   
 
The SIBDQ asks 14 questions related to the impact of disease symptoms on social and personal 
functioning.  The answer to each question is assigned a score of one to seven points, the mean of 
which is the SIBDQ score.  For each question a score of one indicates very poor HRQOL and a 
score of seven indicates optimal HRQOL.      
 
6.4 Results 
6.4.1 Hospital Anxiety and Depression Scale  
6.4.1.1 HADS-anxiety (HADS-A)  
At baseline there was no difference in the median HADS-A score between patients recruited to 
use EEN or PEN to treat active CD (Table 6.1).  Anxiety (HADS-A score of 8 or greater) was 
present in 47 % of patients with active CD (Table 6.1) and HADS-A scores at baseline were not 
correlated with baseline disease activity (p > 0.05).  Baseline HADS-A scores did not differ 
between patients who were newly diagnosed (n = 30) or had existing CD (n = 8) nor between 
patients who withdrew from the study and those who completed EN therapy.   EEN therapy for 
two weeks was associated with improved HADS-A score.  Thirty-three patients (87 %) completed 
two weeks of EEN and the median improvement in HADS-A score during this time was 2.0 
points (W = -283.0, p = 0.0001).  The patients who continued EN therapy and completed either 
EEN or PEN had further improvements in HADS-A score (Figure 6-1).  Nine of these patients had 
anxiety at baseline and four still had a HADS-A score of eight or more at the end of EN 
treatment.  Median HADS-A scores did not change from week 8 (3.0 (range, 0 – 14)), at the end 
of the EN treatment, to the follow up appointment at six months (3.0 (range, 0 – 14)) (W = 0.0, 




One of the patients who used CS treatment moved from borderline anxiety (score 8-10) to 
anxiety (score > 10) at week eight of treatment, whereas the other patient had an improvement 
in anxiety score of five points and moved from a score >10 to a score of < 8 at week eight. 
 
6.4.1.2 HADS-depression (HADS-D)  
At baseline, depression, defined as HADS-D score of eight or more, was present in 19 % of the 38 
patients recruited to use EEN or PEN therapy and the median HADS-D score was 4.0 (range, 1 – 
14) (Table 6.1).  Median HADS-D score did not differ between patients with newly diagnosed and 
existing CD nor between patients who completed EN therapy compared with those who 
withdrew from the study.  There was no statistically significant improvements in median HADS-
D score in patients who completed eight weeks of EEN or PEN treatment (p > 0.05).  Three of 
the patients who completed EN therapy had a HADS-D score of 8 or more at baseline and 
HADS-D score was still high in one patient at the treatment completion.  HADS-D score was not 
correlated with CDAI at baseline or treatment completion (p > 0.05).  The median HADS-D 
score at follow up at six months (1.0 (range, 0 – 9) was not significantly different from scores at 
the conclusion of the EN therapies (2.0 (range, 0 – 9)) (W = -48.0, p = 0.341). 
 
For the two patients who used CS a similar result was observed on the depression questionnaire 
as was seen on the anxiety questionnaire.  One patient who had depression at baseline still had 
depression at week eight and the other patient who had borderline depression at baseline had a 




Table 6.1.  Presence of anxiety and depression in patients with active CD at baseline. 
 
HADS classifications 
EEN group  
(n = 25)  
n (%) 
PEN group  
(n = 13)  
n (%) 
All patients  
(n = 38)  
n (%) 
Newly diagnosed  
(n = 30)  
n (%) 
Existing disease  
(n = 8)  
n (%) 
Anxiety  
(HADS-A > 10) 
8 (32) 3 (23) 11 (29) 7 (23) 4 (50) 
Borderline anxiety  
(HADS-A 8 - 10) 
4 (16) 3 (23) 7 (18) 3 (10) 1 (13) 
HADS-A score  
(median (range)) 
7.0 (1 – 14) 5.0 (3 - 15) 7.0 (1 – 15) 6.5 (1 – 15) 9.5 (7 – 15) 
Depression  
(HADS-D > 10) 
2 (8) 1 (8) 3 (8) 2 (7) 1 (13) 
Borderline depression  
(HADS-D 8 - 10) 
3 (12) 1 (8) 4 (11) 3 (10) 1 (13) 
HADS-D score  
(median (range)) 























Figure 6-2.  Change in HADS depression score during enteral nutrition therapy. 
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6.4.2 Short Inflammatory Bowel Disease Questionnaire 
At baseline the median SIBDQ score of all patients (n = 38) with active CD was 4.2 (range, 1.5 to 
6.3) and baseline SIBDQ score was significantly correlated with CDAI (r = -0.418, p = 0.009).  
The median SIBDQ of female (n = 30) and male (n = 8) patients was 4.25 (range, 1.5 to 5.4) and 
4.35 (range, 1.5 to 6.3) respectively and was not significantly different (p > 0.05).    
 
SIBDQ score increased significantly during treatment with EEN or PEN (Figure 6-3).  At 
treatment completion, 13/14 of the EEN patient group and 7/9 of the PEN patient group had a 
clinically significant quality of life response (SIBDQ > 4.7) (Figure 6-3) and there was no 
difference in median SIBDQ at week 8 between the two treatment groups (p > 0.05).  Upon 
reintroduction of usual foods and fluid median SIBDQ did not significantly change in either of 
the treatment (p > 0.05). 
 
The two patients who used CS also had improvements in IBDQ score.  One patient moved from a 
score of 4.2 to 4.9, which is clinically significant improvement.  The other patient moved from a 
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International research has shown that patients with IBD have higher rates of anxiety and 
depression(94, 95) and poorer HRQOL(83, 84) than the general population.  Active disease has been 
associated with poorer HRQOL(85) and a greater prevalence of anxiety and depression.(100-102) 
Furthermore, some IBD treatments may impact on HRQOL more than others.(101, 104, 109, 111, 112, 114)  
The aim of assessing HRQOL in this patient cohort was to document the characteristics of young 
NZ adults with active CD and to evaluate the impact of EN therapies on HRQOL.   
 
Anxiety, defined as a HADS-A of eight or more, was present in 47 % of patients with active CD 
prior to starting EN therapies.  Anxiety was present in a slightly greater proportion of this 
patient cohort compared with the international research and present in almost twice as many 
patients than previously reported in Canterbury, NZ.(96)  Three Australian studies have 
investigated the presence of anxiety in patients with IBD and have reported that 39 – 43 % of 
patients scored 8 or more on the HADS-A subscale.(97, 100, 103)  These Australian cohorts contained 
a mixture of patients with active and in-active existing CD.  Anxiety is more likely to be present 
in patients with active disease,(100-102) which may explain the slightly higher presence of anxiety at 
baseline in the current study.  This study found no association between CDAI and HADS-A score 
at baseline or treatment completion but, the median HADS-A score did significantly decrease 
during treatment as disease activity indices improved non-significantly.  
 
A recent Canterbury, NZ study by McCombie et al,(96) conducted in the same gastroenterology 
unit as this research, included 54 patients with newly diagnosed IBD.  Anxiety was present in 
half as many patients in that study compared with the current CD cohort and the mean HADS-A 
score at baseline was 5.19 ± 3.36 compared with 7.0 (range, 0 to 15) in the current study.(96)  The 
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discrepancy in the presence of anxiety may be attributed to a range of factors including: the 
lower average age of the current study’s patients (22 years old compared with 34 years old) 
and/or patients who elect to use EN therapies as an alternative to corticosteroid treatment may 
be more anxious about the side effects of CD treatments.  Potentially the greatest difference 
between the studies is that in the current study patients were either treatment naïve or had failed 
other CD treatments when they completed the HADS questionnaire.  Patients in the earlier study 
were newly diagnosed with IBD but 81 % had already started treatment with oral or intravenous 
steroids when recruited to the study.  The current study found that the HADS-A decreased 
significantly with only two weeks of treatment, which may well account for the lower presence of 
anxiety observed in the McCombie et al study.   
 
The presence of depression (HADS-D 8 or more) in IBD cohorts varies in the literature from 4 – 
22 % of patients.(84, 94, 100, 101)  Previous research has found that the presence of depression is more 
likely in patients with symptoms of active disease.(100-102)  Prior to starting EEN or PEN 
treatment, depression was present in 19 % of patients with active CD.  The presence of 
depression and the median HADS-D score reduced consequent to EN therapy and CDAI was not 
correlated with HADS-D scores at baseline or treatment completion.  Previous research has also 
suggested that symptoms of depression are associated with disease severity.(101)  Only a few 
patients in this study cohort had severe CD therefore, no conclusions can be made as to the effect 
of disease severity on the observed baseline and change in HADS-D.  In a larger cohort such a 
sub-group analysis would be possible. 
 
SIBDQ and IBDQ scores are frequently lower in patients with active IBD,(108-110, 115) as was 
apparent in the current study.  The median baseline SIBDQ score of 4.25 in this study is 
comparable to the mean scores (4.34 ± 0.42) of a large study of 150 Canadian patients with 
active CD (CDAI > 150).(115)   This Canadian study validated the 10 question SIBDQ with the 
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more extensive 32-item IBDQ and found that patients with a CDAI of less than 150 had 
significantly higher mean SIBDQ than patients with active disease.(115)  A recent study from 
Canterbury(96) reported SIBDQ scores of patients with recently diagnosed IBD, many of whom 
had recently initiated treatment.  The mean SIBDQ score at baseline was slightly higher (4.67 ± 
1.27) than in the current study, which may be related to recently starting treatment for active CD, 
but as observed in the Canadian study and the current study, SIBDQ significantly increased as 
disease activity reduced.   
 
Gender is another variable, independent of disease activity, which has been associated with 
lower IBDQ scores.  Two studies found that female patients with CD had lower mean IBDQ 
scores than male patients.(111, 112)  This EN therapy study found that the SIBDQ scores of females 
and males were comparable, although there were only eight males, compared to 30 females, 
recruited to use EN therapy.  Other research studies which have used the SIBDQ have not 
reported the scores of males and females separately(115-117) or have reported that there were no 
significant differences between the scores of males and females.(96)   
 
The use of EEN has been associated with improved HRQOL in a group of European children 
with CD(33) and Chinese adults with CD.(86)  The Chinese study reported that IBDQ scores of 
greater than 170 (equivalent to a >4.7 on the SIBDQ scale) were achieved in 10 of the 11 (91 %) 
patients who responded to EEN treatment.(86)  In the current study, a SIBDQ of greater than 4.7 
was achieved in 20 of the 23 (87 %) who completed the treatment.  The SIBDQ scores of the 
three patients with a CDAI of greater than 150 at week eight were all greater than the clinically 
significant cut-off of an SIBDQ of greater than 4.7 as were the SIBDQ score of 17 of the 20 (85 %) 
patients who had a CDAI < 150 after eight weeks of EN therapy.  No other research groups have 




The HRQOL results of this clinical trial have some limitations.  The lack of a control group, due 
to only recruiting two patients into the study to use corticosteroids, means that no conclusions 
can be drawn as to the possible impact of the EN therapies on the improvement on SIBDQ score 
or the presence of anxiety and depression at treatment completion and six months.  This 
limitation may have been mitigated if patients who withdrew from EN treatment were also 
followed out to six months.  In retrospect, HRQOL data from the group of 25 patients who 
withdrew would have allowed for the comparison of HRQOL parameters between patients who 
did and did not use a complete course of EN therapy.   
 
6.6 Conclusion 
This research suggests that the presence of anxiety and depression in young NZ adults with 
active CD is equivalent to, or higher, than rates previously reported internationally.  This is a 
unique cohort of patients in that all the patients had active disease and the majority were 
treatment naïve.  The treatment of active CD with EEN or PEN and the subsequent achievement 
of disease remission resulted in significant reductions in anxiety and depression and clinically 
significant improvements in the SIBDQ score.  These data therefore support the hypothesis that 
enteral nutrition therapy is associated with improvements in patient HRQOL. 
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     Chapter 7 
Faecal Microbiota and Exclusive Enteral Nutrition 
7.1 Introduction 
Each person has their own unique combination of microbes residing in their gut,(133) which are 
influenced by many variables including, but not limited to, route of birth,(224) breast feeding,(224) 
antibiotic use(142, 224) and diet.(142)  Patients with CD have consistently been shown to have a 
different gut microbiota composition, coined dysbiosis, compared with healthy populations.(121, 
122)    
 
Studying the impact of disease and treatments on the microbiota is challenging due to the 
natural variability of the gut microbiota.  Comparing the results of one study with another is 
often difficult due to differences in microbiota analysis techniques.  Researchers have thus tried 
to design methods of grouping individuals according to the prevalence and function of 
phylogenetic groups of bacteria.  Data from the Human Microbiome Project has been used to 
develop one such model called “community types”.(225)  Whereas, another research group has 
developed a similar model referred to enterotypes.(226)  The four “community types” do not 
contain the four most dominant species/families but rather a specific combination of bacteria 
which differentiate the community types from each other.(225)  The characteristics of each 
community type are summarised in Table 7.1.  The grouping of individuals into community types 






Gut dysbiosis in patients with Crohn’s disease is hypothesised to play a role in the development 
and recurrence of inflammation.(229)  Treatment of active paediatric CD with EEN has been 
shown to temporarily reduce the diversity of the faecal microbiota despite improvements in 
disease activity.(152, 153)  One paediatric study has also shown that patients who respond to EEN 
therapy have different microbial changes compared with patients who do not respond.(142)  There 
is limited research which explores the effect of nutrition therapy on the faecal microbiota of 

















Family   
Ruminococcaceae 
A Higher Absent 
 
Lower Lower Absent 
B Lowest Lower Lower Variety of Firmicutes 
species 
Variety of Firmicutes 
species 
C Lower Absent 
 
Higher Higher Higher 
D Lower than A and 
D 





7.2 Aims and Hypotheses 
The aim of this pilot research was to document changes in faecal microbiota structure 
consequent to dietary change in adults with active CD.  It was hypothesised: 




A pilot study of serial faecal samples from the first six patients who had completed EEN 
treatment was funded by a Laurenson Trust Award in collaboration with Professor Gerald 
Tannock and his team in the Department of Microbiology and Immunology, University of Otago, 
Dunedin.   The methods that related to the collection and storage of stool samples are detailed in 
Chapter 2 section 2.1.9.  Stored stool samples were sent to Dunedin by overnight courier on dry 
ice for faecal microbiota analysis and interpretation.  The methods used to extract the bacterial 
DNA and characterise the microbiome are described in detail in Chapter 2 section 2.1.9.3. 
 
The sequenced data was analysed using multiple bioinformatics techniques.  These included 
relative abundance of operational taxonomic units, identification of possible bacteria using the 
operational taxonomic units data, grouping of bacteria into phylogenetic groups, weighted-
UniFrac, a beta diversity metric used to assess differences between microbiota communities, and 





Six patients had serial faecal samples characterised.  The first two patients had samples out to six 
months (seven samples) and the other four had samples up to week 12 (six samples).  All of the 
patients had newly diagnosed CD and were of NZ European ethnicity.  The baseline 
characteristics of the six patients are described in Table 7.2.  All six patients completed the eight 
week EEN treatment and all achieved disease remission (CDAI < 150) at week eight.  
 
Figure 7-1 and Figure 7-2 are three dimensional plots of principle coordinate analysis, which were 
generated from an algorithm which measures diversity.  Figure 7-1 illustrates that the faecal 
microbiota of each patient is distinct and that phylogenetic structure changes in response to 
dietary changes and that these changes are unique to each patient.  Figure 7-2 suggests that there 
may be a trend towards patients with ileal CD having a different phylogenetic structure 
compared with patients with ileocolonic CD.   
 
At baseline, four of the six patients with active CD had a type C faecal microbiota community and 
the other two patients had a type B or type D community structure (Figure 7-3).  The patient with 
a type B community followed a vegan diet at baseline and the patient with a type D community 
consumed a high energy diet.  The abundance of the four bacterial genera or family accounted 
for 40 – 66 % of the microbes present in the stool samples.  After eight weeks of all consuming 
the same fibre deficient oral nutrition formula, all patients had a type C community structure 
characterised by the absence of Prevotella and lower abundance of Bacteroides (Figure 7-3).  The 





The diversity of the faecal microbiota samples tended to cluster by diet.  Figure 7-4 and Figure 7-5 
are principle coordinate analysis plots which show that generally the microbiota at weeks 0, 12 
and 26, when patients are eating a usual diet, cluster together and the microbiota during EEN 
(weeks 2, 4, 6, 8) cluster separately.  These plots indicate that while each patient has their own 
unique microbiota, treatment with EEN results in a taxonomic shift in all patients.  Despite each 
patient having a unique faecal microbiota there was a small group of bacterial species present in 
all of the patient faecal samples, which varied in abundance significantly between the EEN 






Table 7.2.  Baseline characteristics of patients whose faecal microbiota was characterised. 








ESR Baseline FC 
M 30.7 L3 25.1 0.2 169 18 7 3019 
F 26.8 L1 20.3 -0.8 104 3 2 129 
M 23.0 L3 26.2 0.3 39 9 8 564 
F 19.7 L3 23.3 0.5 150 6 21 1421 
F 18.5 L3 23.8 -2.7 207 11 25 3838 
M 17.0 L1 18.5 -1.7 59 24 11 765 




Figure 7-1.  Principle coordinate analysis plot of faecal phylogenetic data across all EEN study time points 
and grouped by patient. 
 






Figure 7-2.  Principle coordinate analysis plot of faecal phylogenetic data across all EEN  
study time points and grouped by disease location. 
 
Note: Each coloured dot corresponds to a patient sample and each patient is represented by a different 
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Figure 7-6.  Bacterial species which varied significantly between EEN and usual diet phases. 
Note: Hespellia includes H. porcina and H. stercorisuis 
 
7.5 Discussion 
High throughput sequencing of faecal samples from patients with CD found that the faecal 
microbiota of each patient were unique.  The finding is in keeping with most microbiota 
research, which reports high faecal microbiota inter-personal variation.(132, 133, 137, 138)  Despite 
inter-personal variation, many studies have found that samples from patients with CD are 
different from healthy controls.(142, 144, 230)  Principle coordinate analysis suggested that the 
phylogenetic structure may vary depending on the site of intestinal inflammation.  One other 
study also noted that the abundance of particular bacteria was different in patients with 
ileocolonic disease compared with other disease locations.(144)   A study of 35 Korean patients 
with CD reported that Gammaproteobacteria was more abundant in faecal samples of 




microbiota is affected by site of inflammation and this hypothesis should be further tested 
with the whole enteral nutrition study cohort of 38 patients. 
 
Faecal microbiota composition varied during the EEN phase compared with when patients 
were consuming their usual diet.  This trend has also been observed in other studies which 
have investigated changes in faecal microbiota in children with CD using EEN.(142, 152, 231)  As 
was observed in the current study, once children started eating usual foods again their faecal 
microbiota tended to return to a similar structure as observed at baseline.(152, 232)  
 
Community type or enterotype characteristics are strongly associated with usual dietary 
habits(227) and possibly by country of residence.(233)  Baseline dietary intake was not collected 
in the current study because the focus of the study was on how the faecal microbiota changed 
in response to a liquid diet and once usual foods and fluids were introduced again.  It was 
assumed that patients returned to their usual dietary habits after the nutrition intervention.  
The patients’ baseline energy requirements and food exclusion habits were collected.  Two of 
the six patients had a different community type at baseline characterised by the presence of 
Prevotella bacteria.  Prevotella are more prevalent in samples from people who eat a diet 
high in carbohydrate,(227) which was most probably the case in the study patient with the type 
D community type.  This patient had a very active job and consequently a high energy intake 
and would therefore have consumed much larger amounts of carbohydrate foods than the 
other study participants.  The patient with a type B community followed a vegan diet, which 
has also been associated with a greater abundance of Prevotella bacteria.(227)  Whereas, a 
Bacteroides dominant enterotype, or community type C, is associated with higher intakes of 
animal protein and saturated fat(227) which happens to reflect the typical NZ diet.(213) 
 
After eight weeks of EEN, all patients had a faecal microbiota consistent with community 




paediatric CD study of five children found that a reduction in the abundance of 
Ruminocacaecaea was associated with achieving disease remission.(231)  The absence of 
Prevotella, the main characteristic of community type C, has not been reported previously, 
although changes in the Bacteroides/Prevotella have been reported.(25, 142, 152)  There has been 
no other published studies in adults or children with CD which have reported the community 
type of patients.  It is not yet known if the community types observed in this pilot study are 
characteristic of other populations of patients with CD. 
 
The significance of the changes in the small number of specific bacterial species described in 
Figure 7-6 is not yet known.  At the time this work was undertaken in 2014, little was known 
about the functions of three of these four bacteria but as high throughput sequencing 
becomes more accessible more research groups are investigating the faecal microbiota 
composition and functions.  The first bacterium which was significantly different in faecal 
samples collected during EEN treatment compared with when patients were consuming their 
usual diet was Barnesiella intestinihominis.  B. intestinihominis has been shown to slow the 
growth of Escherichia coli subsequent to antibiotic treatment.(234) and has been proposed as a 
potential probiotic to use with antibiotic treatment (234)  This bacterium is also more prolific 
in the presence of the oligosaccharide 2’-fucosyllactose which it utilises as an energy 
source.(235)  B. intestinihominis preferentially uses 2’-fucosyllactose, one of the human milk 
oligosaccharides which has recently been approved to be added to infant formula.  Infants 
consuming infant formula containing 2-fucosyllactose have a faecal microbiota closer to that 
of breast fed infants.(236)  The formula used in the current study was a fibre free formula but 
there are products available which have added fibre, usually in the form of inulin, soy/oat 
fibre, soy polysaccharides and/or fructo-oligosaccharides.  The use of fibre containing 
nutrition formula has not been investigated in patients with active CD but given the potential 
protective effects of commensal bacteria which utilise dietary oligosaccharides perhaps fibre 
containing formulas should be considered for supplementary nutrition when disease is in 





There are limited data available on the function and abundance of Hespellia and Alistipes 
putredinis in healthy people or patients with CD.  Hespellia porcina and H. stercorisuis are 
anaerobic bacteria which use simple sugars such as sucrose and glucose as energy and can 
hydrolyse starch.(237)  The nutrition formula used in this study contained partially hydrolysed 
and hydrolysed starch and sucrose as its carbohydrate sources.  The abundance of Hespellia 
in faecal samples doubled during the liquid diet phase compared to when patients were 
consuming their normal diets.  The significant changes in these bacteria may have been 
related to substrate availability.  Further comparisons with the larger cohort and with a 
healthy population are required to explore this hypothesis. 
 
A. putredinis has been reported to be abundant and prevalent in faecal samples of healthy 
Dutch children.(230)  The Dutch study of 60 children with newly diagnosed CD observed that 
that the abundance of A. putredinis in all patients was very low or non-existent compared 
with healthy children.(230)  Patients were offered EEN treatment but the paper did not 
comment if the abundance of this bacterium in particular increased, as seen in the current 
study.  The researchers observed that the faecal microbiota of patients with CD approached 
that of healthy controls as patients achieved disease remission.(230)  No other studies were 
found that referred specifically to the abundance of A. putredinis in the faecal microbiota of 
patients with CD. 
 
In healthy adults Faecalibacterium prausnitzii is one of the most abundant faecal bacterial 
species but has been shown to be reduced in faecal samples from patients with active CD.(143, 
146)  F. prausnitzii ferments dietary fibre, produces butyrate and has been shown to have anti-
inflammatory effects.(135)  This pilot study shows that the abundance of F. prausnitzii 
decreased on the liquid diet, a result which has been observed in many EEN studies.(152, 231)  
Faecal F. prausnitzii also reduced significantly in healthy volunteers consuming a fibre-free 




consequence of the reduction in dietary fibre intake during the liquid phase of the diet.  In 
this pilot study, the abundance of F. prausnitzii increased once patients resumed their usual 
diet. The analysis of the faecal samples of patients with active CD who use PEN will help to 
understand if the addition of whole food dietary fibre to regimen alters the abundance of 
fibre fermenting genus or species such as F. prausnitzii.   
 
Presently, the implications of changes in the faecal microbiota are not fully understood, 
however it appears that reductions in the abundance and diversity of bacteria consequent to 
EEN treatment are associated with improvements in disease activity.  Once more is known 
about the function of specific bacteria and how bacteria interact with each other and their 
environment the implications of these changes may be further interpretable.   
 
7.6 Conclusion 
Each person has their own unique faecal microbiota and not all patients with active CD have 
the same faecal microbiota community type.  Treatment of active CD with EEN can modify 
the community type or phylogenetic structure of the faecal microbiota and changes the 
abundance of specific bacterial species.  The impacts of these changes are not yet fully 
understood.   
 
Further faecal microbiota research with the remaining faecal samples of patients with CD, 
and healthy controls who used EEN for two weeks, will be completed once additional funding 
and expertise is secured.  The further studies will add to the available pilot study data and 
will allow for comparisons between healthy adults and adults with CD using an EEN or PEN 




     Chapter 8 
Gastroenterology Health Professionals 
8.1 Introduction 
Optimal management of CD requires a multidisciplinary approach involving the 
gastroenterologist and/or surgeon, specialist gastroenterology nurses, dietitians, 
psychologists and other specialties.(7, 43)  In NZ, patients are often diagnosed and managed by 
a specialist gastroenterologist in a tertiary centre.  However, much of NZ’s population lives 
outside of cities with a tertiary hospital and outpatient care is provided by gastroenterologists 
and dietitians working in secondary care hospitals, private practice and/or in smaller 
provincial centres.   
 
Traditionally the dietitians’ role in the management of IBD is to optimise nutritional status 
through the management of poor oral intake, weight loss, micronutrient deficiencies and 
control of symptoms, including functional symptoms.  In addition, the paediatric dietitian’s 
role is likely to include management of EEN.(6)  The use of EEN by North American 
gastroenterologists is influenced, in part, by the physicians’ previous experience with the 
treatment.(188)  The use, and perceptions, of EEN by NZ gastroenterologists and dietitians has 
not previously been explored.  
 
8.2 Aims and Hypotheses 
The first aim of this research was to understand the current role(s) of NZ dietitians in the 
management of CD patients and to outline their experience with the use of EEN for patients 
with active CD.  The second aim was to understand NZ gastroenterologists’ perceptions, 
knowledge and experience of EEN.  It was hypothesised: 
 That gastroenterology health professionals have limited experience with, and 





8.3 Methods  
The methodology used to understand of the roles, perception and experience with EEN in the 
treatment of CD of NZ health professionals, namely dietitians and gastroenterologists, is 
detailed in Chapter 2 sections 2.2.2 and 2.2.3.  In summary, NZ dietitians and dietitian 
students and gastroenterologists and gastroenterology trainees were contacted via their 
respective member organisations.  A web-based survey link was disseminated via Dietitians 
NZ’s weekly electronic newsletter during August and September 2013.  Gastroenterologists 
were sent a web-based survey link via email by the NZ Society of Gastroenterology executive 
officer during July and August 2015.   
 
The dietitian and physician survey questions were adapted from a survey used with North 
American physicians to understand their attitudes and use of enteral nutrition to treat 
paediatric CD.(188)  The survey platform was QuestionPro Online Survey Software Application 
(www.questionpro.com).  The surveys were pre-tested with relevant professionals and their 
feedback was incorporated into the final version of the two surveys.   
 
The surveys did not require ethical approval; however, the data collected from dietitians and 
physicians were managed ethically, and anonymity of survey respondents was maintained.  
 
8.4 Results 
8.4.1 Demographics of IBD Health Professionals 
The dietitian survey was started by 102 of the 488 active Dietitians NZ members, which is a 
response rate of 21 %.  Of the 102 dietitians who started the survey, six did not complete it 
and 25 (25 %) did not see patients for gastrointestinal (GI) complaints.  The remaining 77 




few times a year and 58 dietitians saw a patient with CD at least a few times a year.  The 
characteristics of dietitians who saw patients with CD are described in Table 8.1. 
 
The physician survey was sent to approximately 110 members of the NZSG.  These members 
were gastroenterologists, 10 – 15 surgeons and 15 – 20 gastroenterology trainees.  The survey 
was started by 48 members and completed by 42, which is a response rate of 38 %.  The 






Table 8.1.  Characteristics of the New Zealand dietitians and gastroenterology physicians who were 
surveyed. 
Characteristics of physicians and 
dietitians 
Physicians (n = 42) 
n (%) 
Dietitians (n = 58) 
n (%) 
Experience: 
Registrar/< 2 years 
Consultant < 5 years/2 – 5 years 
5 – 10 years 
10 – 20 years 






























Public community setting 
Food service 
































































8.4.2 Dietitian Gastroenterology Case Load 
The majority of dietitians saw a patient with CD a few times a year (n = 31) and eight 
dietitians (three paediatric and five adult dietitians) saw at least one patient with CD every 
fortnight (Figure 8-1).  The dietitians who saw patients with CD more frequently worked in 
public hospitals in larger centres which have a tertiary hospital.  A sub-group analysis found 
that the frequency of presentation of patients with CD did not differ between paediatric and 
adult dietitians (χ2 (2, n = 58) = 2.72, p = 0.25).  All dietitians commonly received patient 
referrals for weight loss: 90 % of paediatric dietitians and 71 % of adult dietitians.  However, 
paediatric dietitians received significantly more referrals for EEN (fisher’s exact test, p < 
0.0001) and micronutrient deficiencies (fisher’s exact test, p < 0.004) compared with adult 





























Figure 8-2.  Common reasons patients with CD were referred to adult (n = 48) and 
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Figure 8-1.  Difference in frequency of presentation of patients with CD and general 
gastrointestinal complaints (n = 77). 
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8.4.3 Health Professional Awareness of Exclusive Enteral Nutrition  
Most dietitians, 10 (100 %) paediatric and 38 (79 %) adult dietitians, who saw patients with 
CD were aware of EEN as a treatment option for active CD.  Dietitians were asked whether 
they believed EEN was an appropriate treatment for their patient group and if there were any 
disadvantages to the treatment.  Five paediatric dietitians and 25 adult dietitians answered 
these questions.  All five of the paediatric dietitians thought that EEN should be offered as a 
treatment option to selected patients.  Of the 25 adult dietitians, 80 % believed that EEN may 
be beneficial for selected patients, two thought there was currently insufficient evidence to 
support its use with adults, and two dietitians were unsure if EEN would be of benefit for 
their patient group.   
 
Thirty (43 %) dietitians felt they had adequate knowledge and/or skills to manage a patient 
referred for EEN.  Half of the dietitians would find further professional development on the 
role of EEN in CD useful.  They would also like more EEN patient resources, and more 
scientific evidence to support the use of EEN with adults, together with professional 
supervision. 
 
Thirty-seven (90 %) gastroenterologists and trainees were aware of EEN as a treatment for 
active CD.  The majority (64 %) considered that EEN was appropriate or sometimes 
appropriate to induce CD remission in adults and 29 % thought that it was rarely an 
appropriate treatment for adults.  In the case of paediatric CD, a third of physicians answered 
not applicable, one third considered that EEN was an appropriate treatment and one third 
were unsure if EEN was an appropriate treatment.  Most physicians (55 %) did not work, or 
had not previously worked, in a unit where EEN was used to treat active CD.  EEN was 
regularly, or very regularly, used in physician’s current unit in 19 % of respondents.  
Physicians considered that EEN treatment had a range of important benefits for the patient 





Table 8.2.  Physicians' perception of the benefits of EEN treatment. 
Possible benefits of EEN treatment Responses  
n (%) 
Steroid sparing 31 (94) 
Avoid immunosuppression 9 (27) 
Improve nutritional status 29 (88) 
Improve growth in children 22 (67) 
 
 
8.4.4 Health Professional Use of Exclusive Enteral Nutrition 
Thirty-five dietitians, 10 paediatric and 25 adult dietitians, reported that they had managed a 
patient with active CD with EEN.  These dietitians were geographically spread across NZ and 
most (26 dietitians) worked in a public hospital.  Seventeen dietitians who worked with adult 
patients had not managed a patient with CD on EEN, and the main reasons for this included 
that gastroenterologists and surgeons do not refer patients for EEN treatment (13 dietitians), 
a limited CD patient case load (9 dietitians) and limited experience using EEN (6 dietitians).  
 
Dietitians’ clinical experience of using EEN to treat active CD varied from one to fifty patients 
with a median of three patients (Figure 8-3).  Ten dietitians (four paediatric, six adult) had 
used EEN with five or more patients. One of these ten dietitians commented that their 
experience was gained while working in the United Kingdom, and one was not currently 
practicing dietetics.  The other eight dietitians practiced in main centres.  All four paediatric 
dietitians who had managed at least five patients on EEN found EEN to be a successful 




managed at least five patients on EEN reported that EEN was only sometimes successful in 
improving disease related symptoms.   
 
Twenty-nine (69 %) physicians reported that they had previously used EEN with their 
patients of which 21 had used EEN with a patient in the last 12 months. Six paediatric 
gastroenterologists had used EEN in the last 12 months with 1 to 15 patients and in a median 
of six patients.  Three physicians managed both children and adults with CD and had used 
EEN with a median of five patients and a range of “less than five” to ten patients.  The 
remaining 12 physicians managed only adult patients and had managed a median of three 
patients (range, 1 to 8).  The physicians who had recently used EEN with their patients were 
geographically spread across NZ but half (n = 6) of the adult gastroenterologists worked in 
Canterbury. 
 
The paediatric gastroenterologists reported that 70 – 100 % of their patients achieved disease 
remission with EEN, the three physicians who manage both adults and children estimated 
that 50 to 70 % of their patients achieve remission consequent to EEN and the adult 
gastroenterologists reported that a lower number of patients complete the treatment and that 
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Figure 8-3.  NZ dietitian and gastroenterologist experience with EEN for the  






8.4.5 Benefits and Barriers of Exclusive Enteral Nutrition 
Dietitians who had used EEN with their patients were asked to comment, in an open-ended 
question, which patients had responded well to EEN.  In their experience EEN was most 
successful for patients who adhered to the treatment, were motivated, did not have 
complicated disease, had newly diagnosed disease and/or were young adults.  Physicians who 
had used EEN in the last 12 months reported that they usually considered EEN for children 
with newly diagnosed CD and patients who are nutritionally compromised.  Two thirds also 
consider EEN for patients with existing disease or moderate to severe disease.  Half of 
physicians (n = 10 to 12) would also consider EEN for adults with newly diagnosed CD and 
patients with mild disease.  Paediatric and adult gastroenterologists had different views on 
the use of EEN for different disease locations Figure 8-4.   
 
Both dietitians and physicians identified barriers to EEN treatment and these are described 
in Table 8.3.  Other barriers mentioned by dietitians included that the treatment is socially 
restrictive if tube feeding required and that there are complications associated with tube 
feeding, children get bored of treatment quickly and that there may be fear associated with 
returning to usual oral foods and fluids.  Other barriers mentioned by physicians included 
that adults have adequate calorie intake and lose weight and that the treatment does not 
always work.   
 
Common reasons that physicians had not used EEN were that patients struggle to maintain 
treatment compliance (65 %), physicians had limited experience using EEN (41 %) and 
patients had limited social support (33 %).  Many physicians somewhat or strongly disagreed 
that there was insufficient evidence to support the use of EEN with children (60 %) and that 
there was limited support from dietitians (43 %).  Thirty-seven % also disagreed that there 





Physicians were asked what would increase the likelihood of them recommending EEN to 
their patients the key themes were multidisciplinary support and evidence based guidance as 
illustrated in Figure 8-5. 
 
 
Table 8.3.  Barriers to using exclusive enteral nutrition with patients with active CD. 
Downsides of EEN Physicians (n = 32) 
n (%) 
Dietitians (n = 42) 
n (%) 
Need for treatment adherence 29 (91) 34 (81) 
Needs multidisciplinary 
approach 
10 (31) 11 (26) 
Cost 6 (19) 8 (19) 
More time intensive 12 (38) 6 (14) 
Requires social support for 
patient 
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Figure 8-4.  Proportion of physicians who would often or always consider using EEN to treat children 
(n = 10 responses) and adults (n = 16 responses) with active CD in a variety of locations. 
Note: A statistical test was not employed due to the low number of responses in each group. 
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Figure 8-5.  Resources required by physicians to increase likelihood of recommending EEN for 
patients with active CD. 




8.4.6 Supplementary Enteral Nutrition 
The use of SEN by dietitians’ to maintain disease remission was variable: 19 % always 
prescribed it, 40 % sometimes prescribed it, 18 % rarely or never prescribed it, and 23 % said 
the question was not applicable or did not answer.  The prescription of SEN was usually used 
to treat nutritional concerns rather than as a means of maintaining remission of CD.  There 
was no standard regimen and dietitians tended to use an individualized approach depending 
on weight, history of weight loss and current oral dietary intake.  Similarly, 
gastroenterologists reported sometimes using SEN and the regimen was often two to three 
cartons per day depending on the patient. 
 
8.5 Discussion  
One of the aims of this research was to understand the role of NZ dietitians in the 
management of CD patients.  This electronic survey suggests that patients with GI complaints 
frequently present to the NZ dietitians surveyed but patients with CD present much less 
frequently despite being at risk of poor nutritional status.  It is estimated that 1 in 500 to 700 
New Zealanders, or approximately 7,000 people, live with CD.(238)  Based on the patient 
caseload of the dietitians which responded to this survey, NZ dietitians only see 
approximately 7 - 13 % of the CD population.  A more detailed survey of NZ dietitians would 
be required to ascertain if IBD service involvement and routine hospital nutritional screening 
is related to the observed low dietitian CD patient caseload.  Regardless, the low exposure of 
NZ dietitians to patients with CD is concerning given the prevalence of undernutrition and 
may lead to poorer outcomes for patients. 
 
Another aim of this research was to quantify NZ dietitians’ and gastroenterologists’ 
experience of using EEN for active CD.  Thirty-five (60 %) dietitians and 29 (68 %) of 
physicians had previously used EEN to treat active CD disease.  Dietitians would 
predominately receive referrals for EEN from gastroenterologists so it was expected that 




recommended as a first line therapy to treat active paediatric CD,(26) and all of the 
gastroenterologists who manage children and nine of the ten paediatric dietitians reported 
previous use of EEN.  However, half of the paediatric dietitians, had managed less than a 
total of five patients on EEN whereas paediatric gastroenterologist had used EEN with 1 to 15 
patients in the last 12 months.  The discrepancy between physician and dietitian responses 
suggests that either more than one dietitian works with each paediatric gastroenterologist or 
dietitians who more commonly manage patients on EEN did not complete the survey or have 
access to the online survey because they are not members of the national dietetic association.   
 
Six of the 48 adult dietitians (12.5 %) commonly received referrals for EEN.  The results of a 
patient survey described in Chapter 3 of this thesis suggests that adults patients are 
interested in using EEN as an alternative to corticosteroids and the recent British Dietetic 
Association dietary guidelines for the management of CD suggest that EEN could be 
considered as alternative to corticosteroids.(239)  Further to this recommendation the UK IBD 
standards(7) suggest that all patients should have access to all types of nutrition therapy.  In 
NZ, referrals to adult dietitians were lower than was observed in a survey of UK adult acute 
care dietetic departments where 76/129 (59 %) had received a referral for EEN in the last 
three months.(8)  The adult dietitians who commonly received EEN referrals were located in a 
small number of locations in NZ, whereas the paediatric dietitians who commonly received 
EEN referrals were spread more evenly across NZ.  This observation suggests that referrals to 
dietitians for EEN may vary between hospitals and/or gastroenterologists which is in keeping 
with the findings of the physician survey.  Physicians who have used EEN in the last 12 
months and work with adult patients were also located in a small number of locations in NZ.   
 
Internationally the use of EEN by paediatric gastroenterologists varies widely between 
countries.(188, 240 , 241)  The results of this survey suggest that NZ gastroenterologists often or 
always considered EEN as a treatment option for paediatric CD.  Whereas, physicians who 




improve their use of the treatment practice guidelines and more evidence of the efficacy of 
EEN in the treatment of adults is required.  The development, or adoption, of national 
treatment guidelines and EEN protocols may improve discrepancies in the geographical use 
of EEN in active CD.   
 
This survey explored not only dietitian and physician use of EEN but also their experience 
managing patients on EEN and their perception of EEN as a treatment for active disease.  
Dietitians were optimistic about the effectiveness of EEN to induce disease remission.  Forty-
five percent perceived that EEN was an effective treatment, and 52 % felt that it was 
sometimes successful and was best used with specific groups of patients.  Physicians would 
often or always consider EEN as a treatment option for many children and half of physicians 
working with adults would often consider using EEN for adults with newly diagnosed CD or 
mild disease.  Literature suggests that the level of health professional support for patients 
using EEN is a major contributing factor to the success of the treatment.(242)  Therefore, 
dietitian and physician perception of the effectiveness of EEN is important, especially as 
patients need intensive dietetic support to optimise nutritional intake and minimise 
intolerance of the nutrition formula.  It is likely that the involvement of optimistic and 
proactive health professionals may affect adherence to the treatment and therefore improve 
treatment outcomes.   
 
The success of EEN, particularly in adults and as was observed in the clinical trial discussed 
in Chapter 4, is often limited by poor adherence to the treatment.  NZ dietitians and 
physicians identified the need for treatment adherence was the main disadvantage of EEN 
treatment.  Other disadvantages of EEN included the need for adequate social support and a 
multidisciplinary approach.  North American and Australian paediatric physicians also 
reported compliance as the main disadvantage of EEN treatment.(188, 240)  Further, North 
American and Australian physicians who rarely used EEN reported that the main barriers to 




support and lack of experience using EEN.(188, 240)  The number of responses in the current 
surveys were too small to complete a similar analysis but limited experience with EEN also 
featured as a barrier for NZ dietitians and physicians.  The survey of North American 
paediatric physicians found that physicians were more likely to recommend EEN to their 
patients if they had worked/trained in a centre that commonly used the EEN.(188)  Half of the 
NZ physicians had not worked in unit where EEN was used to treat active CD and only 19 % 
currently worked in unit where the treatment was regularly used.  Despite physicians 
believing that EEN has many potential benefits the limited exposure of physicians to EEN 
treatment in clinical practice may impact the use of the treatment. 
 
Dietitians identified that professional development, especially for those with limited 
experience utilising EEN, is required and 80 % of physicians selected practice guidelines, 
alongside more efficacy of use in adults, as the main requirement to increase their likelihood 
of recommending EEN for patients with active CD.  Further education may increase dietitian 
expertise and optimise treatment outcomes for patients with active CD and practice 
guidelines and indications for EEN developed in conjunction with the multidisciplinary team 
may increase the use of this nutrition therapy.  Recent paediatric CD guidelines provide 
physicians with more practical guidance on the use of EEN with children(27) and suggest that 
if there is no response after two weeks and alternative treatment could be started.(27)  Such 
guidelines may be helpful for health professionals working with adults interested in using 
nutrition therapy too. 
 
The main limitation of the dietitian survey is whether or not the respondents are 
representative of paediatric and adult dietitians in clinical practice in New Zealand.  Although 
this survey was disseminated via Dietitians NZ, the national dietetic professional 
organization, not all clinical dietitians are members of Dietitians NZ.  Due to a lack of non-
responder data there may a bias towards dietitians who are aware of EEN in the treatment of 




limitation is that survey pre-testing was not completed with clinical dietitians who see 
patients with CD less frequently or have limited experience using EEN.  Further surveys or 
audits that target dietetic departments and private practices that care for patients with IBD 
are required to further understand the specific role and utilisation of dietitians in tertiary 
centres that have a high CD patient caseload and also dietitians in private practice dietitians 
and rural centres who may manage this patient group less frequently.   
 
Likewise, there are limitations with the results of the physician survey.  The survey was sent 
to consultant gastroenterologists and gastroenterology trainees and 29 % of the respondents 
were trainees therefore their experience with EEN may overlap with that of the consultant 
the trainee was working alongside.  Thirty consultant gastroenterologists completed the 
survey and represented most (n = 9) of the 13 regions in NZ which suggests that the survey 
was completed by only some of the gastroenterology physicians.  The results may 
overestimate the usage of EEN with adult patients for two reasons: more physicians with an 
interest in nutrition therapy may have completed survey and half of the physicians who have 
used EEN with adult patients were from Canterbury where a clinical trial, presented in this 
thesis, had been running for the preceding 18 months.   
 
8.6 Conclusion 
These surveys provides a broad understanding of the involvement of NZ dietitians in the 
multidisciplinary care of patients with CD and use of EEN to treat active CD by dietitians and 
gastroenterologists.  This survey has identified that patients with CD present frequently to a 
few NZ dietitians in limited number of centres.  Most dietitians, paediatric dietitians 
included, have limited experience managing patients using EEN and gastroenterologists 
working with adults also have limited experience using EEN to treat active CD.  Both 
dietitians and gastroenterologists would like more guidance on the use of EEN therapy and 
more evidence to support the use of EEN with adults with active CD before recommending 




     Chapter 9 
Conclusion 
This thesis has comprehensively explored EEN as a potential treatment option for young 
adults with active CD.  Surveys of key stakeholders involved in EEN treatment, namely 
patients, dietitians and gastroenterologists, were conducted which  identified that patients 
with CD are interested in nutrition therapy as a treatment option despite a lack of scientific 
evidence supporting the efficacy of EEN as a treatment for adults with CD.   
 
In an attempt to increase the scientific evidence of EEN treatment efficacy a prospective non-
randomised clinical trial of EEN was conducted.  This trial of 25 patients found that EEN 
significantly reduced Crohn’s disease activity; 68 % responded to EEN and 52 % of patients 
achieved disease remission.  As has been observed in previous trials with adults, withdrawals 
from EEN therapy occurred due to intolerance of enteral formula but also for a variety of 
other reasons.  On a per protocol basis, EEN was a very effective therapy with 93 % of 
patients achieving disease remission along with significant reductions in anxiety and 
depression and significant improvements in quality of life. 
 
The use of a sequential EN regimen which combined a short course of EEN followed by PEN 
appears to be a feasible treatment option for adults with active CD.  A pilot study of 13 
patients suggests that PEN may help to minimise weight loss associated with EEN and may 
reduce the incidence of treatment withdrawals.  Furthermore, 62 % of patients responded to 
the PEN therapy and 54 % achieved disease remission.  On a per protocol basis PEN 
effectively induced disease remission in 78 % of patients along with significant reductions in 
anxiety and improved quality of life.  However, improvements in FC were not achieved to the 
same degree as was observed with EEN treatment.  Before PEN treatment is used with 
patients in clinical practice further research is needed to elucidate the optimal combination of 




markers, PEN treatment also needs to be tested in a larger cohort, and ideally in a 
randomised controlled trial of PEN and EEN and/or corticosteroids.   
 
NZ gastroenterologists and dietitians believe that EEN is an appropriate treatment option for 
some patients but would like further evidence to support the use of EEN with adult patients.  
Both gastroenterologist and dietitians would also like guidance on the use of EEN through 
practice guidelines and professional support, and more access to members of an IBD 
multidisciplinary team.  
 
Since the 2007 Cochrane review(38) of EEN in the treatment of active CD, many health 
professionals have not considered nutrition therapies for the management of adult CD.  
Based on the findings presented in this thesis, the use of EEN to treat adults with active CD 
should be discussed again within the profession and presented as an option to patients.  
There is also a need for further research investigating other nutrition therapies, such as PEN, 
that may be more appealing and efficacious for a greater number of adult patients.  EEN 
effectively induces disease remission, and patients who are interested in an alternative to 
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     Appendix A 
Food Reintroduction Guidelines 
Food groups First foods (Stage 1) Next step (Stage 2) Try last (Stage 3) 
Bread White bread, flat 
bread, pita, rolls or 
toast, plain English 
muffins 
Fine wholemeal bread 
 
Coarse wholemeal bread 
Wholemeal pita or flat 
breads 
Very fresh bread 
Wholegrain bread 
Bread containing dried 
fruit, whole grains, 
nuts or seeds 
Cereals Cornflakes, puffed 
rice 
White flour, cornflour 












scones or sponge 
made without 
coconut, dried fruit, 
grains, seeds or nuts 
 
 Snack bars, biscuits, 
cake, crackers, 
muffins and scones 
containing coconut, 
dried fruit, grains, 
seeds or nuts 
Fruit Raw, cooked or 
tinned, without pips, 
seeds or skins 
Fruit juice without 
pulp 
Jams or marmalades 
without seeds or pith 
 
Tinned pineapple Berries, citrus fruit, 
fresh pineapple 
Dried fruit e.g. dates, 
sultanas and apricots 
Fruit juice with pulp 
Vegetables Tender vegetables – 
peeled and cooked 
e.g. carrot, kumara, 
parsnip, potato, 
pumpkin and yam 
Pureed or creamed 
vegetable soup 
Tomato paste or 
puree 
Dahl (not spicy), pureed 
lentils, hummus 
Broccoli or cauliflower tops 
Cabbage, lettuce or 
silverbeet leaves (no stalks) 
Courgettes/marrow without 
skin or seeds, green beans, 
raw carrots 
Creamed corn 
Whole tinned tomatoes with 
seeds removed 
Vegetables with 
coarse stalks, pips, 
seeds and skins e.g. 
corn (including 
popcorn) cucumber, 
garlic, onion, peas, 
raw tomato 
Baked beans, whole 
beans and lentils 
Coleslaw 
Pickle, relish, chopped 






Food groups First foods (Stage 1) Next step (Stage 2) Try last (Stage 3) 
Meat, fish, 
poultry and eggs 
Lean chicken, fish, 
lamb or minced beef 
Fish tinned in water 
Eggs 





Roast meat, steak 






Milk, cheese, cottage 
cheese, cream 
cheese, sour cream 
Plain yoghurt, dairy 
food 
 
Fruit yoghurt (no seeds) Cheese with seeds or 
nuts 
Yoghurt with bits 
 
Nuts and seeds Smooth peanut butter 
 
Finely ground nuts 
Tahini 
Pumpkin sesame or 
sunflower seeds 
Nuts – whole or 
chopped 
Crunchy peanut butter 
Dessert Milk puddings, ice 
cream, jelly, plain 
yoghurt 
 Puddings containing 
coconut, dried fruit, 
nuts, pips, seeds and 
skins 
Miscellaneous Oil, margarine, butter 






it’s a treat) 
Deep fried foods (except 
those in Stage 3) 
Chunky sauces (ie 
satay), sauces with 









     Appendix B 
Hospital Anxiety and Depression Score (HADS) 
Please choose one answer for each statement by ticking in the corresponding box. Do not 
think too long about your answers, and please answer the questions according to how you are 
currently feeling. 
1. I feel tense or wound up… 
□ Most of the time 
□ A lot of the time 
□ From time to time, occasionally 
□ Not at all 
 
2. I still enjoy the things I used to enjoy… 
□ Definitely as much 
□ Not quite as much 
□ Only a little 
□ Hardly at all 
 
3. I get a sort of frightened feeling as if something awful is about to happen… 
□ Very definitely and quite badly 
□ Yes, but not too badly 
□ A little, but it doesn’t worry me 
□ Not at all 
 
4. I can laugh and see the funny side of things… 
□ As much as I always could 
□ Not quite as much now 
□ Definitely not so much now 
□ Not at all 
 
5. Worrying thoughts go through my mind… 
□ A great deal of the time 
□ A lot of the time 
□ From time to time, but not too often 





6. I feel cheerful… 
□ Not at all 
□ Not often 
□ Sometimes 
□ Most of the time 
 
7. I can sit at ease and feel relaxed… 
□ Definitely 
□ Usually 
□ Not often 
□ Not at all 
 
8. I feel as if I am slowed down… 
□ Nearly all the time 
□ Very often 
□ Sometimes 
□ Not at all 
 
9. I get a sort of frightened feeling like 'butterflies' in the stomach: 
□ Not at all 
□ Occasionally 
□ Quite often 
□ Very often 
 
10. I have lost interest in my appearance… 
□ Definitely 
□ I don’t take as much care as I should 
□ I may not take quite as much care 
□ I take just as much care as ever 
 
11. I feel restless as I have to be on the move… 
□ Very much indeed 
□ Quite a lot 
□ Not very much 





12. I look forward with enjoyment to things… 
□ As much as I ever did 
□ Rather less than I used to 
□ Definitely less than I used to 
□ Hardly at all 
 
13. I get sudden feelings of panic… 
□ Very often indeed 
□ Quite often 
□ Not very often 
□ Not at all 
 
14. I can enjoy a good book or radio or TV program 
□ Often 
□ Sometimes 
□ Not often 





     Appendix C 
Short Inflammatory Bowel Disease Questionnaire 
(SIBDQ) 
This questionnaire is designed to find out how you have been feeling during the last 2 weeks. 
You will be asked about symptoms you have been feeling as a result of your inflammatory 
bowel disease, the way you have been feeling in general, and how your mood has been. 
1. How often has the feeling of fatigue or of being worn out been a problem for you during the 
last 2 weeks? (tick 1 option) 
□ All of the time 
□ Most of the time 
□ A good bit of the time 
□ Some of the time 
□ A little of the time 
□ Hardly any of the time 
□ None of the time 
 
2. How often during the last 2 weeks have you had to delay or cancel a social engagement 
because of your bowel problem? (tick 1 option) 
□ All of the time 
□ Most of the time 
□ A good bit of the time 
□ Some of the time 
□ A little of the time 
□ Hardly any of the time 
□ None of the time 
 
3. How much difficulty have you had, as a result of your bowel problem, doing leisure or sports 
activities you would have liked to have done during the last 2 weeks? (tick 1 option) 
□ A great deal of difficulty; activities made impossible 
□ A lot of difficulty 
□ A fair bit of difficulty 
□ Some difficulty 
□ A little difficult 
□ Hardly any difficulty 







4. How often during the past 2 weeks have you been troubled by pain in the abdomen? (tick 1 
option) 
□ All of the time 
□ Most of the time 
□ A good bit of the time 
□ Some of the time 
□ A little of the time 
□ Hardly any of the time 
□ None of the time 
 
5. How often during the last 2 weeks have you felt depressed or discouraged? (tick 1 option) 
□ All of the time 
□ Most of the time 
□ A good bit of the time 
□ Some of the time 
□ A little of the time 
□ Hardly any of the time 
□ None of the time 
 
6. Overall, in the last 2 weeks, how much of a problem have you had with passing large amounts 
of gas? (tick 1 option) 
□ A major problem 
□ A big problem 
□ A significant problem 
□ Some trouble 
□ A little trouble 
□ Hardly any trouble 
□ No trouble 
 
7. Overall, in the last 2 weeks, how much of a problem have you had maintaining or getting to, 
the weight you would like to be at? (tick 1 option) 
□ A major problem 
□ A big problem 
□ A significant problem 
□ Some trouble 
□ A little trouble 
□ Hardly any trouble 







8. How often during the last 2 weeks have you felt relaxed and free of tension? (tick 1 option) 
□ None of the time 
□ A little of the time 
□ Some of the time 
□ A good bit of the time 
□ Most of the time 
□ Almost all of the time 
□ All of the time 
 
9. How much of the time during the last 2 weeks have you been troubled by a feeling of having 
to go to the bathroom even though your bowels were empty? (tick 1 option) 
□ All of the time 
□ Most of the time 
□ A good bit of the time 
□ Some of the time 
□ A little of the time 
□ Hardly any of the time 
□ None of the time 
 
10. How much of the time during the last 2 weeks have you felt angry as a result of your bowel 
problem? (tick 1 option) 
□ All of the time 
□ Most of the time 
□ A good bit of the time 
□ Some of the time 
□ A little of the time 
□ Hardly any of the time 







     Appendix D 
Patient Questionnaire 
 
Palatability of drink A 
Please rank the drinks for the following qualities. 
 
0   1  2  3  4  
Extremely Slightly Neither Slightly Extremely 
 
Difficult to drink      Easy to drink 
0  1  2  3  4  
 
Unpleasant flavour       Pleasant flavour  
0  1  2  3  4  
 
Poor mouth feel      Good mouth feel 
0  1  2  3  4  
 
Weak aftertaste      Strong aftertaste 
0  1  2  3  4  
 
Not acrid*       Acrid* 
0  1  2  3  4  








Palatability of drink B 
Please rank the drinks for the following qualities.  
 
0  1  2  3  4  
Extremely Slightly Neither Slightly Extremely 
 
Difficult to drink      Easy to drink 
0  1  2  3  4  
 
Unpleasant flavour       Pleasant flavour  
0  1  2  3  4  
 
Poor mouth feel      Good mouth feel 
0  1  2  3  4  
 
Weak aftertaste      Strong aftertaste 
0  1  2  3  4  
 
Not acrid*       Acrid* 
0  1  2  3  4  






Drink A compared with Drink B 
 




Prefer drink A    Neutral           Prefer drink B 
 
 
Thinking about Drink A 
On a scale of 0 – 10 how likely is it that you could drink this 6-8 times per day? 
 
0 1 2 3 4 5 6 7 8 9 10 
 
Very unlikely               Highly likely 
 
 
Thinking about Drink B 
On a scale of 0 – 10 how likely is it that you could drink this 6-8 times per day? 
 
0 1 2 3 4 5 6 7 8 9 10 
 




Nutrition therapy with these drinks can greatly improve disease 
symptoms and may put disease into remission.   
 
Have you taken prednisone previously for Crohn’s disease?   Yes    No 
 
 
Knowing what you do about prednisone, would you rather take either of these drinks and not 
eat and drink (other than water) for 8 weeks OR take a course of prednisone for 8 weeks? 
   Drinks    Prednisone 
 
 
If these drinks could put your disease into remission would you consider using them and not 
eating or drinking (apart from water and black unsweetened tea or coffee) for 8 weeks if you 
had: 
 severe symptoms?    Yes     No 
 moderate symptoms?   Yes     No 
 mild symptoms?     Yes     No 
 
 
General information about you 
Your date of birth  ________________ 
 
Your sex     Male     Female 
 
 
Thank you for your time. 
Catherine Wall 







     Appendix E 
New Zealand Dietitian Survey Questions 









Food service management 
Not currently practicing 
Other  
 















Outside of New Zealand 





How many years of dietetic experience do you have? 
< 2 
2 – 5 
5 – 10 
10 – 20 
More than 20 years 
 




A few times a year 
Never 
 




A few times a year 
Never 
 























Thinking about your patient group, do you think that EEN is an appropriate treatment for active CD? 
Yes, for all my CD patients 
Yes, for selected CD patients/patient groups 
No, there is insufficient evidence to support its use with my patient group 




For which patients/groups do you think EEN is an appropriate treatment? 
 
What do you see as the downsides of EEN? 
Patient compliance with treatment 
Need for multidisciplinary approach 
Cost 
More time intensive for dietitian 
Requires patient to have adequate social support 
Other  
 




With approximately how many patients have you used EEN? 
 
What are the main reasons that you have not used EEN? (tick as many as applicable) 
Gastroenterologist does not offer it to their patients 
Surgeon does not offer it to their patients 
There is currently insufficient evidence to support its use with children 
There is currently insufficient evidence to support its use with adults 
We have limited dietetic resources to support people on EEN 
We have limited experience with using EEN 
Doctor manages any patients using EEN 
Gastoenterology nurse manages any patients using EEN 




What PERCENTAGE of patients that you have treated do you estimate have successfully completed a 
course of EEN? (just enter the number and not the % sign) 
 





If sometimes, in which patients have found it to be most successful?  
 
What PERCENTAGE of your patients do you estimate have achieved disease remission with EEN? 
(just enter the number without the % sign) 
 







Please describe your standard maintenance regimen  
 





Is there anything you require to increase your confidence/ability to manage patients that may be 




More evidence of the effectiveness of EEN as a suitable treatment for children 
More evidence of the effectiveness of EEN as a suitable treatment for adults 
No, I feel confident in my ability to manage patients referred for EEN 
Other  
 






     Appendix F 





Years of experience 
Gastroenterology Registrar 
Consultant < 5 years 
Consultant 5 – 10 years 
Consultant 10 – 20 years 
Consultant > 20 years 
 

























Which patient groups to do manage? 
Adults 
Children 
Adults and children 
 




Exclusive enteral nutrition (EEN) is the provision of all of a patient’s nutritional requirements from a 
nutritional formula (eg. Fortisip).  EEN can be managed in an inpatient or outpatient setting.  EEN is 
often prescribed for a period of 6 – 8 weeks and may be used in conjunction with other medication.  
During the course of EEN the patient is not allowed any solid foods and is usually only allowed to 
drink additional water and black unsweetened tea or coffee. 
 
Have you previously trained/worked in a unit where EEN is regularly used? 
No, EEN was never used 
EEN was rarely used 
EEN was sometimes used 
Yes, EEN was used regularly 
Yes, EEN was used very regularly 
 
Do you currently work in a unit where EEN is used regularly? 
No, EEN is never used 
EEN is rarely used 
EEN is sometimes used 
Yes, EEN is used regularly 
Yes, EEN is used very regularly 
 
Do you consider that EEN has a role as a therapy in the induction of remission for children with active 
CD? 
No, never appropriate 
Rarely appropriate 
Sometimes appropriate  
Yes, it is appropriate 





Do you consider that EEN has a role as a therapy in the induction of remission for adults with active 
CD?   
No, never appropriate 
Rarely appropriate 
Sometimes appropriate  
Yes, it is appropriate 
Yes, it is very appropriate 
 
Have you used EEN with any of your patients? 
Children - Yes/No 
Adults - Yes/No 
 
If answered YES: 
What do you see as the most important benefits of EEN? 
 Steroid sparing      
 Avoid immunosuppression 
 Nutritional        
 Improve growth in children   
Other:    
 
What do you see as the downsides of EEN? 
Patient compliance with treatment 
Need for multidisciplinary approach (eg Dietitian and Nurses) 
Cost 
More time intensive  
Requires patient to have adequate social support 
Other  
 
What are the main reasons that you have not used EEN? (tick as many as applicable) 
 There is currently insufficient evidence to support its use with children 
 There is currently insufficient evidence to support its use with adults 
 Patients struggle to maintain treatment compliance 
Limited support from dietitian 
 Limited support from nursing staff 
 Limited experience with using EEN 
 Limited social support for patients – maybe likert scale 
 Cost 




What would you require to increase the likelihood of recommending EEN for your CD patients?  
Practice guidelines 
Access to a dietitian 
Access to a nurse specialist 
More evidence of efficacy in children 
More evidence of efficacy in adults 
Other  
 
For those whose gastroenterologists that have used EEN in last 12 months. 
In the last 12 months approximately how many of your patients have been treated with EEN?  
 
For which Crohn’s disease patient group/s do you usually consider EEN? Yes/No 




Patients who are nutritionally compromised 
Patients with mild disease 
Patients with moderate to severe disease 
Other 
 
Would you consider EEN for children with CD who had disease in the following locations? 
never/rarely/sometimes/often/always 
I manage children  
Colonic 
Ileocolonic 
Isolated upper gut disease 
Upper + lower gut disease 
Perianal disease 
 
Would you consider EEN for adults with CD who had disease in the following locations? 
never/rarely/sometimes/often/always 
I manage adults  
Colonic 
Ileocolonic 
Isolated upper gut disease 






What duration of EEN do you usually recommend? 




> 12 weeks 
 
What percentage of patients that you have treated with EEN do you estimate have successfully 
completed a course of EEN? 
 




 If sometimes, in which patients have found it to be most successful?  
 
What percentage of your patients do you estimate have achieved disease remission with EEN? 
 








How do you judge the success of EEN? 
Clinical (e.g. improvement of symptoms) 
 Nutritional (e.g. weight gain)    
 Biochemical (e.g. ESR, platelets)  
 Radiological      
 Disease activity index     












If yes, please describe your standard maintenance regimen? 
 
Do you ROUTINELY use other therapy in conjunction with EEN? 
 Nil    
 5-ASA   
 Steroids  
 Azathioprine  
 6MP   
 Methotrexate  
 Infliximab   
 Other   
 
For all gastroenterologists: 
Additional comments: Please provide any additional comments or thoughts:  
 
Thank you for your assistance in the completion of this questionnaire. 
 
 
 
 
